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ABSTRACT
Introduction: The endogenous Damage-associated Molecular Pattern (DAMP) 
molecules which play a vital role in chronic inflammatory process, have been 
implicated at stages of cancer initiation, proliferation and progression. Previous 
research in our unit has examined the expression of the DAMPs S100A8/A9 and 
HSP27 in colorectal tumours. The tumour microenvironment of colorectal 
tumours was found to contain fewer SI00AS- but not S100A9-positive 
inflammatory cells, when the tumours were Smad4-negative, whilst HSP27 was 
shown to be a prognostic marker of poor outcome in rectal cancer patients. The 
current study explored the impact of S100A8, S100A9 and HSP27 on cancer cell 
motility and proliferation. To address the impact of environmental S100A8/A9 
chemokines on tumour cells, the effects of exogenously added S100A8 and 
S100A9 proteins on cellular migration and proliferation in relation to Smad4 
status of cancer cells were investigated. In addition, die potential of HSP27 
expression to be a predictive marker of response to adjuvant therapy in colorectal 
cancer patients was examined, followed by in vitro assessment of the role of 
HSP27 in cell sensitivity to chemo-radiation.
Methods: Colorectal cancer cell lines were used to examine cell motility and 
proliferation with Modified Boyden Chamber and MTS assays respectively. 
Transient Smad4 and HSP27 depletions were performed using siRNAs. 
Recombinant GST-tagged S100A8, S100A9 and control GST proteins were 
generated and purified from E. coli. Previously characterised tumoural HSP27 
expression in resected colorectal cancer specimens were correlated with 5-year' 
cancer-specific survival of patients treated with adjuvant 5-fluorouracil (5-FU).
II
Following HSP27 depletion, changes to cell cycle profile were assessed using 
flow cytometry, and changes to cell sensitivity to chemotherapy (5-FU, 
irinotecan and oxaliplatin) and gamma irradiation were measured using annexin- 
V/propidium iodide apoptosis assays.
Results: Exogenously added S100A8 and S100A9 enhanced migration and 
proliferation in Smad4-positive and Smad4-negative cancer cells. However, 
transient depletion of Smad4 resulted in loss of responsiveness to exogenous 
S100A8, but not S100A9. S100A8 and S100A9 activated Smad4 signalling as 
evidenced by phosphorylation of Smad2/3; blockade of the receptor for the 
advanced glycation end products (RAGE) inhibited this response. Among 
patients treated with combined surgery and adjuvant 5-FU, patients with high 
tumoural HSP27 had poorer survival (P=0.01) compared to patients with low 
HSP27 and showed no improvement in survival compared to patients treated 
with surgery only (P=0.45). HSP27 depletion resulted in a significant reduction 
in cell motility, inhibited cell proliferation and led to cell cycle arrest, and 
significant increases in cell apoptosis in response to 5-FU, irinotecan, oxaliplatin 
and gamma radiation.
Conclusion: This study provides evidence of the cancer-promoting activities of 
S100A8, S100A9 and HSP27, suggesting crucial roles of inflammatory 
mediators in carcinogenesis. Further research in modulating the immune 
response with respect to these DAMPs may provide attractive therapeutic targets 
for colorectal cancer treatment.
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CHAPTER 1: 
INTRODUCTION
1.1 Colorectal cancer (CRC)
CRC is the third most commonly diagnosed cancer in the UK after breast and 
lung. In 2007, over thirty eight thousand new cases of large bowel cancer were 
registered in the UK, of which around two-thirds occurred in the colon and 
one-third in the rectum1. This equates to around 100 new cases of CRC 
diagnosed each day, in which 54 % are in male patients. According to the 
National Bowel Cancer Audit Project 20072, 28 % of CRC patients are of 
working age (< 65), 12 % over 85 and 4 % over 95 (median age 73 years).
Most cases of CRC arise in the left side of the large intestine, with the sigmoid 
colon and rectum being the most prevalent sites. Adenocarcinoma (mucinous 
or signet ring types) is the commonest type of CRC. Other cellular types 
include scirrhous, neuroendocrine and carcinoid tumours. It has been reported 
that synchronous tumours occur in 4-5 % of cases3. CRC can spread directly to 
the surrounding structures, or via the lymphatic, blood and transcoelomic 
routes.
CRC is the second most common cause of death from cancer in the UK after 
lung cancer. The majority of deaths occurred in elderly patients, 80 % in 
patients aged 65 and over and almost two-fifths in the over 80s. In contrast to 
incidence trends, bowel cancer death rates have been falling continuously since 
the early 1990s and over the last decade death rates have dropped by around 13 
% attributed to medical advances1.
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1.1.1 Surgical anatomy of the colon and rectum
The large intestine, consisting of the colon and rectum, extends from ileocaecal 
valve to the anus. It measures approximately 1.5 m long and 4 cm in diameter. 
The colon has the following subdivisions: caecum, ascending colon, transverse 
colon, descending colon and sigmoid colon4. In clinical practice, cancers that 
occur in these subdivisions are collectively known as colonic cancers.
In the pelvis, at the level of the second to third sacral vertebra, the sigmoid colon 
joins the rectum. The rectum is defined as the distal segment of the large bowel 
lying below the peritoneal reflection. On rigid sigmoidoscopy, it extends for 
approximately 15 cm from the anal verge. In surgical oncology practice, the anal 
verge has been used as the anatomical landmark for benchmarking rectal 
tumours as it affects permanent colostomy rates, the percentage of anastomotic 
leaks and local recurrence rates. It is the distance between the lower edge of the 
tumour and the anal verge that influences the type of neo-adjuvant or adjuvant 
therapy, the type of surgery and most importantly the outcome5.
The epithelial mucosa lining the colon and rectum forms the innermost layer of 
the large intestine, followed by a thin sheet of muscle called the muscularis 
mucosa. This is then surrounded by a submucosal layer of loose stromal tissue, 
followed by muscularis propria and subserosa/serosa6. It is the understanding of 
this microscopic anatomy that allows the pathologist to stage CRC following 
surgical resection.
The colon and rectum mucosa are simple columnar epithelia. Most food is 
absorbed before reaching the large intestine and hence there are no plicae
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circulares, villi or cells that secrete digestive enzymes. However, the mucosa in 
the large intestine is thicker, its abundant crypts are deeper, and there are huge 
numbers of goblet cells in the crypts. This reflects the function of the large 
intestine. Lubricating mucus produced by goblets cells eases the passage of 
faeces and protects the intestinal wall from irritating acids and gases released by 
resident bacteria.
1.1.2 Aetiology and risk factors
1.1,2,1 Genetic basis of colorectal cancer, adenomatous polyps and 
hereditary CRC
Studies have shown that the accumulation of genetic mutations or alterations 
within epithelial cells of the colon and rectum result in colorectal cancer 
formation. Mutations in the adenomatous polyposis coli (APC) gene, genes on 
chromosome 18q, the KRAS and p53 genes may each represent alternative, 
multiple mutational pathways in colorectal carcinogenesis, with distinct 
clinical outcomes7,8.
Most CRCs are sporadic in occurrence, but 5 % occur as a result of hereditary 
genetic mutations. In hereditary CRC, the germline mutations in the tumour 
suppressor gene APC (in Familial Adenomatous Polyposis, FAP) and the 
DNA-mismatch repair genes (in Hereditary Non-Polypoidal Colorectal Cancer, 
HNPCC, also called Lynch syndrome) increase the lifetime risk of developing 
CRC to 80 - 100 % compared to the general population9.
In approximately 85 % of sporadic CRCs, allelic losses, chromosomal 
amplifications and translocations have been identified10. Deletion at Ip and 8p,
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as well as loss of heterozygosity (LOH) of 17p and 18q are frequent in CRC. 
Such alterations are characteristics of the chromosomal-instability pathway 
(CIN) with stability of microsatellite DNA — these are referred to as 
microsatellite stable (MMS) tumours (Figure l)11. The second pathway which 
represents approximately 15 % of sporadic CRCs is known as the 
microsatellite-instability pathway (MSI). Such tumours display frameshift 
mutations and base-pair substitutions that are commonly found in short, 
tandemly repeated nucleotide sequences known as microsatellites. This 
population of CRCs is associated with mutations in DNA mismatch repair 
genes, which lead to an accumulation of widespread mutations in genes, such 
as the genes encoding type IITGF-P receptor, the apoptosis regulator BAX, the 
insulin-like growth factor II receptor and others12, 13. Lastly, epigenetic 
silencing through the cytosine phosphoguanosine (CpG) Island Methylator 
Phenotype (CIMP) has been proposed as a third pathway in CRCs, 
characterised by hypermethylation and functional silencing of CpG islands in 
various tumour-suppressor genes. The expression of these tumour-suppressor 
genes in cancer cells can be reduced or eliminated through ‘silencing’, a 
process with changes in methylation (the promoters of genes that are 
hypermethylated will be ‘silenced’) as an alternative mechanism to genetic 
mutation14.
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Chromosomal instability pathway (CIN)- Genetic alterations through 
chromosomal losses and gains e.g. DCC, k-ras, ARC, p53
\
Normal
-U
Early A Intermediate r
Late
mucosa r adenoma / -y adenoma adenoma
Microsatellite instability pathway (MSI) - Genetic alterations through 
defective DNA mismatch repair proteins e.g. TGF-fJ RH, IGF-RII
Figure 1: Genetic instability in colorectal cancer. APC, adenomatous polyposis 
coli; DCC, deleted in colorectal cancer; IGF-I1R, insulin-like growth factor II 
receptor; TGF-RII, transforming growth factor II receptor".
Genetic mutations result in histological transition from normal mucosa to 
adenomatous polyps, which are non-obligate precursors of malignant lesions. 
Adenomatous polyps account for half to two-thirds of colorectal polyps and are 
found in about a quarter of people by the age of 50 years'3. The relationship 
between the characteristics of adenomas and the risk of cancer has been 
established by a British study of 1618 patients, which showed that individuals 
with tubulo-villous, villous or large (> 1 cm diameter) adenomas were more 
than three times more likely to develop colonic cancer than the general 
population. In the case of multiple recto-sigmoid polyps with advanced 
pathology, the risk of developing cancer increases to six times16. The concept 
of an adenomatous-carcinoma sequence in CRC has also been derived from 
indirect evidence as follows:
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• Cancers and adenomatous polyps have a similar anatomic distribution 
in the large intestine17.
• Large adenomas display greater cellular atypia and genetic mutations 
than small adenomas18.
• Patients with one or more large polyps of more than 1 cm diameter 
have been found to be at increased risk of future CRC with cancers 
arising at the site of polyps left in place19.
• Removing adenomas significantly reduces the incidence of CRC20.
• Patients with FAP have hundreds to thousands of adenomatous polyps 
which are pre-malignant and share similar histological features to those 
of sporadic adenomas21.
In addition to the conventional-type adenoma-carcinoma sequence following 
chromosomal instability pathway described above, the serrated pathway has 
been recognised as a separate entity in colorectal tumourigenesis. It is 
associated with somatic BRAF mutation and widespread hypermethylation of 
CpG islands in gene promoters22. Sessile serrated adenomas (SSAs) are the 
pre-malignant lesion of the serrated pathway. These lesions show distinct 
histological features and proximally located in the right colon22.
FAP is an autosomal dominant disorder caused by a mutation in the tumour 
suppressor gene, APC, located on chromosome 5q2123. Patients with FAP have 
hundreds to thousands of adenomas in the colon and rectum, usually starting in 
adolescence. Almost all of these patients get CRC at around 40 years old, 
significantly younger than the sporadic CRC population. Less than 1 % of CRC 
only is caused by FAP.
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Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is the most common 
form of hereditary CRC, accountable for 1-5 % of all CRC. It is inherited 
autosomal dominantly and carries an 80 % risk of colorectal cancer and a 50- 
60 % risk of endometrial cancer in women24. At least 5 genes have been 
identified implicated in HNPCC, with MSH2 on chromosome 2p and MLH1 
on chromosome 3p responsible for the majority of HNPCC . All of the 
HNPCC genes are named mismatch repair (MMR) genes, demonstrating 
microsatellite instability.
There are other rare inherited conditions associated with CRC, such as the 
Peuz-Jeghers Syndrome and Familial Juvenile Polyposis. The genes implicated 
in all of the above conditions are summarised in Table 1.
Hereditary condition Genes implicated
Hereditary Non-Polyposis Colorectal Cancer MLH1, MSH2, MSH6,
(HNPCC) PMS1, PMS2
Familial Adenomatous Polyposis (FAP) APC
Peuz-Jeghers Syndrome STK11
Familial Juvenile Polyposis PTEN, SMAD4, BMPR1A
Table 1: Inherited predisposition to CRC, summarised from Gatalica and 
colleagues24.
1.1.2.2 Family history other than the hereditary conditions
Having a family history of CRC other than the hereditary conditions mentioned 
above, increases the risk to an individual developing the disease, possibly due 
to the interplay between environmental and genetic factors. Having a single
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relative with CRC increases the risk of developing this disease 2-3 fold among 
the first degree relatives25. The finding of more numbers of closely related 
individuals increases the risk to their relatives further. If the single affected 
relative is young, for example, under 40 years old, the risk increases to 5 folds. 
In the majority of families with a history of CRC, lower penetrance genes may 
play a role, although the mechanism of cancer susceptibility in this group of 
patients remains poorly understood25.
1.1.2.3 Inflammatory bowel disease (IBD)
Patients with IBD are at higher risk of CRC than the general population. 
Cancers that develop in IBD do not arise from adenomatous polyps but from 
areas of pre-cancerous dysplasia due to chronic inflammation. This causative 
factor is further described in chapter 1.2.
1.1.2.4 Metabolic syndrome
It has long been observed that CRC is associated with hypercholesterolaemia, 
obesity and diabetes mellitus, which fulfil the criteria for metabolic 
syndrome26. The National Cholesterol Education Program’s Adult Treatment 
Panel III defined metabolic syndrome as having three or more of the criteria27: 
hypertension, central body adiposity, low high-density lipoprotein cholesterol, 
hypertriglyceridaemia and impaired glucose tolerance.
Several large cohort and cross-sectional studies have found association 
between CRC and metabolic syndrome, in which either the metabolic 
syndrome or its components increase the risk for CRC by approximately 50 
%28 31 ■ This risk seems to be higher in men than in women.
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It is also interesting to note that several studies have reported the association 
between coronary artery diseases with advanced CRC. Chan and colleagues32 
reported that coronary artery disease remained associated with advanced CRC 
after adjusting for several confounding factors. Also, Limburg and colleagues33 
and Chung and colleagues34 have found increased risk of CRC among diabetic 
patients. Furthermore, the risk of recurrent CRC increases in patients with 
insulin resistance disorder35. It is therefore apparent that the association of 
coronary artery disease with CRC described above shares several of the 
common criteria in defining metabolic syndrome. However, the strength of the 
association would need to be further evaluated following adjustment for many 
other confounding factors. More clinical and laboratory studies are needed to 
elicit the mechanisms of each of the independent factors in the metabolic 
syndrome leading to CRC. These undeniably important risk factors to CRC can 
then be incorporated into clinical practice in risk stratification for inviting 
patients for CRC screening programme.
1.1.2.5 Cigarette smoking
Numerous epidemiologic studies dated from the early twentieth century have 
investigated the association between cigarette smoking (CS) and CRC risk. In a 
review analysis by Giovannucci36, all the studies conducted in 1950s and 1960s 
on men and women, who have not exceeded four decades of CS failed to show 
any significant association with CRC. However, studies conducted in US after 
1970s, when most smokers have exceeded four decades of CS, showed that 
smoking significantly increases the risk of CRC, suggesting a long time lag of 
up to 35-40 years for CS to be accountable for increased risk for CRC.
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Giovannucci concluded that 1 in 5 cases of CRC is attributable to tobacco use 
in the United States. A more recent meta-analysis consisting of 42 
observational studies showed that CS seems to be associated with increased 
risk of colorectal adenoma (a precursor lesion for colorectal cancer 
development), including lesions with advanced clinico-pathological features37. 
To establish cause and effect between CS and CRC, two case-control studies 
have shown that CS was differentially associated with tumours that exhibit a 
high level of MSI, jBiMF-mutated status, or the CpG island methylator 
phenotype38,39. Further studies are needed to clarify the molecular pathways 
concerning tobacco-derived carcinogens and the development of CRC.
1.1.3 Clinical presentation and screening
The common clinical presentations of CRC patients include changes in bowel 
habits, iron deficiency anaemia, weight loss, abdominal pain, per-rectal 
bleeding, abdominal or rectal mass, or being acutely unwell with bowel 
obstruction or perforation. Generally, the symptoms are related to the site of 
CRC, e.g. iron deficiency anaemia and abdominal mass are more common in 
right-sided tumour, whereas fresh per-rectal bleeding is more common with 
recto-sigmoid cancer. However, all these are non-specific signs and symptoms 
of CRC as they are common in numerous other bowel pathologies.
Unfortunately, patients with CRC may have no clinical signs or symptoms until 
the late stage of the disease. Approximately 55 % of all patients diagnosed with 
CRC present with lymph node or distant metastases at the time of diagnosis 
with significantly lower survival rates40. Therefore, early detection before the 
presentation of clinical signs and symptoms is essential to reduce mortality.
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CRC development is a process that spans many years, thereby providing an 
opportunity for early detection or prevention with a screening programme. In 
the UK, the National Health Service Bowel Cancer Screening Programme 
commenced in 2006 and invites men and women aged 60-69 (to 75 in 2010) to 
participate via submission of a faecal occult blood test (FOBT) every 2 years. 
Those with a positive FOBT are offered colonoscopy as a second line 
screening41. There are two types of FOBTs: the guaiac test which is based on 
the peroxidase-like activity of haem in haemoglobin and the immunochemical 
test which detects the globin moiety in haemoglobin. The guaiac-based FOBT 
has been adopted as the screening test because it has been shown to reduce 
both the incidence and mortality of CRC by ~20% and ~16% respectively42. 
The FOBT has several advantages: it is non-invasive, examines the entire 
colorectal tract, can be carried out in the privacy of one’s own home, requires 
no patient preparation, and is simple and affordable. However, it suffers from 
the disadvantages of having low sensitivity and specificity for both adenoma 
and CRCs. In addition, the ingestion of certain foods (red meats, fruits and 
vegetables) and medicines (non-steroidal anti-inflammatory drugs) can yield 
false positive results42.
1.1.4 Pathological staging, survival and other pathological 
prognostic factors
CRC staging system is an essential tool for diagnostic, predictive and 
prognostic purposes of the disease course. It is also paramount for tailoring 
appropriate patient management and meaningful clinical research. The late 
English physician and pathologist, Cuthbert Dukes (1890 - 1977) set a
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standard in surgical pathology in 1932, when he established that the wall 
penetrance and nodal involvement were the most important factors in staging 
rectal cancer for determining clinical outcome43. The original Dukes’ 
classification was divided into three simple stages, A to C (Table 2), and 
described the staging for rectal cancer only but it also applies to colonic cancer. 
Dukes’ classification was then modified by Astler and Coller in 195444, 
followed by the introduction of the tumour, node, metastasis (TNM) staging by 
the American Joint Committee on Cancer (AJCC) in 1957.
Stage Definition
A Invasive carcinoma not breaching the muscularis propria.
B Invasive carcinoma breaching the muscularis propria, but not involving regional 
lymph nodes.
Cl Invasive carcinoma involving the regional lymph nodes (apical node negative).
C2 Invasive carcinoma involving the regional lymph nodes (apical node positive).
Note: Dukes’ stage D was added later to mean the presence of distant metastases.
Table 2: Dukes’ staging definitions45.
The TNM staging system (Table 3) of the AJCC and the International Union 
Against Cancer (UICC) is now the standard for colorectal cancer staging in the 
UK and United States46. It is internationally adopted due to its comprehensive 
set of definitions that ensure uniform use by multidisciplinary members, and is 
continuously improved upon through expert review of existing data47. 
However, Dukes’ classification is still widely used owing to its simplicity and 
reproducibility. The staging systems illustrate that there are high percentages of
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permanent cure for CRC in the early stages of the disease, with poor survival 
when the disease involves lymph nodes (Table 4).
Apart from the tumour (T), nodal (N) and metastatic (M) pathological features, 
there are other pathological prognostic factors that predict outcome in CRC. 
The microscopic grade, or degree of tumour cell differentiation, is an 
independent predictor of survival, with higher grades being associated with 
increasing wall penetration and nodal or distant metastasis and therefore worse 
prognosis48. Lymphatic vessel invasion49, blood vessel invasion^1 and 
perineural invasion^1 have also been associated with poorer prognosis. On the 
other hand, peritumoural lymphocytic infiltration^2 and the observation of sinus 
histiocytosis and paracortical immunoblastic activity in the lymph nodes 
draining the tumour5^ have been reported to correlate with improved survival.
Molecular features of CRC also provide prognostic information. Patients with 
tumours possessing a high degree of MSI have a favourable prognosis than 
those patients who tumours are microsatellite stable^4. In addition, loss of 
heterozygosity at chromosome 18q is associated with a worse prognosis, 
possibly due to the loss of the tumour suppressor gene - deleted in colon 
cancer (DCC)55.
Category Definition
Primary Tx Primary tumour cannot be assessed.
tumour (T) TO No evidence of primary tumour.
Tis Carcinoma in situ (intraepithelial or intramucosal
carcinoma).
T1 Tumour invades the submucosa.
T2 Tumour invades the muscularis propria.
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T3 Tumour invades through the muscularis propria into the
subserosa or non-peritonealised pericolic or perirectal
tissues.
T4 Tumour directly invades other organs or structures
(T4a) or perforates the visceral peritoneum (T4b).
Regional Nx Regional lymph nodes cannot be assessed.
lymph nodes NO No regional lymph nodes metastasis.
(N) N1 Metastasis in one to three lymph nodes.
N2 Metastasis in four or more lymph nodes.
Distant Mx Presence of distant metastasis cannot be assessed.
metastasis MO No distant metastasis.
(M) Ml Distant metastasis.
Table 3: AJCC/UICC TNM definitions46.
TNM Modified Astler- Dukes Frequency 5-year
Coller survival
Stage 0 Tis NO MO N/A N/A N/A N/A
Stage I T1 NO MO Stage A A 11% 80-85 %
T2 NO MO Stage B1
Stage UA T3 NO MO Stage B2 B 35% 72-75 %
Stage IIB T4 NO MO Stage B3 65-66 %
Stage IIIA Tl, T2 N1 MO Stage C1 C 26% 55-60 %
Stage 11IB T3, T4 N1 MO Stage C2, C3 35-42 %
Stage IIIC Any T N2 MO Stage Cl, C2, C3 25-27 %
Stage IV Any T Any N Ml Stage D D 29% 0-7 %
Table 4: CRC staging grouping of various classification systems with
frequency and 5-year survivals46,56.
15
1.1.5 Biomarkers in CRC
Over the years, various research groups have performed genomic and 
proteomic analysis on CRC tissues, serum and faeces in order to identify 
biomarkers which could improve outcomes for CRC patients, by finding 
markers for early detection (diagnostic markers), prognosis (prognostic 
indicators), tumour responses (predictive markers), and disease recurrence 
(monitoring markers).
The Cancer Research UK (CR-UK) describes several stages in 
prognostic/predictive biomarker discovery (Figure 2)57, which begins with 
identifying the rationale and clinical need of a biomarker in a cancer type, 
followed by assay development to assess the potential biomarker, and 
ultimately validate the correlation between the biomarker and clinical outcome 
in prospective randomised clinical trial before transferring the biomarker to 
routine clinical practice.
Kuramitsu and colleagues58 in their comprehensive review on proteomic 
analysis on CRC tissues, have compiled a list of proteins that are up-regulated 
or down-regulated in CRC tissues. Despite extensive lists of proteins, the lack 
of sensitivity and specificity, or lack of thorough validation has precluded their 
use in clinical setting at present. Likewise, there is insufficient data to 
recommend the routine use of p53, thymidylate synthase, dihydropyrimidine 
dehydrogenase, thymidine phosphorylase, 18q loss of heterozygosity, or 
deleted in colon cancer (DCC) protein in the management of patients with 
CRC59.
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Figure 2: The Cancer Research UK (CRUK) prognostic/predictive biomarker 
roadmap57.
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However, several existing serum and tissue markers have been recommended 
by the European Group on Tumour Markers (EGTM)60 and the American 
Society of Clinical Oncology (ASCO)59 for routine clinical use: serum 
carcinoembryonic antigen (CEA), FOBT, and several genetic tests for genetic 
susceptibility to CRC such as APC for identifying subjects at high risk of 
developing FAP, and MSI/MLH1/MSH2/MSH6 for identifying subjects at 
high risk of developing HNPCC.
Serum CEA remains the oldest and the most widely used biomarker in patients 
with CRC. EGTM and ASCO recommend the use of serum CEA as a 
surveillance following curative resection or monitoring for the response to 
therapy in advanced disease. Several meta-analyses61'64 have reported that the 
use of an intensive follow-up regimen resulted in a modest improvement in 
outcome compared to minimal follow-up regimen. Specifically, using serial 
CEA measurement had a significant impact on improved survival compared to 
not using CEA61,63, Moreover, serum CEA measurement is inexpensive and 
causes minimal inconvenience for patients. However, it is not recommended 
for use as a screening test due to its poor sensitivity despite the specificity for 
CRC identifying occult CRC being high65.
Perhaps, one of the most significant recent developments with respect to 
biomarkers in this field has been the observation that the presence of mutant 
KRAS in tumours is predictive of failure to derive treatment benefit from 
EGFR-targeted agents in patients with metastatic colorectal cancer66,61. This 
leads to the use of EGFR-targeted agents, for instance, cetuximab as approved 
by the National Institute for Health and Clinical Excellence (NICE) for patients
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with wild-type KRAS, non-resectable, liver-only metastatic colorectal cancer in 
the UK68.
In addition, there are evidence that patients who have Stage II colorectal 
tumours with high-frequency MSI do not derive benefit from adjuvant 5-FU69, 
and the current expert opinion is that prior testing of MSI status of these 
patients could be useful to determine which of these patients should be treated 
with adjuvant 5-FU70.
1.1.6 Management of CRC
1.1.6.1 Surgery
Surgery remains the definitive treatment for localised CRC, offering the only 
chance of cure. This involves complete resection of the primary tumour with 
adequate margins (distal margins of at least 5 cm), including the artery supply, 
venous drainage and lymph node groups that drain the diseased segment. At 
least 12 lymph nodes should normally be harvested and examined to allow 
accurate staging of the tumour2. In rectal cancer surgery, total mesorectal 
excision, which involves the removal of the tumour as well as the fatty tissue 
around the rectum, has become the standard procedure for mid- and low rectal 
tumours. It results in higher local control and increased disease-free survival71.
The liver is a major site of distant metastasis in colorectal cancer. It has been 
reported that as many as 25 % of CRC patients have liver metastasis at initial 
presentation, and a further 20-30 % of patients develop metachronous disease 
following colorectal cancer surgery72. Of these patients, only about 20 % 
would be amenable to curative resection of liver metastasis which substantially
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improves 5-year survival rates of up to 37-58 %72. A variety of therapeutic 
approaches have been employed to improve liver surgery and increase number 
of patients undergoing treatment of liver metastasis, which include pre­
operative embolisation or chemotherapy, cryotherapy, radiofrequency ablation 
of small lesions and two-stage liver resection70.
1.1.6.2 Neo-adjuvant and adjuvant therapy
For the last two decades, 5-fluorouracil (5-FU) has formed the basis and the 
mainstay of therapy for CRC, with the developments revolving around 5-FU in 
search of optimum combination regimens. Recently, the arrival of two new 
drugs, oxaliplatin and irinotecan, has provided promising outcomes in treating 
CRC either as an independent agents or in combination regimens. Specifically 
to rectal cancer, radiotherapy has been the gold standard treatment. 
Chemotherapy and radiotherapy can be given either pre-operatively (neo­
adjuvant) or post-operatively (adjuvant).
1.1.6.3 Fluorouracil-based therapy
Fluorouracil is a fluorinated pyrimidine that acts through inhibition of 
thymidylate synthetase, the rate-limiting enzyme in pyrimidine nucleotide 
synthesis73. It induces cell cycle arrest and leads to apoptosis by inhibiting the 
ability of cells to synthesise DNA.
In the early 1990s, a large clinical trial conducted by the Eastern Cooperative 
Oncology Group which involved 1296 patients showed that adjuvant treatment 
containing 5-FU significantly reduced the risk of disease recurrence by 41 % 
and the risk of death by 33 % compared to surgery alone in stage III disease but
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not in stage II disease74’75. Therefore, the National Cancer Institute Consensus 
Conference recommended the use of fluorouracil-based adjuvant therapy as 
standard of care in patients with resected stage III colon cancer . Later, 
leucovorin (LY, also called folinic acid), a reduced folate has been shown to 
enhance the anti-tumour effect of 5-FU by stabilising the interaction of 
fluorouracil with thymidylate synthetase77. The 5-FU/LV combination 
produced an increase in 5-year disease-free survival from 42 % to 58 % and 5- 
year overall survival from 51 % to 61 % in stage III disease78, which is now the 
routine treatment regimen.
Various administration schedules in terms of lengths of treatment, dosages, 
routes of administration of 5-FU/LV have also been investigated (Table 5)79, 
The use of oral 5-FU, capecitabine, has been shown to confer similar efficacy 
to infusional 5-FU80. de Gramont regimen is one of the most widely used 
regimens in Europe. The Medical Research Council (MRC) CR06 trial showed 
that there was no significant difference in efficacy between de Gramont, 
Lokich or raltitrexed regimen, but raltitrexed regimen resulted in more serious 
adverse events81. Therefore, the infusional 5-FU/LV for 6 months remains the 
regimen of choice in the UK. However, the choice of regimen ultimately 
depends on variable side effect profiles between individual patients. For 
example, the Mayo Clinic regimen frequently causes neutropenia and 
stomatitis, and the Roswell Park regimen can result in debilitating diarrhoea. 
The continuous infusion regimen (e.g. Lokich) can be associated with less 
haematological and gastrointestinal toxicity, but more commonly related to 
hand-foot syndrome .
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Although fluorouracil-based adjuvant therapy produces great survival benefits 
to patients with stage III disease, many trials failed to demonstrate such benefit 
in patients with stage II colon cancer. A systemic review which included 37 
trials and 11 meta-analyses concluded that adjuvant therapy is associated with 
only a small disease-free survival but no overall survival benefits for patients 
with stage II colon cancer . This is consistent with the findings from a recent 
meta-analysis of The Cochrane Collaboration . However, a large trial 
conducted by a Birmingham (UK) group (Quick and Simple and Reliable study 
- QUARSAR) found that in patients with stage II CRC, adjuvant 5-FU/LV 
incurs small absolute survival improvements, by assuming that the 5-year 
mortality without chemotherapy is 20%84. Therefore, it seems essential to 
discuss the benefits of adjuvant systemic chemotherapy with stage II cancer 
patients, taking into considerations the co-morbidities and likelihood of side 
effects to allow informed decision to be made.
Name Country
research
group
of Regimen
Mayo USA Bolus low-dose LV 20 mg/m2/day followed by 
5FU 425 mg/m /day given daily days 1-5,
every 28 days
De
Gramont
France LV 200 mg/m2 2-hour infusion, 5-FU bolus 
400 mg/m2 and 5-FU 600 mg/m2 22-hour 
infusion, days 1 and 2, 14 days
Modified
De
Gramont
UK LV 175 mg (flat dose) 2-hour infusion, 5-FU 
bolus 400 mg/m2 and 5-FU 2,800 mg/m2 46- 
hour infusion, every 14 days
Lokich UK Continuous infusion 5-FU 300 mg/m /day (10
22
weeks or more)
Roswell
AIO Germany LV 500 mg/m2 + 5-FU 2,600 mg/m2/24-hour 
infusion, weekly x 6, every 8 weeks 
United States LV 500 mg/m2 2-hour infusion followed by 5-
Park FU 500 mg/m2 bolus 1 hour after the start of 
LV infusion, weekly x 6, every 8 weeks
Table 5: The commonly used 5-FU regimen79.
1.1.6.4 Irinotecan
Irinotecan is a semi-synthetic derivative of the natural alkaloid camptothecin. 
Its active metabolite SN38 causes cytotoxicity by inhibiting topoisomerase 1, 
an enzyme that catalyses breakage and rejoining of DNA strands during DNA 
replication8^. There is good clinical evidence that irinotecan as a single agent86, 
or used in combination with 5-FU87’88, is an effective second-line treatment of 
patients with 5-FU resistant disease or as first line in metastatic disease. 
However, the addition of irinotecan to 5-FU/LV as first line adjuvant treatment 
(IFL regimen) following curative resection of stage III disease has been shown 
to incur increased toxicity and confer no improvement in outcome89, 90. 
Therefore, the use of irinotecan is currently limited to patients with advanced 
disease.
1.1.6.5 Oxaliplatin
Oxaliplatin is a diaminocyclohexane platinum compound that forms DNA 
adducts in a similar manner to cisplatin, leading to impaired DNA replication 
and cellular apoptosis91. Oxaliplatin treatment benefits patients with metastatic 
CRC when it is administered with 5-FU/LV but not as single agent92, 93. The 
FOLFOX regimen which involved infusional 5-FU, LV and oxaliplatin
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improved overall survival significantly in metastatic disease when compared 
with IFL regimen or a combination of irinotecan and oxaliplatin . This finding 
has led to the investigation of FOLFOX regimen in patients with stage IT and 
stage III diseases. The Multicenter International Study of 
Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon 
Cancer study94 and the National Surgical Adjuvant Breast and Bowel Project- 
07 trial95 found that adding oxaliplatin to 5FU/LV significantly improved 
disease-free survival and overall survival in the adjuvant treatment of stage III 
colon cancer. Therefore, FOLFOX regimen is now considered the standard of 
care for completely resected colon cancer in fit and young patients.
1.1.6.6 Chemo-radiation in rectal cancer
In patients with rectal cancer, distant metastasis is the most common cause of 
death. Patients with loco-regional and pelvic recurrences suffer from severe 
sacral or deep pelvic pain which is associated with significant morbidity and 
poor quality of life. Therefore, unlike colon cancer, loco-regional recurrence is 
also a paramount end point in the treatment of rectal cancer.
The benefits of radiotherapy in rectal cancer were established in the late 1980s. 
Studies have shown that combined adjuvant radiotherapy and 5-FU therapy 
resulted in a significant reduction in the rate of local recurrence and an increase 
in the rate of overall survival when compared with surgery alone96,97.
Later, pre-operative chemoradiotherapy for rectal cancer has also been 
extensively investigated because of certain advantages over post-operative 
therapy as below:
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• Capable of down-staging the tumour, improving surgical resectability, 
and ultimately increasing curative surgical resection with adequate
* 98margins .
• Allows tumours to be resected with limited longitudinal surgical 
margins, hence increasing the level to which sphincter-sparing 
procedures can be performed in the distal rectum instead of abdomino­
perineal resection that leads to permanent colostomy".
• Associated with reduction in tumour spillage and the potential for 
dissemination of tumour cells during surgery, thus leading to lower risk 
of recurrence100.
• Before surgery, the tumour bed blood supply is well preserved. This 
enhances oxygenation, thereby improving irradiation efficacy101.
• Reduced risk of chemoradiation-induced morbidity, for instance 
radiation enteritis, because small bowel is less likely to be adherent in 
the treatment field prior to surgery98.
The German Rectal Cancer Study Group conducted a large clinical trial, in 
which 823 patients with clinical stage T3 or T4 or node-positive rectal cancer 
were randomised to receive either the pre- or post-operative 
chemoradiotherapy102. This study demonstrated that pre-operative treatment 
had doubled the rate of sphincter-sparing operations and reduced significantly 
the rates of local recurrence, acute toxicity, and long-term toxicity compared to 
post-operative treatment. However, there was no difference in disease-free or 
overall survival between the two treatment arms. Furthermore, the Swedish 
Rectal Cancer Trial103 and the MRC CR07/NCIC-CTG C016104 have shown 
that pre-operative radiotherapy in resectable rectal cancer significantly reduced
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the rates of local recurrence compared with post-operative chemoradiotherapy. 
Given these compelling results, following pre-operative MRI assessment of the 
circumferential resection margin, patients undergo surgery alone or treated 
with neo-adjuvant short-course radiotherapy (25 Gy in 5 fractions) if this 
margin is likely to be negative at the time of surgery. If this margin is likely to 
be positive or in node-positive disease, then patients are managed with long- 
course neo-adjuvant chemoradiation (50.4 Gy in 28 fractions)70.
1.1.6.7 New therapeutic agents for CRC
L 1.6.7.1 Epidermal growth factor receptor (EGFR) inhibitors
The Human EGFR (erbB, or HER) family plays an important role in cellular 
growth, proliferation and apoptosis. In CRC, EGFR expression has been 
demonstrated in up to 70 % of tumours105 and these tumours carry a poorer 
prognosis106. Cetuximab and panitumumab are monoclonal antibodies targeting 
EGFR specifically, both licensed for use in patients with advanced, wild-type 
KRAS colorectal cancer after failure of 5-FU, oxaliplatin and irinotecan- 
containing regimens. Pre-clinical models have shown an additive effect of 
cetuximab and irinotecan in tumour cells sensitive to and resistant to 
irinotecan107. A phase II study carried out in patients with metastatic disease, 
refractory to irinotecan showed that the combined treatment of cetuximab and 
irinotecan resulted in an increased response rate108. A further trial has 
confirmed the effective, synergistic activity of cetuximab and irinotecan, as 
cetuximab itself is markedly ineffective109. The use of anti-EGFR in adjuvant 
setting, and in combination with 5FU/leucovorin/oxaliplatin in pre-operative
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setting among patients with curative, resectable colon cancer (known as the 
FOxTROT trial) is currently under examination.
1.1.6.7.2 Angiogenesis inhibitors
Vascular endothelial growth factor has been identified to be the predominant 
angiogenic factor in human CRC and its high expression is associated with 
metastases and poor prognosis110. Bevacizumab is a humanised monoclonal 
antibody directed against vascular endothelial growth factor. Its anti-tumour 
effect has been investigated in patients with metastatic disease, in combination 
with 5-FU/LV111, irinotecan/5-FU/LV112, or FOLFOX regimen113. These trials 
demonstrated that bevacizumab, when used in combination with other 
chemotherapy improves survival in patients with metastatic CRC. Like 
cetuximab, the role of bevacizumab in adjuvant setting of curative resected 
CRC is under examination.
1.2 The link between inflammation and cancer
The link between inflammation and cancer has been explored. In fact, this 
association was first hypothesised in 1863 by the late German physician and 
pathologist, Rudolph Ludwig Carl Virchow (1821-1902), who observed the 
presence of inflammatory cells in biopsied samples from tumours, and cancers 
frequently took place at sites of chronic inflammation114. However, his 
observation was not taken in seriously until the report by Harold Dvorak in 1986, 
which noted that the tumour stroma and inflammatory structure in wound 
healing shared similarities. This prompted him to refer to tumours as ‘wounds 
that do not heal’115. Recent years of cancer research have seen the renaissance of
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Virchow’s hypothesis with mounting evidence which contributes to the 
understanding of the cellular and molecular mechanisms in cancer-related 
inflammation (CRI). While the renowned six hallmarks of cancers (self- 
sufficiency of growth signals, insensitivity to anti-growth signals, evasion of 
apoptosis, limitless replicative potential, sustained angiogenesis and the ability to 
invade tissues and metastasise) were described by Hanahan and Weinberg116 
approximately a decade ago, the bearing of CRI as the seventh hallmark of 
cancer has only been acknowledged and generated great interest recently117.
Balkwill and Mantovani have summarised the evidence from epidemiological 
and laboratory studies that links several types of cancer and inflammation (see 
review118). In colorectal, this association was apparent among patients with 
inflammatory bowel disease i.e. ulcerative colitis (UC) and Crohn’s disease, that 
they inherit approximately 2-3 folds risk than the general population of 
developing CRC119. A meta-analysis study including 116 studies by Eaden and 
colleagues120 showed that the estimated risk of CRC in patients with UC to be 
3.7% at 10 years. However, more recent studies reported the risk of CRC in 
patients with inflammatory bowel disease to be much lower than that reported by 
Eaden et al’s meta-analysis. For instance, Rutter and colleagues121 from St. 
Mark’s Hospital in the United Kingdom reported that the cumulative incidence 
of CRC in UC patients was 2.5% at 20 years, 7.6% at 30 years and 10.8% after 
40 years of disease, hi addition, a population based study in Hungary showed the 
cumulative incidence of CRC was 0.6% after 10 years, 5.4% after 20 years and 
7.5% after 30 years of chronic UC122. Furthermore, studies from Denmark and 
the Mayo clinic found no increased risk between UC and CRC when compared 
to the general population123,124. The observed change in incidence could be due
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to the result of increased colonoscopic surveillance and improved medical and 
surgical treatments among patients with inflammatory bowel disease. Despite 
this, the link between CRC and chronic inflammation in inflammatory bowel 
disease is supported by the evidence that the risk of CRC increases with higher 
degree of inflammation: early age at the diagnosis of inflammatory bowel 
disease, long duration of symptoms, and the full extent of the disease 
anatomically such as pancolitis which features severe inflammation in the whole 
of colon with high prevalent of dysplasia-carcinoma cascade125.
Perhaps, the most direct evidence linking the significance of inflammation and 
colorectal cancer comes from studies investigating cancer risk in relation to the 
long term use of non-steroidal anti-inflammatory drugs (NSAIDs). Several 
epidemiological studies have reported an inverse relationship between colorectal 
cancer risk and aspirin use126"129. Moreover, randomised clinical trials have 
shown that NSAIDs are effective in the primary prevention of CRC130,131 and 
regular use after the diagnosis of CRC is associated with lower risk of 
mortality132. This is further supported by experimental in vivo studies in a murine 
model of familial adenomatous polyposis, NSAIDs had been shown to inhibit 
tumour formation and caused regression of existing tumours by inhibiting cyclo­
oxygenases (COX-1 and -2) which are essential factors in the inflammatory 
cascade133, 134.
However, the above clinical studies did not investigate the potential hazards of 
long term aspirin in comparison with its benefits in chemo-prevention of 
colorectal cancer. Also, in the presence of alternative, effective prevention 
strategy (The UK National Bowel Cancer Screening Programme) for colorectal
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cancer, the necessity and benefits of long term use of aspirin is unknown. With 
these uncertainties, aspirin is currently not recommended for the general 
population for colorectal cancer prevention.
There are two pathways which depict CRI118, 135: the extrinsic pathway, also 
known as inflammation-induced cancer, driven by chronic inflammatory process 
such as that in inflammatory bowel disease which promotes carcinogenesis; and 
the intrinsic pathway, or cancer-induced inflammation, arises from genetic 
alterations such as oncogenes leading to tumour-mediated host inflammatory 
response in the tumour microenvironment. Either way, numerous inflammatory 
mediators which are normally expressed or released in response to cellular stress 
or damage/necrosis, known as the endogenous damage-associated molecular 
pattern molecules (DAMPs) or alarmins, have been implicated in tumour 
development and progression135.
In our Research Unit, at the Division of Surgery and Oncology, we described 
high level expression of stromal S100A8/A9 proteins and their association with 
tumoural levels of the tumour suppressor protein Smad4136, 137, In a separate 
study, the prognostic value of epithelial HSP27 protein expression in rectal 
tumours was elucidated138. Both S100A8/A9 and HSP27 proteins are 
endogenous DAMP molecules and elaborating their functions in colorectal 
cancer formed the basis of the research undertaken for my project.
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1.2.1 The endogenous damage-associated molecular pattern 
(DAMP) molecules
The noted immuno-biologist at Yale University Medical School, the late Charles 
Alderson Janeway, Jr (1943-2003) proposed that the immune system of multi­
cellular organisms protects the host from foreign infectious pathogens via 
evolved receptors of the antigen-presenting cells which recognise conserved 
products of microbial origins, also known as the pathogen-associated molecular 
patterns (PAMP) molecules and thus allow the immune system to distinguish 
infectious non-self from non-infectious self139, hi the absence of the exogenous 
PAMP molecules, robust immune responses are also elicited against several 
conditions such as tissue transplants, tumours, autoimmune diseases etc on the 
basis of detecting and protecting the host against endogenous danger, 
corresponding to the ‘danger model’ proposed by a scientist called Polly 
Matzinger in 1994140. Through pattern recognition as seen on the response to 
exogenous microbial molecules as well as a tissue-driven immune system in the 
absence of external factors, Matzinger then described the concept that antigen- 
presenting cells also respond to endogenous molecules released from cell stress, 
injury or necrosis which promote immune responses and inflammation140. 
Together, these endogenous molecules, also called alarmins, and PAMPs 
constitute the DAMPs135.
The endogenous DAMPs are intracellular proteins, DNAs, RNAs or nucleotides 
which have been classified into various categories and described in detail by 
Rock and Kono141. DAMPs include High Mobility Group Box 1, SI00 proteins, 
heat shock proteins (HSPs), uric acids and interleukins. Due to their particular
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relevance to the research described in this thesis, the tumourigenic role of 
extracellular S100A8 and S100A9 and their part in the crosstalk between tumour 
and its stromal cells is described in section 1,22 of this chapter, whilst the role of 
intracellular HSP27 in cancer is described in section 1.23 of this chapter.
1.2.2 The crosstalk between tumour and its stroma
1.2,2.1 Tumour stroma/microenvironment
More than a hundred years ago, the renowned English surgeon Stephen Paget 
proposed the ‘seed and soil’ hypothesis to explain the non-random 
dissemination patterns of certain human malignancies, and that while many 
researchers have been studying ‘the seeds’, ‘the soils’ may reveal valuable 
insights into the ‘metastatic peculiarities’ of cancers142. Recent years have seen 
the hypothesis revisited following the recognition that the microenvironment of 
a developing tumour is a crucial regulator of carcinogenesis.
The tumour microenvironment consists of three main components143: insoluble 
extracellular matrix; stroma consisting of fibroblast, adipose, vasculature and 
resident immune cells; and the conventional milieu of cytokines and growth 
factors.
In normal circumstances, the complex interplay, known as the ‘crosstalk’ 
between parenchymal cells and their microenvironments is aimed at 
maintaining balanced homeostasis in tissue function. The disruption of the 
interplay between parenchyma and their microenvironment can induce aberrant 
cell proliferation, adhesion, function and migration that might promote 
formation of malignancy144. Studies have shown that changes in stromal
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behaviour can promote epithelial transformation145, 146. Upon abnormal 
transformation, these cells may recruit and activate the vasculature and stroma 
through production and secretion of stimulatory growth factors and cytokines. 
In turn, the locally activated cellular and extracellular elements of the host 
microenvironment secrete molecules that can influence the malignant 
phenotype and modify the proliferative and invasive behaviour of the tumour 
cells through three mechanisms: increasing the genetic instability of tumour 
cells147; inducing signalling cascades in tumour cells via tumour-associated 
receptors thereby controlling gene expression in these cells; and by exerting 
selective pressures on the cells148.
The crosstalk between tumour and its microenvironment is a bi-directional 
process and involves an extremely complex cohort of molecules. The 
understanding of such complex molecular crosstalk between tumour and its 
microenvironment may lead to the development of novel therapeutic agents in 
cancer management. Some of these well-characterised processes and molecules 
are summarised below:
a) Fibroblasts produce chemoattractants such as scatter factor/hepatocyte 
growth factor, which increases tumour cell motility by binding to the 
Met receptor .
b) Tumour cells secrete angiogenesis factors such as vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor, which bind to 
receptors on stromal vascular cells, resulting in increased vascular 
permeability, endothelial proliferation, migration and invasion150.
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c) Fibroblasts and endothelial stromal cells produce enzymes including 
matrix metalloproteinases and urokinase plasminogen activator which 
bind on the surface of the carcinoma invadopodia and become 
activated, thereby degrading the extracellular matrix and clearing a 
pathway for tumour cell invasion151.
d) Extracellular matrix degradation releases growth factors such as TGF-P 
and EGF, which then bind to receptors (TGF-[3R and urokinase 
receptor) on the carcinoma cells152.
1.2.2.2 The S100 proteins
SI 00 proteins are a family of highly acidic, low molecular weight proteins that 
were originally found in large concentration in the brain153. They constitute the 
largest group of calcium binding proteins. The name ‘SlOO’ derives from the 
property of these proteins being soluble in a 100 % saturated ammonium 
sulphate solution153. More than twenty SI00 proteins have been identified to 
date. They not only display cell tissue and cell specific expression patterns, 
they are also present in extracellular space when they are thought to function 
like cytokines in regulating protein phosphorylation, calcium homeostasis, 
cytoskeletal dynamics, cell growth and differentiation, and the inflammatory 
response154.
1.2.2.2.1 The structure and expression ofSIOOAS and S100A9 proteins
S100A8 (Myeloid-related Protein-8, calgranulin A) and S100A9 (Myeloid- 
related Protein-14, calgranulin B) are cytosolic molecules characterised by two 
EF hands. When illustrated diagrammatically, the EF hand motifs contains the 
helix-loop-helix conformation, where two alpha helices are positioned nearly
34
perpendicular to each other and linked by a short loop regions that binds 
calcium ions155. The S100A8 and S100A9 proteins can exist as homodimer, or 
form heterodimers, tetramers or oligomers depending on the presence of 
calcium156,157.
S100A8/A9 are inflammatory proteins constitutively expressed in myeloid 
cells, including monocytes and neutrophils and secreted at sites of 
inflammation . It has been recognized that monocytes can be recruited from 
the blood circulation to the areas of inflammation or tumour microenvironment 
where they differentiate into macrophages159. While maturing and 
differentiating from monocytes into mature macrophages, their expression of 
S100A8 and S100A9 also change. Initially both of these proteins are expressed 
in the monocytes. As they mature, S100A8 expression diminishes leaving only 
S100A9, which is also subsequently lost as the cell matures further160. The 
differential pattern of S100A8 and S100A9 expression in macrophages has 
been shown to correlate with the severity of inflammatory process161.
7.2.2.22 The functions of S100A8/A9
The importance of the expression of S100A8 and S100A9 in myelo-monocytic 
cell differentiation is unknown but generally it has been proposed that SI00 
proteins play a specific role in cell-cycle progression, and involved in cell 
maturation, differentiation and activation162. However, a functional role of 
intracellular S100A8 and S100A9 in phagocytes was established for the 
interaction with microtubules, although binding with other cytoskeletal 
intermediate filaments has also been described163'165. S100A8/A9 binds to 
tubulin in the presence of calcium and promotes tubulin polymerisation and
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therefore stabilisation of tubulin filaments which is crucial for phagocyte 
migration163. Indeed, Yogi and colleagues163 showed that the migration of 
phagocytes and wound healing ability were diminished in S100A9-/- mice that 
lack functional S100A8/A9 complex which resulted in significantly lower 
amount of polymerised and cytosolic tubulin.
Much of the functions of S100A8/A9 have been described as extracellular 
proteins. Rammes and colleagues166 provided evidence that upon stimulation 
by inflammatory cytokines, S100A8/A9 were secreted actively by monocytes 
via an energy-dependent novel pathway following activation of protein kinase 
C. This specific process requires an intact microtubule network and is 
independent of the classical endoplasmic reticulum/Golgi route.
Upon secretion, S100A8/A9 binds with high affinity specifically to heparan 
sulphate proteoglycan167 and carboxylated N-glycans168 on enthothelial cells, 
or the receptor for advanced glycation end products (RAGE) which is 
expressed in many cell types including smooth muscle cells, monocytes, 
lymphocytes and endothelial cells. These bindings provoke the release of 
various inflammatory cytokines and adhesion molecules in orchestrating a pro- 
inflammatory and thrombogenic response. This was shown by Viemann and 
colleagues169 in experiments using human micro vascular endothelial cell lines 
and oligonucleotide microarray technology. They have also shown in in vitro 
experiments that the binding of S100A8/A9 to endothelial cells resulted in a 
loss of cell-cell contacts and an increased permeability of endothelial 
monolayer, which is a pre-requisite for leukocyte extravasation and recruitment 
of inflammatory cells from intra-vascular to extra-vascular space in
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inflammation. In addition, S100A8 and SI00A9 are potent chemokines for 
neutrophils170, and they induce neutrophil adhesion to fibrinogen by activation 
of the p2 integrin Mac-1171. These highlight the role of extracellular 
S100A8/A9 as an endogenous danger signal, which mimics endogenous toll­
like receptor ligand involved in the inflammatory activation of phagocytes in 
response to the microbial lipopolysaccharides. Beside its pro-inflammatory 
property in combating infection, S100A8/A9 has also been shown to possess 
direct anti-microbial ability in inhibiting bacterial and fungal growth in vitro 
through zinc chelation172'174.
With their roles in inflammatory process uncovered, S100A8/A9 has not only 
been perceived as a valuable biomarker of inflammatory processes, but also 
implicated in the pathogenesis of several chronic pathological inflammatory 
conditions such as rheumatoid arthritis, transplant rejection, systemic lupus
117^erythematous, vasculitis, psoriasis etc ’
1.2.2.2.3 S100A8/A9 and cancer
The cluster of SI00 genes is located at the chromosomal region of Iq21-q23, 
which is also been shown to be the common malignancy-associated regions of 
transcriptional activation frequently observed in human epithelial tumours176. 
Earlier proteomic studies using 2D-gel analysis and mass spectrometry 
revealed up-regulation of S100A8 in the pancreatic177 and S100A8 and 
S100A9 in colorectal tumours178. S100A8 and S100A9 were also found to be 
present in cystic fluid from ovarian carcinomas and serum of the corresponding 
patients, but absent in fluid or serum from patients with benign ovarian 
cysts179. Using tissue microarrays and immunohistochemistry, Cross and
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180 •colleagues reported the expression of S100A8 and S100A9 in various cancer 
types, on a very small number scales (n = 1-10 for each cancer types). Recently 
at the Division of Surgery and Oncology, University of Liverpool, in a more 
detailed analysis of protein expression profile of pancreatic tumours. Sheikh 
and colleagues undertook 2-DE analysis of laser capture microdissected 
malignant and stromal components of tumours and benign ductal elements, and 
identified high levels of S100A8 and S100A9 proteins in tumour-associated 
stroma but not in benign or malignant epithelia. Furthermore, using IHC, 
S100A8 and S100A9 expression was observed in the stroma of myeloid cells 
of pancreatic tumours. Indeed, Stulik and colleagues178 also reported that 
S100A8- and S100A9-positive cells were present in the stroma and invasive 
margin of colorectal carcinoma.
Associations between the expression of S100A8 and S100A9 and clinico- 
pathological parameters have also been reported in several cancer types (Table 
6). In particular, over-expression of S100A9 in cancer cells has been associated 
with poor tumour differentiation in lung181, breast182, liver183 and thyroid184 
adenocarcinomas. In prostate cancer, significantly higher levels of S100A9 
have been reported compared to healthy controls or patients with benign 
prostate hyperplasia185.
Cancer types Authors
Pulmonary Arai et al.,
adenocarcinoma 2001181
Breast (invasive Arai et al., 
ductal) 2008186
Findings
S100A9 immunopositivity in pulmonary cancer 
cells correlated to poor tumour differentiation (n = 
70). S100A8 expression was not examined.
S100A8 and S100A9 immunopositivity in ductal
adenocarcinoma cells showed significantly:
a) A positive correlation of immunoreactivity
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Breast (invasive 
ductal)
Hepatocellular
adenocarcinoma
Prostate
Arai et al., 
2004182
Arai et ai, 
2000183
Herman! et 
aL, 2005185
between S100A8 and S100A9.
b) The percentage of S100A9-positive tumour cells 
was higher than that of S100A8-positive tumour 
cells
c) Immunofluorescence showed S100A8 and 
S100A9 co-expressed, but S100A9 also observed in 
S100A8-negative cells.
d) Each SI00A8 and S100A9 correlated with the 
mitotic activity, HER2 overexpression, node 
metastasis, poor pT stage and overall pStage.
e) Co-expression of both proteins was associated 
with tumour differentiation, vessel invasion, node 
metastasis, poor overall pStage (n = 101).
S100A9 immunopositivity correlated significantly 
with poor tumour differentiation, especially in 
nuclear pleomorphism and mitotic activity. No 
significant differences in the number of 
myelomonocytic cells expressing S100A9 (n = 
70). S100A8 expression was not examined.
S100A9 immunopositivity correlated significantly 
with poor tumour differentiation grade (n = 70). 
No immunopositivity was observed in the normal 
hepatocytes and bile duct epithelia. S100A8 
expression was not examined.
S100A8, S100A9 and RAGE were over-expressed 
in prostatic intra-epithelial neoplasia especially in 
high-grade adenocarcinomas. Benign tissue 
showed no or weak expression of the proteins. 
There was a high degree of overlap of the 
expression of these proteins. S100A9 serum levels 
were significantly elevated in cancer patients 
compared with benign patients or healthy 
individuals (n = 75)
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S100A9 immunoreactivity correlated highly with 
undifferentiated carcinomas (n = 19). S100A8 
expression was not examined.
Strong expression of S100A8 and S100A9 in 
stromal myeloid cells (CD14+/CD68~ monocytes) 
but not cancer cells. S100A8 co-expressed with 
S100A9. The presence of S100A8- and S100A9- 
positive cells did not correlate significantly with 
clinico-pathological parameters. The
microenvironments of tumours which lacked 
Smad4 expression had significantly reduced 
numbers of S100A8-immunopositive but not 
S100A9-immunopositive cells.
Table 6: The expression of S100A8 and S100A9 in cancers and its clinical 
significance.
Using a proteomic-based approach, Mr Ilyas Khattak (an MD student) and Dr 
Taoufik Nedjadi (a Post-doctoral Research Associate) at the Division of 
Surgery and Oncology, University of Liverpool, investigated variation in the 
protein expression in primary CRC specimens of stage-matched patients. 
Proteins isolated from the stroma of twelve frozen colorectal cancer specimens 
were subjected to two-dimensional gel analysis followed by liquid- 
chromatography tandem mass spectrometry (LC-MS/MS), which resulted in 
the identification of differential expression of S100A8 protein in colorectal 
tumours (see Figure 1 of the published paper by Ang and colleagues136 
appended to this thesis). Immunohistochemistry (IHC) undertaken by Ms 
Elizabeth Tweedle (an MD student. Division of Surgery and Oncology, 
University of Liverpool) for the detection of S100A8 and its dimerisation 
partner, S100A9, revealed the expression of both S100A8 and S100A9 proteins
Thyroid
Pancreas
Ito et al., 
2005184
Sheikh et
al., 2007 137
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in cells scattered throughout the tumour stroma (see Figure 2A of Ang and 
colleagues136). Colorectal tumours generally expressed fewer S100A8-positive 
than S100A9-positive cells, and loss of Smad4 expression in primary colorectal 
tumour cells was associated with a significantly lower median count of 
S100A8-positive but not S100A9-positive stromal cells (see Figure 2C of Ang 
and colleagues136), as observed previously by Sheikh and colleagues137 in 
pancreatic cancer. Furthermore, co-localisation of S100A8 or S100A9 was 
observed in some cells with the monocyte marker CD 14 but not the 
macrophage marker CD68 (see Figure 2B of Ang and colleagues136), indicating 
that the S100A8/A9 population may be at an early stage of 
monocyte/macrophage maturation.
The degree of stromal S100A8/A9-positive infiltration showed no correlation 
with the parameters of age at surgery, gender, site of tumour, depth of tumour 
invasion or nodal metastases. However, high S100A9 cell counts were 
associated with poor differentiation grade (P — 0.036), and independently 
associated with large tumour sizes (P = 0.02) (see Supplementary Table 1 of 
Ang and colleagues136).
Neither S100A8-positive nor S100A9-positive stromal cell counts were 
associated with patient survival. Nevertheless, for the smaller cohort of patients 
exhibiting loss of Smad4 expression, high S100A8/A9 cell counts predicted poor 
3-year survival, while no survival difference was observed for either high 
S100A8 or S100A9 counts at 60 months in this Smad4-negative cohort (see 
Figure 3 of Ang and colleagues136). This suggests that Smad4-negative tumours
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have a shorter time to recurrence or metastases in the presence of high stromal 
S100A8- or S100A9-expressing monocytes.
The roles of S100A8 and S100A9 in cancer have also been examined in in 
vitro and in vivo experiments. Yui and colleagues187, 188 reported the apoptotic 
activity of S100A8/A9 on tumour cells (mouse lymphoma and human 
leukaemia cells) and fibroblasts via a zinc-dependent mechanism. Further study 
by the group showed that S100A8/A9 bind directly to mammary carcinoma 
cells which resulted in the induction of apoptosis via a specific receptor- 
dependent mechanism189. Indeed, these findings have been supported by 
Ghavami and colleagues190, who reported the apoptotic effect of S100A8/A9 
on colonic carcinoma cell lines via zinc exclusion from the target cells and an 
undefined mechanism involving specific cell receptors. More recently, 
Ghavami and colleagues191 also provided in vitro evidence that S100A8/A9 
triggered cell death via a RAGE-independent pathway but involved several 
components of the mitochondrial death pathway, including Bak, 
Smac/DIABLO and Omi/HtrA2. Therefore, it seems that the extracellular 
S100A8/A9 released from phagocytes might be involved in anti-tumour 
activity, as a host innate immune response against tumour. However, in the 
present literature, the anti-tumour role of S100A8/A9 has not been confirmed 
in in vivo studies.
On the other hand, Ghavami and colleagues192 reported tumour-promoting 
activity of S100A8/A9, in which low concentration of S100A8/A9 promoted 
cancer cell growth via RAGE signalling and Mitogen-activated protein kinase- 
dependent pathway. This is further supported by Turovskaya and colleagues193,
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who demonstrated that carboxylated glycans are expressed on a subpopulation 
of RAGE and mediate S100A8/A9 binding to RAGE, led to activation of NF- 
RB and colonic cancer cell proliferation. In the in vivo experiments, the group 
observed high infiltration of S100A8- and S100A9-expressing myeloid 
progenitor cells in the stromal regions of dysplasia and adenoma in human 
colonic tumour tissues and in a mouse model of colitis-associated 
carcinogenesis. The administration of anti-carboxylated glycan antibody 
reduces chronic inflammation and tumourigenesis, and that RAGE-deficient 
mice were resistant to the onset of colitis-associated carcinogenesis. All in all, 
their findings suggested that inflammation-associated colonic carcinogenesis 
was mediated by S100A8/A9 through complex tumour-stromal crosstalk. 
Indeed, Cheng and colleagues194 also provided in vivo evidence that tumour- 
induced up-regulation of SI00A9 in stromal myeloid progenitor cells inhibits 
dendritic cell and macrophage differentiation, resulted in the accumulation of 
myeloid-derived suppressor cells (MDSCs) and led to the suppression of anti­
tumour immune response. In addition, the MDSCs not only express receptors 
for S100A8/A9, but also synthesise and secrete these proteins which serve as 
an autocrine feedback loop that sustains accumulation of MDSCs195.
More interestingly, recent data has suggested that S100A8/A9 mediates distant 
tumour metastasis via chemokinetic mechanisms, independent of its direct 
binding to cancer cells. Hiratsuka and colleagues196 showed that cytokines such 
as TNF-a, TGF-p and VEGF were released from tumours, and these factors 
induced S100A8/A9 in a distant organ. As a chemokine with pro-inflammatory 
property, the tumour-induced S100A8/A9 in a distant organ plays a role in 
establishing inflammatory ground that forms pre-metastatic niches, which then
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facilitates immigration and metastasis of cancer cells. In a separate study by 
Hiratsuka and colleagues197, S100A8/A9 was shown to induce the expression 
of serum amyloid A3, which binds to toll-like receptor-4 and resulted in NF-kB 
signalling and facilitated metastasis.
1.2.2.3 Smad4 and cancers
Mutations in genes on chromosome 18q21 have been identified as important in 
colorectal carcinogenesis. Over 60 % of CRC show loss of heterozygosity 
(LOH) at chromosome 18q198> 199, in which DCC (Deleted in Colorectal 
Carcinoma) gene, Smad4 and Smad2 genes have been located200, 201. Several 
studies have shown that LOH at 18q21 in CRC is not just an adverse prognostic 
factor affecting postoperative survival202'204, it is also a predictive factor of poor 
outcome following adjuvant chemotherapy in stage III colon cancer205. Evidence 
from these articles is varied, but loss of heterozygosity or deletion at 18q is
OA1generally associated with a reduction in Smad4 protein expression * .
Smad (Mothers Against Decapentaplegic homologue {Drosophila}) proteins 
are a group of proteins that modulate the activity of TGF-(3 ligands. Smads 
form complexes with other Smads to serve as transcription factors in the cell 
nucleus. They are divided into three classes207:
• The receptor-regulated Smads - Smadl, Smad2, Smad3, Smad5 and 
Smad9.
• The common-mediator Smads — Smad4 which interact with receptor- 
regulated Smads in regulating signalling pathways.
• The inhibitory Smads - Smad6 and Smad7 which inhibit the receptor- 
regulated and common-mediator Smad.
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The protein product of the Smad4 gene is a tumour suppressor. It binds to 
receptor regulated Smads following TGF-P signalling and form the heteromeric 
complex. This complex migrates into the nucleus initiating gene transcription, 
which negatively regulates epithelial cell growth208. It has been reported that 
loss of Smad4 occurs in 10-15 % of overall CRC209, and 30-35 % in tumours 
with metastases210. Howe and colleagues211 and Woodford-Richens and 
colleagues212 demonstrated that germline mutation of the Smad4 gene causes 
human familial juvenile polyposis. This autosomal dominant disorder is 
characterised by a predisposition to Smad4-negative gastrointestinal polyps and 
cancer at a young age. This is further supported by Takaku and colleagues213,
214 who constructed Smad4 (+/-) knock-out mice that proceeded to develop the 
phenotype of Familial Juvenile Polyposis, including Smad4-negative 
gastrointestinal polyps.
Using immunohistochemical assays, Smad4 expression has been investigated in 
several human cancer types with correlation between Smad4 expression and 
prognosis reported in pancreatic215,216, gastric217, endometrial218, breast219 and 
oesophagus220 cancers. Although most studies found that low levels or loss of 
Smad4 expression correlated with poorer prognosis, Liu and colleagues218 
reported that Smad4 expression was not associated with tumour progression or 
clinical outcome in endometrial cancer, while Stuelten and collegues219 observed 
that patients with Smad4 negative breast cancer tended to have longer survival 
times compared to Smad4 positive cancer patients.
In CRC, Maitra and colleagues221 reported that loss of Smad4 in colonic 
adenocarcinoma correlates with the presence of advanced and metastatic
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disease, suggesting that Smad4 inactivation might be associated with the 
acquisition of a metastatic phenotype. Other studies have reported that Smad4 
loss correlated with lymph node and liver metastasis . Alazzouzi and 
colleagues examined Smad4 protein levels in 86 stage III colorectal cancer 
specimens and found that low Smad4 levels correlated with poor overall and 
disease-free survival compared to high levels. Furthermore, Alhopuro and 
colleagues reported that low Smad4 protein levels were associated with poor 
prognosis after 5-fluorouracil-based adjuvant therapy.
In the Division of Surgery and Oncology, University of Liverpool, Ms 
Elizabeth Tweedle employed a tissue microarray-based IHC assay to examine 
Smad4 expression in 303 stage I-III colorectal cancers and its relationship to 
clinico-pathological parameters. Smad4 loss was observed in 10.8 % (n = 4/37) 
of cases in Stage I, 13.5 % (n = 18/133) of Stage II, and 15.6 % (n = 20/128) of 
Stage III tumour. There were significantly higher cases of Smad4 loss in rectal 
cancer group (55 %, n = 23/42) than the colon cancer group (45 %, 19/42). 
Smad4 status was also significantly correlated with pT-stage, with 29 % of 
cases of pT4 in the Smad4-negative group compared to 11 % in the Smad4- 
positive group. There was no significant association between Smad4 
expression and patients’ age, gender, size of tumour, differentiation, resection 
margin status and pN-stage. Smad4 status was not associated with survival in 
the node-positive cancer group, but in the node-negative cancer group, patients 
with Smad4 loss had poorer survival compared to patients with preserved 
Smad4 expression (Figure 3). Subsequent multivariate Cox regression 
confirmed that loss of Smad4 expression as an independent prognostic marker 
for poor survival in patients with node-negative CRC.
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Figure 3: Disease outcome by Smad4 status in colorectal cancer (used with 
kind permission of Miss Tweedle). (A) In patients with node-positive tumours, 
no difference in survival was observed according to Smad4 status. (B) In 
patients with node-negative tumours, having Smad4 negative tumours 
conferred to poorer survival compared to Smad4 positive tumours.
The role of Smad4 inactivation in CRC malignant progression through tumour- 
stroma crosstalk has been suggested recently. Using a mouse model of colon 
cancer, Kitamura and colleagues226 reported that Smad4-negative tumours 
recruited a specific type of myeloid cell which promoted invasion through 
crosstalk with tumour cells. Indeed, several proteins have been identified to be 
differentially secreted by Smad4-deficient colon carcinoma cells which could 
be relevant for tumour-stroma interactions and carcinogenesis227.
1.2.3 The heat shock protein 27 (HSP27)
Heat shock proteins (HSPs), also known as stress proteins, are a cohort of 
highly conserved proteins. Mammalian HSPs are classified into five families
47
according to their molecular weights (kDa): HSP100, HSP90, HSP70, HSP60, 
and the small HSPs such as HSP27, HSP40> a-crystallin and HSP17228. Each 
HSP is either constitutively expressed or regulated inductively. For example, in 
normal cells, HSP70 and HSP27 are either not detectable or expressed at very 
low levels, whereas HSP90 is abundantly expressed. The expression of HSPs 
can be induced by a wide range of cellular insults, including heat shock 
(increased temperature), exposure to chemicals such as ethanol, irradiation, 
viral infection, and ischaemia-reperfussion phenomena14. Several HSPs are 
also present in the extracellular space, which could be due to the release from 
necrotic cells or secretion from cells228. Evidence has shown that secreted large 
HSPs such as HSP60 and HSP70 interact with monocytes/macrophages which 
result in various state of activation, suggesting the roles of extracellular HSPs 
in cellular response to stress and inflammation229. In contrast, extracellular 
HSP27 has been shown to inhibit the differentiation of monocytes to 
macrophages or dendritic cells, indicating an immuno-suppressive function of 
the secreted HSP27229’ 230. While the roles of intracellular HSP27 in cancer 
have been largely established and described, its extracellular function has not 
been linked to cancer.
1.2.3.1 The regulation of HSP27 expression
The expression of small HSPs is controlled at the transcriptional level by the 
activity of Heat Shock Factors (HSFs) 1-4231. Under normal, resting conditions, 
HSF1 retains its dormant state by binding to HSP70, HSP90, HSP-binding 
protein 1, or by phosphorylation of HSF-specific proline/serine motifs232, 233. 
Following stress, trimerisation of the HSF1 occurs, and the active trimers then
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translocate to the nucleus and bind to the Heat Shock Element located in a
specific promoter region of the HSP gene consisting of arrays of the 5-bp unit 
nGAAn consensus motif arranged as inverted repeats234. This induces 
concomitant expression of both large and small HSPS, which then provides a 
reciprocal negative feedback for HSF1 activity via HSP70233. The induction of 
HSPs also occurs through a HSF1-independent pathway, namely the oestrogen- 
sensitive promoter, which accounts for the observed increased expression of 
small HSPs in oestrogen-sensitive tissues and tumours (Figure 4)235-237. The 
roles of other HSFs are however less well characterised at the present time.
Following transcription of HSPs, post-translational modifications are essential 
to determine the activity of small HSPs. Small HSPs are phosphorylated at 
three different sites by mitogen activated protein kinase activated protein 
kinase 2 (MAPKAPK-2)/stress-activated protein kinase 2 (SAPK-2)/stress- 
activated kinase p38 (p-38a), MAPKAPK-5, extracellular signal regulated 
kinases (Erk), G-proteins and protein kinase C238. The phosphorylation of 
HSP27 is mainly regulated by MAPKAPK-2/SAPK-2/p-38a and MAPKAPK- 
5 pathways. The small HSPs phosphorylated through MAPKAPK-2 pathways 
play an important role in chemo-resistance and inhibiting apoptosis, whereas 
MAPKAPK-5 pathway is essential in response to pro-inflammatory 
cytokines239,240.
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Figure 4: The expression and biological activity of small HSPs are regulated 
on transcriptional and translational levels241.
1.2.3.2 The molecular structure of HSP27
The structure of HSP27, like other small HSPs, is characterised by a highly 
conserved amino acid sequence of 80-100 residues called a-cystallin domain at 
the C-terminus. These amino acid sequences form (3-sheets which are essential 
for the formation of stable dimers242. The C-terminus is flanked by a variable 
hydrophobic, less conserved region called N-terminus (WD/EPF domain) and a
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short flexible C-terminal extension243. The flexible C“terminal extension 
enhances the solubility of small HSPs.
The WD/EPF region at the N-terminus is essential for the development of high 
molecular oligomers, through aggregation of stable dimers to tetramers and 
then to unstable oligomers243. Cell physiology, the phosphorylation status of 
HSP27, and the exposure to exogenous stress all dictate HSP27 
oligomerisation. Upon phosphorylation, HSP27 multimers dissociate into small 
oligomers, which are active at conditions where other proteins are denaturing, 
so they can down-regulate chaperone activity and influence actin 
polymerisation244.
1.2.3.3 The functions of intracellular HSP27 and their roles in 
tumourigenesis
1.2.3.3.1 HSP27 as a molecular chaperone and a potent regulator of 
cytoskeletal dynamics
The intracellular accumulation of misfolded proteins can induce a stress 
response and lead to increased HSP expression245. These misfolded, damaged 
proteins can form large aggregates which trigger cellular apoptosis. HSP27 
functions as a molecular chaperone by forming complexes with such proteins 
and by doing so facilitates the repair or destruction of these proteins246. HSP27 
also stabilises F-actin microfilaments to maintain the structure of the 
cytoskeleton and prevent its disaggregation during exposures to stress247. This 
ability of HSP27 promotes cell recovery, prevents induction of apoptosis and 
hence increases cell survival rate. The molecular chaperone function of HSP27 
in apoptosis has also been shown in relation to protein kinase B (Akt). During
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cellular stress, Akt is activated through an association with HSP27 which then 
leads to apoptosis inhibition248. This HSP27-mediated Akt activation thus 
confers increased resistance to apoptosis in cells over-expressing HSP27249.
1.2.3.3.2 The roles ofHSP27 in apoptosis pathway
Studies have shown that HSP27 regulates various apoptotic pathways (Figure 
5) . HSP27 has been shown to inhibit the activation of pro-caspase-9 by
interacting with cytochrome-c251. The observation of HSP27 blocking the 
release of cytochrome-c, suggests that HSP27 may function in a similar manner 
to another endogenous anti-apoptotic protein, Bcl-2, in preventing the 
formation of apoptosome complex252. In addition, HSP 27 can also regulate 
apoptosis by inhibiting caspase-3 activity through interaction with pro-caspase- 
3 molecules.
HSP27 has also been shown to inhibit apoptosis via a cytochrome-c 
independent pathway, by interacting with Daxx, a nuclear protein that has been 
implicated as a mediator of Fas-induced apoptosis. Daxx translocates to the cell 
membrane during Fas-mediated apoptosis, binds to the Fas receptor (also 
known as death receptor) and also to Askl, thus mediating a caspase- 
independent apoptosis253. By preventing the translocation of Daxx to the 
membrane, HSP27 can hinder apoptosis independent of the cytochrome-c and 
caspase cascade.
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Figure 5: HSP27 inhibits apoptosis via several pathways2^0.
By understanding the complex roles of HSP27 in cellular homeostasis and 
apoptosis, it is not surprising that the aberrant expression of HSP27 is 
associated with tumourigenesis. Inappropriately high level of HSP27 can result 
in dysregulation of apoptotic signalling which is a common feature in cancer 
initiation, growth and progression. As such, the protective role of HSP27 to 
cellular insults may also render tumours resistant to chemotherapeutic agents.
1.2.3.4 The expression of HSP27 in human cancers and its clinical 
repercussions
The expression of HSP27 has been reported in a wide range of human cancers. 
Numerous studies have provided evidence on the expression of HSP27 in
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tumours and its repercussions in the clinical setting, particularly in cancer 
diagnosis, prognosis, prediction and treatment.
The differential expression of HSP27 has been implicated in several hormone- 
dependent malignancies such as breast, endometrial, ovarian and prostate 
cancer. In breast cancer, the immune-cytochemical staining of fine needle 
aspiration smears for HSP27 positively predicts the presence of malignancy254. 
High expression of HSP27 has also been detected in the serum of patients with 
breast cancer using two-dimensional electrophoresis (2-DE) followed by mass 
spectrometry (MS) identification255. However, very conflicting data exist about 
the relationships between HSP27 expression, metastasis and survival in breast 
carcinoma. For example, the expression of HSP27 in breast cancer is 
associated with small tumour size and low proliferative index, but its 
expression in node negative cases is linked with short disease-free survival256. 
Several studies have also shown that the expression of HSP27 in breast cancer 
has no correlation with disease-free survival or overall survival257'259. In 
ovarian carcinoma, high HSP27 expression is associated with more advanced 
tumours . HSP27 is also associated with increased hyperplastic 
endometrium261, positively correlated with oestrogen receptor262, and 
overexpressed in some endometrial malignancy236. In prostate cancer, Storm 
and colleagues263 reported that HSP27 is absent in the normal and malignant 
tissues. However, Conford and colleagues264 found that the early in-situ 
neoplastic transformation of normal prostatic epithelium is associated with loss 
of HSP27 expression, and that in advanced cancers, HSP27 expression is 
associated with poor clinical outcome.
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The clinical implication of HSP27 expression has also been reported in other 
cancer types. In osteosarcoma265 and gastric266,267 cancer, HSP27 expression is 
associated with poor overall survival. In leukaemia268, oral269, renal270 and 
bladder”6' cancers, HSP27 expression has no correlation with disease-free 
survival or overall survival. Interestingly, lower expression of HSP27 is 
associated with poor survival in squamous cell oesophageal carcinoma271 and 
high expression of HSP27 is correlated with better prognosis272.
Several studies have also explored the use of HSP27 expression to predict the 
response of cancer patients to specific treatments (Table 7). Given the cyto- 
protective role of HSP27 in apoptosis, it is not surprising that the role of 
HSP27 in chemoresistance has been largely studied and relationship to 
outcome determined in many cancer types. For cancers such as ovarian260, 
oesophageal273, prostate274 and pancreas275 carcinomas, high levels of HSP27 
are associated with chemo or radio-resistance and poor prognosis. These 
studies provide proof-of-principle that HSP27 can potentially be used to tailor 
the treatment strategy for individual cancer patients. However, findings remain 
inconclusive in breast cancer, with high HSP27 linked to poor response to 
chemo- and endocrine therapy in a study276, with no association with therapy 
detected in others257,277.
Cancer types Study n Findings
Breast Seymour et al,
1990276.
51 HSP27 expression correlated with better
response to chemotherapy and tamoxifen
for Oestrogen Receptor+ tumours.
Damstrup et 
al, 1992257.
119 Did not predict response to endocrine
therapy.
Ciocca et al, 205 Did not predict response to tamoxifen.
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199 8277.
Ovarian Langdon et ai,
1995260.
Oesophageal Takeno et ai, 
2001273.
Rectal Rau et ai,
I999278
Prostate Bubendorf et
ai, 1999274.
Pancreas Mori-Iwamoto
et ai, 2007275.
72 High expression correlated with resistant to 
chemotherapy.
34 HSP27 predicted the therapeutic effect of
combined radiotherapy and chemotherapy in 
T4 oesophageal squamous cell carcinoma.
23 Differential HSP27 expression did not
correlate with the level of clinical response 
in patients treated with pre-operative 
chemotherapy, radiotherapy or
hyperthermia for locally advanced rectal 
cancer.
264 Overexpression of HSP27 correlated with
31 % of hormone refractory tumours, 5 % 
of primary tumours and 0 % in benign 
prostate specimens.
11 Increased HSP27 expression in tumour
specimens was related to higher resistibility 
to gemcitabine in patients of pancreatic 
cancer.
Colorectal C\\o\ etai, 
2007279.
20 HSP27 expression levels of tumour 
specimens from irinotecan-non-responding 
patients were significantly higher compared 
to those of irinotecan-responding patients.
Table 7: The predictive implications of HSP27 in various cancer types.
The association of HSP27 in several cancer types and clinical correlations has 
generated an exciting new avenue in the field of cancer treatment via two main 
strategies: pharmacological modifications of HSP expression or molecular 
chaperone activity, and the use of HSP as adjuvant to present tumour antigens 
to the immune system" . At present, the study of cancer treatment by targeting
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HSP27 is still in its infancy at the molecular level in cell lines and animal 
experiments, utilising short interfering RNA (siRNA) or antisense 
oligonucleotide (ASO) to suppress protein expression. Several such studies 
have been reported with promising outcomes (Table 8).
Authors
Rocchi et al., 
2004281.
Yang et al., 
2008282.
Kamada et al., 
2007283. 
Rocchi et al, 
2005284.
Rocchi et al, 
2006285.
Zhang et al, 
2007286.
Zoubeidi et al, 
2007287.
Hadaschik et al, 
2008288.
Findings
Antisense oligonucleotide (ASO)-induced silencing of HSP27 
in a prostate cancer cell line enhanced apoptosis and delayed 
tumour progression.
The suppression of HSP27 expression by HSP27 ASOs 
enhanced vincristine and adriamycin chemosensitivity in a 
human gastric cancer cell line.
HSP27 ASO inhibited bladder tumour growth and enhanced 
paclitaxel sensitivity in mice.
HSP27 ASO treatment in athymic mice bearing prostate 
tumours significantly delayed tumour growth after castration, 
decreasing mean tumour volume and serum prostate-specific 
antigen levels by 57 % and 69 % respectively.
Silencing of HSP27 in prostate cancer cells by siRNA increased 
apoptotic rates 2.4-4 fold and caused 40-76 % inhibition of cell 
growth in prostate cancer cells.
Knockdown of HSP27 resulted in an increase of the apoptotic 
fraction from ~22 % to 31 % in the cervical cancer cells exposed 
to cisplatin chemotherapy.
Knockdown of HSP27 using the antisense drug OGX-427 
increased prostate cancer cell apoptotic rates.
Intravesical OGX-427 (HSP27 ASO) instillation therapy 
targeting HSP27 showed promising anti-tumour activity and 
minimal toxicity in an orthotopic mouse model of high-grade 
bladder cancer. These findings provide pre-clinical proof-of- 
principle for the use of ASO as an intravesical agent for non­
muscle-invasive bladder cancer.
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Mori-Iwamoto et 
ai, 2007275.
Choi et ai, 
2007279.
Aloy et ai, 
2008289.
Garrido et ai, 
1996290.
Knocked down HSP27 in a gemcitabine-resistant pancreatic 
cancer cell line resulted in restoration of gemcitabine 
sensitivity.
Inhibition of HSP27 expression in several human colorectal 
cancer cell lines using an ASO increased irinotecan sensitivity 
in cancer cells.
HSP27 protects against gamma irradiation-induced apoptosis in 
several cancer cell lines. Inhibition of HSP27 expression 
radiosensitised these radioresistant cells, suggesting that 
targeting HSP27 offers a potential adjuvant to radiation-based 
therapy of resistant tumours.
Colonic cancer cells were stably transfected with HSP27 anti- 
sense or sense. Cells over-expressed HSP27 showed increased 
resistance to doxorubicin as compared to increased sensitivity 
to doxorubicin among cells under-expressed HSP27. The 
sensitivity of the different transfected cells to 5-FU was no 
difference.
Table 8: Targeting HSP27 in cancer treatment {in vitro and in vivo studies).
The evidence of clinical implications of HSP27 in colorectal cancer is 
relatively sparse in the present literature. Rau and colleagues278 reported that in 
patients with locally advanced rectal cancer, HSP27 was detectable in most 
tumours and surrounding tissues before and after neo-adjuvant treatment. 
However, the differential HSP27 expression did not correlate to the level of 
clinical response in patients treated with pre-operative chemotherapy, 
radiotherapy or hyperthermia. This study involved only 23 patients. In 
addition, Choi and colleagues279 examined the expression of HSP27 in the 
surgically resected primary colorectal tumours from 20 patients using 
immunohistochemistry. The level of HSP27 expression was then correlated to
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patients’ clinical response to adjuvant irinotecan therapy. The group found that 
among patients who did not response to irinotecan, the level of HSP27 
expression in the tumours was significantly higher compared to those of 
irinotecan-responder, suggesting that HSP27 is involved in the irinotecan 
resistance of CRC. The group also reported that HSP27 inhibition using ASO 
increased the irinotecan sensitivity of colorectal cancer cells.
Using a proteomic approach similar to that described above (section 1.2.2.23, 
page 37) for the identification of differential expression of S100A8 in the 
stroma of colorectal tumours, Mr Ilyas Khattak and Dr Taoufik Nedjadi 
identified differential expression of HSP27 protein in colorectal tumours (see 
Figure 1 of the published paper, Tweedle EM, Khattak I, Ang CW and 
colleagues138 appended to this thesis).
To validate the proteomic findings and to establish the cellular basis for the 
variability of HSP27, immunohistochemistry (IHC), for the detection of HSP27 
in 404 formalin-fixed colorectal adenocarcinomas was undertaken by Ms 
Elizabeth Tweedle. While the variability in HSP27 expression was not altered by 
pre-operative administration of radiotherapy and largely no association with 
patient clinico-pathological parameters was observed, high HSP27 expression 
was associated with incomplete resection margins in rectal cancer patients. More 
importantly, high HSP27 expression was strongly correlated with poor cancer- 
specific survival in rectal cancer but not colonic cancer (see Figure 3 of Tweedle 
and colleagues138). Further multivariate statistical analyses showed that high 
HSP27 expression was an independent predictor of survival in rectal cancer 
patients.
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CHAPTER 2: 
AIMS & OBJECTIVES
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As described in the Introduction, in my project I undertook analysis of aspects of 
S100A8/A9 and HSP27 in colorectal cancer. The Aims and Objectives of these 
distinct pieces of research are set out separately below in sections 2.1 and 2.2 
respectively.
2.1 The roles of S100A8 and S100A9 and their 
relationship to tumoural Smad4 in carcinogenesis.
The expression of S100A8 and S100A9 proteins has been reported in several 
cancer types and the proteins have been implicated in carcinogenesis via 
crosstalking with cancer cells. Recent work in the Division of Surgery and 
Oncology, University of Liverpool has shown that S100A8 and S100A9 were 
localised to colorectal tumour-associated inflammatory cells and that the 
microenvironment of Smad4-negative colorectal tumours had significantly 
reduced numbers of S100A8-expressing cells compared to the 
microenvironments of Smad4-positive tumours. We therefore wondered 
whether the expression of Smad4 in cancer cells affected their response to 
exogenous S100A8 and S100A9. The aims and objectives of this research 
were:
Aim 2.1.1: To examine the effects of S100A8 and S100A9 on colorectal 
cancer cell motility and proliferation.
Aim 2.1.2: To determine if depleting Smad4 in colorectal cancer cells would 
influence the impact of S100A8 and S100A9 on cell motility and proliferation.
Aim 2.1.3: To determine the relationship between S100A8 and S100A9 
intracellular signalling in relation to Smad4 and the RAGE receptor.
61
Objective 2.1.1: To generate recombinant S100A8 and S100A9 proteins.
Objective 2.1.2: To carry out motility (modified Boyden Chamber) and 
proliferation (MTS) assays in order to determine cell motility and proliferation 
in the presence of exogenous recombinant S100A8 and S100A9 proteins.
Objective 2.1.3: To characterise the expression of Smad4 in colorectal cancer 
cell lines and to deplete (knockdown) Smad4 in these cells.
Objective 2.1.4: To carry out motility and proliferation assays on Smad4 
depleted cells in the presence of S100A8 and S100A9 proteins.
Objective 2.1.5: To characterise the effect of exogenous S100A8 and S100A9 
on the cellular expression of phospho-Smad2, phospho-Smad3 and phospho- 
Smad 1/5/8 in the presence/absence of anti-RAGE receptor antibody using 
Western blotting and cyto-immunofluorescence.
The outcome of these experiments could help to determine some of the 
potential functional consequences of high levels of S100A8 and S100 A9 in the 
microenvironment of CRC tumours and unravel the relationship between 
S100A8, S100A9 and Smad4 in CRC.
2.2 The clinical relevance of tumoural HSP27 expression 
as a predictive marker of response to adjuvant therapy 
in colorectal cancer
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The current literature suggests that HSP27 overexpression correlates with poor 
clinical prognosis in several cancer types and that HSP27 depletion in cancer 
cells increases chemotherapy efficacy in vitro. Recent work in the Division of 
Surgery and Oncology, University of Liverpool indicated that HSP27 
overexpression correlated with poor survival in patients with rectal but not 
colonic cancer. However, a comprehensive analysis of the effects of HSP27 
levels on treatment response in these patients was lacking.
It has been reported in the literature that HSP27 depletion in colonic cell lines 
enhanced cell sensitivity to irinotecan and doxorubicin. To our knowledge, 
nothing is known about the effects of HSP27 levels on the response of rectal 
cancer cells to treatment. The aims and objectives of this research were:
Aim 2.2.1: To examine if HSP27 expression was predictive of response to 
neoadjuvant/adjuvant therapy in CRC patients.
Aim 2.2.2: To examine colorectal cancer cell behaviour upon HSP27 
depletion, with a particular focus on rectal cancer cells, which have received 
little attention in the past.
Aim 2.2.3: To determine if depleting HSP27 expression would increase the 
effectiveness of chemotherapy and radiotherapy in killing or slowing the 
growth of colorectal cancer cells.
Objective 2.2.1: To obtain, for a cohort of 404 CRC patients for which a large 
database of clinico-pathological data and HSP27 expression already existed, 1. 
Detailed neoadjuvant and adjuvant therapy data from the Clatterbridge Centre
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for Oncology, Wirral, UK and 2. Verified causes of death from the North West 
Cancer Intelligence Service, Liverpool, UK.
Objective 2,2.2: To use the information obtained in Objective 2.1.1 to 
determine whether HSP27 expression was predictive of response to 
neoadjuvant/adjuvant therapy in CRC patients.
Objective 2.2.3: To characterise the expression of HSP27 in colon and rectal 
cancer cell lines and to deplete these levels by siRNA-mediated knockdown.
Objective 2.2.4: To determine the IC50 of three chemotherapeutic agents: 5- 
fluorouracil, oxaliplatin and irinotecan and radiotherapy for each cell line, 
including rectal cell lines where no published data were available.
Objective 2.2.5: To carry out apoptosis assays following incubation of HSP27 
depleted cells with chemotherapeutic agents or exposure to radiotherapy.
Objective 2.2.6: To examine cell cycle profiles, cell motility (modified Boyden 
Chamber) and proliferation (MTS assay) on control and HSP27-depleted cells.
The outcomes of analyses on the large cohort of CRC patients could lead to a 
greater understanding on the predictive role of HSP27 in response to adjuvant 
treatment. The in vitro experiments would inform whether targeting HSP27 in 
colon and rectal cancer cells could enhance the efficacy of chemo/radiotherapy. 
This would have a major impact on new cancer drug development and future 
direction in neo-adjuvant/adjuvant therapy of colorectal cancer.
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CHAPTERS:
MATERIALS & METHODS
3.1 Materials
The reagents used in this study are summarised in Table 9 below.
Materials Company Product code
Acrylamide-bis ready-to-use solution 30% 
for electrophoresis
VWR international, 
Lutterworth, Leics, UK
1.00639.1000
Ammonium persulfate Sigma Aldrich, Gillingham, 
Dorset, UK
A3678
Ampicillin sodium salt Sigma Aldrich, Gillingham, 
Dorset, UK
A9518
Annexin V-FITC Apoptosis Detection Kit Abeam, Cambridge, UK ab14085
Aqua-resist 100 ml VWR international, 
Lutterworth, Leics, UK
462-7000
Bacto™ Tryptone, Enzymatic digest of 
casein
BD, Oxford, UK 211705
Bacto™ Yeast Extract BD, Oxford, UK 212750
bisBenzimide H (Hoechst stain) Sigma Aldrich, Gillingham, 
Dorset, UK
B2883
Blotting paper Whatman GB004 VWR international, 
Lutterworth, Leics, UK
732-4234
BCA Protein Assay Kit ThermoFisher Scientific, 
Surrey, UK
23225
BD cell insert with 8.0 micron membrane for 
24 well plate
Scientific Laboratory 
Supplies, Nottingham, UK
353097
P-Mercaptoethano 1 Sigma Aldrich, Gillingham, 
Dorset, UK
M6250
Bovine serum albumin solution Sigma Aldrich, Gillingham, 
Dorset, UK
A7284
Bromophenol Blue Sigma Aldrich, Gillingham, 
Dorset, UK
B0126
Centrifuge Tube 15mL, Conical, Loose,
Sterile
Star Labs, Milton Keynes, 
UK
E1415-0200
Centrifuge Tube 50mL, Conical, Loose,
Sterile
Star Labs, Milton Keynes, 
UK
El 450-0200
Citric acid monohydrate Sigma Aldrich, Gillingham, 
Dorset, UK
C7129
Coomassie Blue Sigma Aldrich, Gillingham, 
Dorset, UK
C4351
Cuvet Semi Micro PS 1 * 100 items) VWR international, 
Lutterworth, Leics, UK
634-2501
Dimethyl sulfoxide (DMSO) Sigma Aldrich, Gillingham, 
Dorset, UK
D5879
DL-Dithiothreitol Sigma Aldrich, Gillingham, 
Dorset, UK
D9779
DPX mountant for microscopy VWR international, 
Lutterworth, Leics, UK
360292F
Dulbecco's Modified Eagle’s Medium PAA, Pasching, Austria E15-810
Eight-Well Culture Slide VWR international, 
Lutterworth, Leics, UK
734-0089
EZ4U - Non-radioactive cell proliferation 
and cytotoxicity assay
Biomedica, Vienna, Austria B1-5000
Foetal Bovine Serum Gold PAA, Pasching, Austria A15-151
Geneticin (G418) Sulphate GIBCO, Paisley, UK 345812
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Glycerin Sigma Aldrich, Gillingham, 
Dorset, UK
G2289
Glycerol BDH Laboratory Supplies, 
Dorset, UK
101184K
Glycine ThermoFisher Scientific, 
Surrey, UK
BP381-5
Goat anti-human RAGE antibody R&D Systems, Abingdon, 
UK
AF1145
Goat anti mouse immunoglobulins HRP Dako, Ely, Cambridgeshire, 
UK
P0447
Goat anti-rabbit IgG antibody (fluorescein 
isothiocyanate-conjugated)
Jackson ImmunoResearch 
Laboratories Inc., PA, USA
GT26001-1000
Goat anti rabbit immunoglobulins HRP Dako, Ely, Cambridgeshire, 
UK
P0448
Goat serum Sigma Aldrich, Gillingham, 
Dorset, UK
G9023
Glutathione, reduced VWR international, 
Lutterworth, Leics, UK
1.04090.0005
Glutathione Sepharose GE Healthcare, Amersham, 
Bucks, UK
17-0756-01
Hanks' balanced salt solution Sigma Aldrich, Gillingham, 
Dorset, UK
H6648
HEPES Sigma Aldrich, Gillingham, 
Dorset, UK
H3375
Human HSP27-targetting SiRNAl 
siGENOME
Dharmacon Inc., Chicago,
US
D-005269-03
Human HSP27-targetting SiRNA2 
siGENOME
Dhannacon Inc., Chicago,
US
D-005269-05
Human insulin solution Sigma Aldrich, Gillingham, 
Dorset, UK
19278
Human non-targeting siRNA control 1 Dharmacon Inc., Chicago,
US
BOYMA-000021
Human non-targeting siRNA contro!2 Dharmacon Inc., Chicago,
US
D-001210-0X
Human Smad4-targetting siRNA 1 siGenome Dhannacon Inc., Chicago,
US
D-003902-05
Human Smad4-targetting siRNA2 siGenome Dharmacon Inc., Chicago,
US
D-003902-06
HRT-18 European Collection of
Cell Cultures (ECACC), 
Salisbury, UK
86040306
Hydrochloric acid Sigma Aldrich, Gillingham, 
Dorset, UK
H0636
Irinotecan Sigma Aldrich, Gillingham, 
Dorset, UK
11406
lsopropyl-P-D-thiogalactopyranoside (1PTG) Calbiochem, Darmstadt, 
Germany
420291
L-15 Medium (Leibovitz) Sigma Aldrich, Gillingham, 
Dorset, UK
L5520
Lipofectamine 2000 Invitrogen, Renfrew, UK 11668-019
Microcentrifuge tubes, safe-lock 0.5ml VWR international, 
Lutterworth, Leics, UK
211-2140
Microcentriftige tubes, safe lock. 2.0 ml VWR international, 
Lutterworth, Leics, UK
211-2120
Mouse anti-P-Actin antibody Sigma Aldrich, Gillingham, 
Dorset, UK
A5441
Mouse anti-human HSP27 antibody Santa Cruz, Heidelberg, scl3132
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Germany
Mouse anti-human SMAD4 antibody Santa Cruz, Heidelberg, sc7966
Germany
Mouse anti-RAGE antibody Santa Cruz, Heidelberg, sc80652
Germany
Mowiol VWR international, 475904-100
Lutterworth, Leics, UK
Mycoplasma testing control (Positive and 
negative) slides
Bionique Testing M-600
Laboratories, NY, USA
N,N,N',N'-Tetramethylethylenediamine
(TEMED)
Sigma Aldrich, Gillingham, T7024
Dorset, UK
Nitrocellulose membrane Hybond ECL 
30cm*3m
GE Healthcare, Amersham, RPN303D
Bucks, UK
Non-fat dry milk, Blotting-Grade Blocker
OPTIMEM^ I Reduced Serum Medium
Biorad, Hertfordshire, UK 170-6404
GIBCO, Paisley, UK 31985-047
(IX), liquid - with L-Glutamine
Oxaliplatin Sigma Aldrich, Gillingham, 09512
Dorset, UK
PageRuler Prestained Protein Ladder Fermentas, York, UK #SM0671
Paraformaldehyde BDH Laboratory Supplies, 28794.295
Dorset, UK
Phosphatase Inhibitor Cocktail Tablets 
supplied in EASYpacks
Roche Applied Sciences, 04906845001
Burgess Hillf UK
Phosphate Buffered Saline tablets 
(Dulbecco 'A’ - 50 Tablets)
Oxoid, Hampshire, UK BR0014G
Poly-Prep Chromatography Columns Biorad, Herdfordshire, UK 731-1550
Protease Inhibitor cocktail tablets Roche Applied Sciences, 11836170001
Burgess Hill, UK
Quick-Diff Stain kit IBG IMMUCOR, West 102164
Sussex, UK
Rabbit polyclonal anti-GAPDH (FL-335) 
Antibody
Santa Cruz, Heidelberg, Sc-25778
Germany
Rabbit anti-phospho-Smad 1 /Smad5/Smad8 
antibody
Cell Signalling 9511
Technology,
Massachusetts, USA
Rabbit anti-phospho-Smad2 antibody Cell Signalling 3108
Technology,
Massachusetts, USA
Rabbit anti-phospho-Smad3 antibody Cell Signalling 9520
Technology,
Massachusetts, USA
Rabbit anti-phospho-Smad2/Smad3 antibody Cell Signalling 9510
Technology,
Massachusetts, USA
Rhodamine phalloidin Invitrogen, Renfrew, UK R415
Ribonuclease A from bovine pancreas. Sigma Aldrich, Gillingham, R5250
Dorset, UK
RNAse free water Dharmacon Inc., Chicago, B-003000-WB-045
US
RNase inhibitor Promega, Southampton, N2511
UK
kPMI-1640 Medium PAA, Pasching, Austria E15-840
Sodium chloride Sigma Aldrich, Gillingham, S7653
Dorset, UK
Sodium dodecyl sulfate
SigmaUltra
Sigma Aldrich, Gillingham, L6026
Dorset, UK
Sodium Hydroxide Sigma Aldrich, Gillingham, S8045
-
Dorset, UK
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Sodium phosphate dibasic Sigma Aldrich, Gillingham, 
Dorset, UK
S7907
Staurosporine Sigma Aldrich, Gillingham, 
Dorset, UK
S4400
SW 837, Human Caucasian rectum 
adenocarcinoma
European Collection of
Cell Cultures (ECACC), 
Salisbury, UK
91031104
T25 cell culture flask Nunc, NY, USA 156367
T75 cell culture flask Nunc, NY, USA 156499
TGF-p PeproTech EC Ltd,
London, UK
100-21C
Tris (hydroxymethyl)methylamine BDH Laboratory Supplies, 
Dorset, UK
443866G
Triton® X-100 Sigma Aldrich, Gillingham, 
Dorset, UK
T8532
Trypsin-EDTA solution Sigma Aldrich, Gillingham, 
Dorset, UK
T3924
TWEEN® 20 Sigma Aldrich, Gillingham, 
Dorset, UK
P1379
Western Lighting Chemiluminescence 
Reagent Plus
PerkinElmer Life Sciences, 
Inc, Cambridge, UK
NEL105001EA
X-Ray Kodak Film 18x24 cm ThermoFisher Scientific, 
Surrey, UK
AUT-300-040D
Table 9: Materials.
3.2 Methods
3.2.1 Cell lines and cell culture
Four colonic (SW480, HCT116, SWK3 and SWD20), two rectal (HRT18 and 
SW837) and one pancreatic cancer cell line, PANC1 (used as a control, since the 
research group in which I worked had much relevant data with this cell line) 
were initially cultured and maintained as outline in Table 10. The SW480, 
HCT116 and PANC1 cell lines were from the liquid nitrogen storage of the 
Division of Surgery and Oncology, School of Cancer Studies, University of 
Liverpool. The SW837 and HRT18 were purchased from the European 
Collection of Cell Cultures. The SWK3 and SWD20 were kind gifts from Dr 
Irmgard Schwarte-Waldhoff (University of Bochum, Germany), and were
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0Q1described previously ’ . Briefly, they are neomycin resistant clonal
derivatives of a Smad4-deficient SW480 cells, stably re-expressing Smad4 
(SWD20) and a negative control transfectant (SWK3), and were maintained in 
medium containing geneticin (0.2 mg/mL). All these cell lines display adherent 
growth and an epithelial morphology. They were last authenticated by Mr Robert 
Ferguson (laboratory technician of the Division of Surgery and Oncology, 
University of Liverpool) in October 2009 using short tandem repeat profiling 
against the international reference standard for cell lines.
All cell culturing media were supplemented with 10 % Foetal Bovine Serum 
(FBS), L-glutamine 5 ml (2 nM), and penicillin-streptomycin solution 5 mL. All 
media, phosphate buffered saline and trypsin were warmed to 37 (>C in a 
waterbath prior to use.
Culturing of cells was undertaken using aseptic technique in a Class II laminar 
flow tissue culture cabinet. Cells were cultured as monolayer at 37 °C with 5 % 
CO2 except for SW837 cells, which were maintained in a C02-free incubator. 
Cells were routinely maintained in 75 cm2 tissue culture flasks and sub-cultured 
every 3-4 days, when confluency reached approximately 80-90 %.
For subculturing, culture medium was removed and cells were washed with 10 
mL sterile Dulbecco Phosphate Buffered Saline (PBS) to remove any residual 
medium. 2 mL of Trypsin-EDTA solution (0.5 g porcine trypsin and 0.2 g 
EDTA in Hanks’ Balanced Salt Solution with Phenol Red) were added to cover 
the cells and then incubated at 37 °C for several minutes until the cells detached 
from the flask base. The trypsin was then neutralised with 8 mL of culture 
medium. Cells were repeatedly aspirated and released from a sterile pipette to
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produce a single cell suspension, and then re-plated at the ratios shown in Table 
10. Fresh culture medium was then added to the flasks to a total of 20 mL.
C ell line Organ
source
Tumour
Stage
Disease Culture medium Splitting
ratio
SW480 (and
subclones SWD20
and SWK3)
Colon Stage II Adenocarcinoma Dulbecco Modified
Eagle’s Medium
1:10
SW837 Rectum Stage IV Adenocarcinoma L-15 Leibovitz’s
medium
1:5
HCT116 Colon Stage III Adenocarcinoma Dulbecco Modified
Eagle’s Medium
1:10
HRT18 Rectum Stage III Adenocarcinoma RPMI-1640 medium 1:10
PANC1 Pancreas Adenocarcinoma RPMI-1640 medium 1:10
Table 10: Cell lines used in the experiments.
3.2.2 Cell freezing and thawing
Cell freezing media 55 % of serum free medium, 25 % of Foetal Bovine 
Serum, 20 % of DMSO
Box 1: Reagents used in cell freezing for storage in liquid nitrogen.
For cell freezing, cells were harvested following trypsinisation as described 
above and subjected to centrifugation at 1300 rpm for 8 minutes. The pellet was 
then resuspended in 250 pL of freezing medium (Box 1) diluted with 750 pL of 
normal medium, and aliquoted into sterile cryo-vials. The vials were kept on ice 
for 1 hour, followed by storage at -80 °C for 48 hours before transferring to 
liquid nitrogen.
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For cell thawing from liquid nitrogen storage, cells were thawed at 37 °C and 
immediately transferred into a 15 mL tube containing pre-warmed PBS. 
Following centrifugation at 1300 rpm for 8 minutes, this washing step was 
repeated once more before transferring cells to culture medium.
3.2.3 Mycoplasma detection using DNA staining
Citrate-Phosphate working Solution I: 28.39 g of dibasic sodium phosphate
buffer dissolved in 1 L of distilled water.
Solution 11: 10.51 gof citric acid monohydrate and 14.2
g of dibasic sodium phosphate dissolved in 1 L of
distilled water.
Small amount of Solution I added to 1 L of Solution II
until a pH of 5.5, autoclaved and stored at 4 °C.
Glycerin mounting medium Equal volume of glycerin was mixed with citrate- 
phosphate working buffer, filtered and stored at 4 °C.
Stock DNA stain 5 mg of bisBenzimide H (Hoechst stain) added to 100
mL of Hanks' balanced salt solution, mixed for 30
minutes while protected from light, filtered and stored
at 4 °C.
Working DNA stain 0.3 mL of stock DNA stain made up to 100 mL with
citrate-phosphate working buffer protected from light.
Carnoy’s Fixative 3 parts methanol: 1 part acetic acid.
Box 2: Reagents used in the experiment for mycoplasma detection.
Using a 24-well plate and 1cm diameter glass slide/well, 5 x 104 cells/mL 
(duplicate) were plated, incubated overnight with ImL/well of antibiotic-free cell 
culture media in each well.
The following day, cell culture media were discarded, and 1 mL of Camoys’ 
fixative (Box 2) was added and incubated for 5 minutes. Then, the fixative was
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discarded; another 1 mL fixative was added and incubated for 10 minutes. The
glass slide was then left to air dry for at least an hour.
The air-dried slides, along with the prefixed control (positive and negative 
control) slides were immersed into a staining chamber containing enough 
working DNA stain (Box 2) to fully cover the slide. This was incubated at room 
temperature in the dark for 30 minutes.
Then, the staining solution was discarded, the slides were rinsed with distilled 
water twice, and mounted on a microscopic slide with drops of glycerine 
mounting medium (Box 2). This was then covered with a large cover glass, and 
viewed under a fluorescent microscope (Figure 6).
Positive controls:
The presence of mycoplasma DNA fluorochrome staining in the cytoplasm confirms mycoplasma 
infected cells.
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Negative controls:
The absence of mycoplasma DNA fluorochrome staining in the cytoplasm confirms mycoplasma- 
free cells.
SW480 - mycoplasma-free cells
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SWD20 - mycoplasma-free cells
SWK3 - mycoplasma free-cells
SW837 - mycoplasma free-cells
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HRT18 - mycoplasma free-cells
HCT116 - mycoplasma free-cells
PANC1 - mycoplasma free-cells
Figure 6: Mycoplasma screening on cell lines used in this study.
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3.2.4 Western blotting
3.2.4.1 Cell lysate preparation
SDS ceil lysis buffer 7 mL of distilled water, 2 mL of 10 % SDS solution, 1
mL of 1 M Tris pH 6.8, 1 tablet of protease inhibitor 
cocktail, ± 1 tablet of phosphatase inhibitor cocktail 
tablet (for probing phopho- proteins).
Box 3: Reagents used in cell lysis.
Cells were washed twice with PBS and centrifuged at 1300 rpm for 8 minutes to 
obtain a pellet. 100-300 pL of SDS cell lysis buffer (Box 3) was then added to 
the pellet, and then sonicated. Samples were then spun at centrifuge at 10,000 ref 
at 4 °C for 10 minutes, with the consequent supernatant kept for western blotting 
and the pellet discarded.
3.2.4.2 Bicinchoninic acid (BCA) protein assay to measure cell lysate protein 
concentration
BCAim Protein Assay kit was used to measure cell lysate protein concentration. 
This protein assay is a detergent-compatible formulation based on BCA for the 
colorimetric detection and quantification of total protein. The method combines 
the well-known reduction of Cu2+ to Cul+ by protein in an alkaline medium (the 
biuret reaction) with the highly sensitive and selective colorimetric detection of 
the cuprous action (Cu2+) using a unique reagent containing BCA. This water 
soluble complex exhibits a strong absorbance at 562 nm that is nearly linear with 
increasing protein concentrations over a broad working range (25-2,000 pg/mL).
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To prepare diluted albumin standards, the content of one albumin standard 
ampoule at 2000 pg/mL (provided in the assay kit) was diluted serially using 
SDS cell lysis buffer to produce a set of diluted standards (Table 11). Working 
reagent was prepared by mixing 50 parts of BCA1M Reagent A with 1 part of 
Reagent B. 50 pL of each sample usually diluted (1:5-1:100) and standards A-I 
were added to each cuvette, followed by 1 mL of working reagent. This mixture 
was then covered and incubated for 2 hours at room temperature. The standards 
were read on the spectrophotometer using the BCA function. Following 
standardisation, the samples were then read to determine the protein 
concentration of each sample.
Vial Volume of
diluents (pL)
Volume of albumin solution Final albumin
concentration (pg/mL)
A 0 300 pL of albumin ampoule 2000
B 125 375 pL of albumin ampoule 1500
C 325 325 pL of albumin ampoule 1000
D 175 175 pL of Vial B 750
E 325 325 pL of Vial C 500
F 325 325 pL of Vial E 250
G 325 325 pL of Vial F 125
H 400 100 pL of Vial G 25
I 400 OpL 0
Table 11: Dilution of Albumin Standard to make up standards for BSA protein 
assay.
78
3.1.4.3 Tris-Glycine SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
10 x Tris-Buffered Saline 24.2 g Tris, 80 g NaCl, made up to 1 L and pH to 7.6 with
(TBS) hydrochloric acid.
Sample loading buffer 2 % of SDS, 10 % of glycerol, 60 mM of Tris-hydrocholoric
acid (PH 6.8), 0.001 % of Bromophenol blue, 200 mM DL-
Dithiothreitol.
5 % blocking milk
solution
5 g of non-fat dry milk powder, made up to 100 mL with TBS
Tween.
15 % Tris-glycine SDS-
Polyacrylamide gel
To cast one gel (5 mL):
1.1 mL distilled water, 2.5 mL 30 % acrylamide mix, 1.3 mL 1.5
M Tris (pH 8.8), 0.05 mL 10 % SDS, 0.05 mL 10 % ammonium
persulfate, 0.002 mL A^jY^-Tetramethylethylenediamine.
12 % Tris-glycine SDS-
Polyacrylamide gel
To cast one gel (5 mL):
1.6 mL distilled water, 2 mL 30 % acrylamide mix, 1.3 mL 1.5
M Tris (pH 8.8), 0.05 mL 10 % SDS, 0.05 mL 10 % ammonium
persulfate, 0.002 mL 7Vv/VrA,',A’-Tetramethylethylenediamine.
10 % Tris-glycine SDS-
Polyacrylamide gel
To cast one gel (5 mL):
1.9 mL distilled water, 1.7 mL 30 % acrylamide mix, 1.3 mL 1.5
M Tris (pH 8.8), 0.05 mL 10 % SDS, 0.05 mL 10 % ammonium
persulfate, 0.002 ml A^/^A^-Tetramethylethylenediamine.
5 % Stacking solution for
Tris-glycine SDS-
Polyacrylamide gel
To cast one gel (2 mL):
1.4 mL distilled water, 0.33 mL 30 % acrylamide mix, 0.25 mL
1.0 M Tris (pH 6.8), 0.01 mL 10 % SDS, 0.01 mL 10 %
ammonium persulfate, 0.002 mL NJVJVJV’-
Tetramethylethylenediamine.
10 x Running buffer 30 g Tris-base, 144 g Glycine, 10 g SDS, made up to 1 L with
distilled water.
Transfer buffer 800 mL gel running buffer, 200 mL Methanol.
Membrane stripping buffer 20 mL 10 % SDS, 12.5 mL 1 M Tris-hydrochloric acid (pH 6.5),
0.7 mL |3-mercaptoethanol, made up to 100 mL with distilled
water.
Box 4: Reagents used to perform SDS-PAGE and Western Blotting.
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The percentage of the acrylamide gel used depended on the size of protein of 
interest. Larger proteins can be resolved better on lower percentage gels. Glass 
plates (0.75 mm in thickness) were cleaned with 70 % ethanol, air dried and set 
up in a Bio-Rad kit. Resolving gel solutions (Box 4) were poured between the 
plates within 1.5cm of the top, covered with distilled water and left to 
polymerise. The distilled water was then removed with blotting paper and 
stacking gel solutions (Box 4) were added and a 10-well comb inserted. Once the 
stacking gel had polymerised, the comb was removed and the gel and plates 
were placed into a Mini Protean III electrophoresis chamber.
Generally 20 pg/well of cell lysates were calculated and prepared, and mixed 
with 1 x sample loading buffer (Box 4). The mixtures were then heated at 95 °C 
for 10 minutes for protein denaturation. Then, the samples were loaded onto the 
gel alongside a pre-stained molecular weight ladder. Gels were subjected to 55 
mA for 60-90 minutes.
The running chamber was then dismantled, the stacking gel removed and the 
proteins in the resolving gel transferred onto a Hybond Enhanced Chemo- 
Luminescense (ECL) nitrocellulose membrane. The gel and membrane were 
sandwiched between 3mm Whatman chromatography paper and sponges. This 
assembled apparatus was then returned to the chamber which was filled with 
transfer buffer (Box 4), along with an ice block for cooling. The transfer took 
place on a magnetic stirrer which allowed circulation of transfer buffer, for 1 
hour at 110 volts.
Following the transfer procedure, the membrane was removed and washed in 
Tris buffered saline tween (TBST) solution repeated twice each for 5 minutes.
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The membrane was then blocked using 5 % blocking milk TBST solution for 90 
minutes. Following blocking, the membrane was incubated overnight in 4 °C 
with primary antibody indicated in Table 12.
Following overnight incubation with primary antibody, the membrane was 
washed at room temperature with TBST for 4 cycles, 15 minutes each cycle. 
Then, the membrane was incubated with secondary horse radish peroxidase- 
linked antibody (dilution 1:2000, in 5 % milk TBST solution) for 90 minutes. 
Four cycles of TBST washes were repeated as before after incubation with 
secondary antibody. Using ECL Reagent Plus, equal quantities of the enhanced 
luminal and oxidising reagents were mixed and then applied to the membrane for 
5 minutes. The membrane was then blotted dry, wrapped in cling film and 
secured in a Kodak light safe developing cassette. In the dark room, blots were 
exposed to medical x-ray film at a range of exposure lengths in order to optimise 
the imaging of various proteins being studied, and to gain an accurate 
appreciation of the expression levels. The film was consequently developed in 
Kodak developer and fixer for two minutes respectively. Finally the film was 
rinsed in tap water and allowed to air dry.
The membrane was then washed twice for 15 minutes with TBST and incubated 
with stripping buffer at 75 °C for 30 minutes. This was followed by two cycles of 
TBST washes before probing for p-actin or Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) overnight at 4 °C. Subsequent procedures were as 
described above. These steps were performed to check whether equal amount of 
protein were loaded into each lane (loading control) on the gel during the initial 
stage of the SDS-PAGE procedure.
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Proteins Gel Primary antibody
HSP27 12% Mouse anti-HSP27 antibody, 1:5000 in 5
% milk TBST
Smad4 10% Mouse anti-Smad4 antibody, 1:500 in 5 %
milk TBST
Phospho-Smad2 10% Rabbit anti-phospho-Smad2 antibody,
1:1000 in 5 % Bovine Serum Albumin
(BSA) TBST
Phospho-SmadS 10% Rabbit anti-phospho-Smad3 antibody,
1:1000 in 5% BSA TBST
Phospho-Smad 1/5/8 10% Rabbit anti-phospho-Smad 1/5/8 antibody,
1:1000 in 5% BSA TBST
RAGE 12% 1:500 in 5% milk TBST
p-actin (as loading - Mouse anti-p-actin antibody, 1:10000 in 5
control) % milk TBST
GAPDH (as loading - Rabbit anti-GAPDH antibody, 1:500 in 5
control) % milk TBST
Table 12: Gel electrophoresis for detection of proteins
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3.2.5 Transient HSP27 and Smad4 depletion/knockdown
HSP27 and Smad4 knockdowns were performed using siRNAs (all at 10 nM) 
with target sequences as below:
• Human HSP27-targetting-siRNA 1: GGCAGGACGAGCAUGGCUAUU
• Human HSP27-targetting-siRNA 2: CAAGUUUCCUCCUCCCUGU
• Human Smad4-targetting siRNA 1: GUGUGCAGUUGGAAUGUAA
• Human Smad4-targetting siRNA 2: GUACAGAGUUACUACUUAG
• Human non-targeting siRNA control 1: GGACGCAUCCUUCUUAAUU 
(kind gift of Dr Mark Boyd, Reader in Molecular Biology, University 
of Liverpool).
• Human non-targeting siRNA control 2: sequence not provided by 
Dharmacon company.
Cells were harvested, washed, counted, and plated onto 6-well plates. Routinely, 
1x105 cells were plated into each well to achieve cell density of -60-70 %. 
Approximately 3 mL of culture media was added into each well and the plate 
incubated at 37 °C for 24 hours.
The following day, siRNAs and lipofectamine 2000 mixtures were prepared. 
Briefly, for transfection of each well, 4 pL of lipofectamine 2000 was added to 
200 pL of Optimem I in one 15 mL tube, and siRNAs (10 nM for both HSP27 
and Smad4 knockdown) were added to 200 pL of Optimem I in another 15 mL 
tube. These two tubes were incubated for 5 minutes in the hood before mixing 
their contents together and incubating for further 20 minutes.
The 6-well plates were retrieved from the incubator, the wells washed with PBS
and 2.6 mL of antibiotic-free culture media was added into each well. The
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siRNA and lipofectamine 2000 mixture was then added to the wells in a drop- 
wise manner. The plates were returned to the incubator for 48-96 hours and 
harvested for further experiments. Knockdowns were confirmed using western 
blotting.
3.2.6 Gamma irradiation to cells
Cells were harvested into either 50 mL polypropylene tubes or alternatively, 
200,000 cells were plated into 10 cm2 flat-sided tube flasks before exposure to 
a gamma source - Cs137 (Gamma Cell 1000, Atomic energy of Canada Ltd, at 
the Division of Immunology, University of Liverpool). At the current state of 
decay, 21 seconds exposure correlated to 1 Gray (Gy) of irradiation. Cells were 
then collected for further experiments.
3.2.7 Cell sensitivity and proliferation assay: The MTS assay
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), similar to MTT (3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide), is a yellow water-soluble tetrazolium dye 
that is reduced by live cells to an insoluble purple formazan product. The 
amount of MTS-formazan produced can be determined spectrophotometrically 
once solubilised in a suitable solvent. This provides an indirect measurement of 
the number of living cells.
Three chemotherapeutic agents were selected for experiments: 5-fluorouracil 
(5-FU), Oxaliplatin and Irinotecan. Oxaliplatin was diluted in PBS whereas 5- 
FU and irinotecan were diluted in DMSO as per the manufacturer’s instruction.
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Cells were harvested and plated into 96-well plates. Routinely, 3,000 cells in a 
volume of 100 pL were plated per well. The following day, variable 
concentrations of chemotherapy agents in a volume of 100 pL were added into 
the wells, to the final volume of 200 pL per well and incubated for 96 - 120 
hours depending on the chemotherapeutic agents and cell lines. Following this, 
the MTS Assay Kit (EZ4U) was used according to the manufacturer’s 
instruction. Briefly, 2.5 mL of activator was added to the substrate. Then, 20 
pL of the mixture was added into each well. The plates were then immediately 
read at 450 nm with the biophotometer machine to determine the 0 hour 
readings. The plates were subsequently read every hour for 4-5 hours. Using 
the 450 nm measurements, graphs were then plotted to determine the IC50.
To determine cell proliferation in general, MTS assays were performed as 
described above with the exception that cells were suspended in 200 pL of 
culture media into each well, and readings were performed at 24, 48 and 72 
hours to measure cell proliferation over different periods of time. Recombinant 
S100A8-GST and S100A9-GST at concentrations of 0.4 pg/mL and 2 pg/mL 
were prepared in culture media containing 1 % FBS, the controls were culture 
media containing 1 % FBS, 10 % FBS, and GST.
For both cell sensitivity and cell proliferation assays, experiments were 
performed at least twice with five wells utilized for each treatment.
3.2.8 Flow cytometric cell cycle analysis
Cells (0.5-lxl06) were harvested and washed twice in PBS (centrifuged 1000 
rpm, 5 minutes each). PBS was removed, and the cell pellet re-suspended to
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create a single cell suspension. 5 mL of ice cold 70 % ethanol (stored at -20 °C) 
was added drop-wise while gently vortexing. The samples were then incubated 
on ice for 60 minutes. Samples were then centrifuged at 1000 rpm for 5 
minutes, washed twice in PBST to remove residual ethanol and re-suspended 
after each wash cycle. After pelleting the cells for the final time, PBST were 
removed and 100 pL of Ribonuciease A (10 mg/mL) was added and ceils re­
suspended. The samples were incubated on ice for 5 minutes, followed by the 
addition of staining solution containing 850 pL of PBS and 50 pL of 
propidium iodide (1 mg/mL) into each sample. The samples were incubated on 
ice in the dark for 30 minutes. The stained wells were then analysed using a 
FACScan flow cytometer (Beckman Coulter) (at the Division of pathology, 
University of Liverpool) and subsequently by WinMDI 2.9 software.
3.2.9 In-vitro cell motility/migration (chemotaxis) measurement 
- The modified Boyden Chamber assay
To set up a modified Boyden Chamber (Figure 7), a cell culture insert with 
PET membrane transwell 8pm pores was placed onto each well of a 24-well 
plate as an upper chamber. Cells (5000 for PANC1, 50,000 for 
SW480/SWK3/SWD20/HCT116, 100,000 for SW837/HRT18) were harvested 
and plated in 500 pL of 1 % FBS culture media in the upper chamber whereas 
the lower chamber contained 750 pL of cell culture media. Recombinant 
S100A8-GST and S100A9-GST at concentrations of 0.4 pg/mL and 2 pg/mL 
were prepared in culture media containing 1 % FBS, the controls were culture 
media containing 1 % FBS, 10 % FBS, and GST, These were plated in the 
lower chamber. For HSP27 experiments, 10 % FBS culture media were plated
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in the lower chambers. The chambers were incubated at 37 °C for 18 hours at 
which time non-migrating cells were removed from the upper surface of inserts 
with a cotton swab. Cells which had migrated through the pores to the under­
surface of the insert membrane were fixed and stained using Diff-Quick Stain 
Kit, the membrane was cut out and mounted onto glass slides. Using a 
microscope at 40 x magnification, stained cells were counted, n=2 inserts per 
treatment, and the average number of migrated cells calculated. Experiments 
were performed at least twice.
Cancercells B
suspended in l\ / Cell culture
1%FBS culture l\ / 1/ insert
media and 1 \ /
plated in the It ¥
upperchamber \ \ /
<—- 24-well plate
Insert membrane /
(Spin pore size) \ B \
B\ * Cancercells
S100A8-GST, \ • -— migratingthroughaft the membrane
GST proteins I
prepared in 1% 1 Cancercells have
FBS culture —B ^ migrated through the
media and plated membrane and
in the lower attached to the bottom
chamber of the insert
Figure 7: Modified Boyden Chamber.
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3.2.10 Apoptosis assay - Annexin-V/Propidium Iodide staining 
and flow cytometry analysis
Cells (~lxl06) were harvested and centrifuged at 1000 rpm for 5 minutes at 4 
°C. The pellet was then washed twice with PBS and re-suspended in 1 mL of 1 
x Annexin V binding buffer (Annexin V-FITC Apoptosis Assay Kit) and kept 
on ice. 500 pL of each sample was aliquoted into a flow cytometer tube, and 5 
pL of FITC conjugated Annexin V and 10 pL of propidium iodide were added. 
This mixture was incubated on ice for 10 minutes in a dark box to prevent 
photo bleaching, after which the samples were ready to be analysed by 
FACSan. The data obtained were analysed by WinMDI 2.9 software.
For this experiment, staurosporine (1 pg/mL) was initially incubated with cells 
for 12 hours, to induce cell apoptosis as a positive control. This was used to set 
up the flow cytometric parameters and adjust for channel colour compensation.
3.2.11 The generation of GST-tagged S100A8 and S100A9 
proteins
Luria-Bertani 10 g Bacto-tryptone, 5 g yeast extract, 10 g sodium chloride, made up
(LB) media to 1 L with distilled water, pH to 7.0 with sodium hydroxide.
SLIP buffer 5 mL of 50 mM HEPES, 10 mL glycerol, 0.1 mL of Triton, 15 mL of
150 mM sodium chloride, made up to 100 mL with distilled water.
Elusion 2.5 mL 1 M Tris pH 8.0, 0.154 g Glutathione (reduced), made up to 50
buffer mL with distilled water.
Coomasie 2.5 g Coomasie blue G, 450 mL methanol, 100 mL acetic acid, made
stain solution up to 1 L with distilled water.
Destaining 300 mL methanol, 100 mL acetic acid, made up to 1 L with distilled
buffer water.
Box 5: Reagents used in the generation of recombinant proteins.
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Plasmids encoding S100A8-GST and S100A9-GST fusion proteins196 were the 
kind gift of Y, Mam, Tokyo Women’s Medical University School of Medicine, 
Japan and were transformed into Escherichia coli by Mr Adnan Sheikh (an MD 
student, Division of Surgery and Oncology, University of Liverpool). For 
induction of protein expression, bacteria were cultured in Luria-Bertani media 
(Box 5, containing ampicillin 50 mg/mL) until they reached an optical density 
of 0.8 at 600 nm. Isopropyl-b-D-thiogalactopyranoside was added to a final 
concentration of 0.5 mM and cultures incubated for a further 4 hours. The 
cultures were then centrifuged at 3,000 rpm for 8 minutes in 4 °C. GST fusion 
proteins were extracted by lysing the bacteria pellet in SLIP buffer (Box 5) 
using a sonicator, followed by incubating the supernatant with glutathione 
sepharose beads on an oscillator at 4 °C for 2 hours. The samples were then 
centrifuged, the supernatants were kept. 20 mL of ice cold PBS were added for 
washes. The samples were then aliquoted into the columns, with initial 1 mL of 
ice cold PBS added to the pellet, gently mixed. Proteins were then eluted and 
collected using 4 mL of elusion buffer (Box 5) into each column. The quantity 
of recombinant GST-S100A8 and GST-S100A9 was assessed by performing 
Coomasie-stained ID SDS-PAGE against serial dilutions of a reference 
standard of BSA for comparison (1-15 pg/lane) followed by densitometric 
evaluation of the Coomassie-stained gels using TotalLab software.
The methodology for running Coomassie-stained gels for S100A8-GST and 
S100A9-GST proteins were similar to Tris-glycine gels as described in section 
3.2.4.3. Following running of the Tris-glycine gels, Coomasie stain solution 
was added to the gels and incubated for at least one hour before de-staining 
buffer was added to visualise the presence of stained bands.
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3.2.12 Cellular phospho-Smad expression and blocking of 
receptor of advanced glycation end products (RAGE)
Cells were cultured for 48 hours in serum free medium supplemented with 
bovine serum albumin (10 (ig/mL) and human insulin (5 pg/mL) and then 
treated with S100A8-GST, S100A9-GST, GST or TGF-(3 (10 ng/mL) (as 
positive control) for 1 hour, followed by cell collection for western blotting as 
described above. For RAGE blocking, cells were treated with RAGE-blocking 
antibody (40 ]ig/mL or 80 pg/mL) for 1 hour before the addition of 
recombinant proteins.
3.2.13 Cellular immunofluorescence
Cells on glass slides were fixed with 4 % paraformaldehyde for 15 minutes at 
room temperature, washed with PBST, and then permeabilised with 0.1 % Triton 
X-100 for 10 minutes. Further washes with PBST were performed, followed by 
incubation with 10 % goat serum for 30 minutes. Rabbit anti-phospho-Smad2/3 
antibody (1:50 dilution in 3 % BSA in PBST) was added and incubated 
overnight.
The following day, slides were washed three times with PBST (5 minutes each), 
followed by incubation with secondary goat fluorescein isothiocyanate- 
conjugated anti-rabbit antibody (1:100 dilution in 3 % BSA in PBST) together 
with phalloidin (1: 500 dilution, for labelling actin filaments) for 60 minutes in 
the dark. Further washes with PBST were performed before slide covering with 
mowiol and a cover slip. Slides were analysed using a fluorescence microscope 
at the Division of Pathology, University of Liverpool.
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3.2.14 Statistical analysis
Comparisons between two groups were made using non-parametric continuity 
corrected chi-square test or chi-squared test, when more than two groups were 
analyzed. Continuous variables were compared using the Mann-Whitney U or 
the Wilcoxon signed rank test. To evaluate patient survival, life tables were 
constructed and Kaplan Meier curves plotted. Cancer specific survival was 
measured from date of initial surgery to date of death, counting death from 
colorectal cancer as the end point. Multivariate Cox regression analysis was 
conducted using a stepwise forward selection approach starting with the most 
significant variable on univariate analysis and including every variable with a p 
value of <0.10.
A power calculation was performed based on the observed survival difference of 
30% at 5-years between Dukes’ C cancer patients treated with surgery followed 
by adjuvant chemotherapy and patients treated with surgery only75, 293, and 
would have a power of 0.80 at a 5% level of statistical significance. This 
indicated that a minimum sample size of n = 44 in each arm (high or low HSP27 
expression cancers) was required, assuming that cancer patients with high 
tumoural HSP27 treated with surgery and adjuvant therapy had similar survival 
compared with patients treated with surgery only.
To analyze data from laboratory experiments, continuous variables were 
compared using the student t test and were expressed as mean. All analyses were 
performed using Statview Version 5.01 (SAS Institute Inc). A P -value of less 
than 0.05 was considered significant.
91
CHAPTER 4:
THE ROLES OF S100A8 AND S100A9 AND 
THEIR RELATIONS TO TUMOURAL 
SMAD4 IN CARCINOGENESIS
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4.1 Results
4.1.1 Generation of recombinant GST-tagged S100A8 and 
S100A9 protein.
S100A8-GST and S100A9-GST fusion proteins were generated and purified 
from E. coli as described in Chapter 3 section 3.2.11. The Coomasie-stained 
gels shown in Figure 8 confirmed the generation of S100A8-GST and S100A9- 
GST proteins. This was followed by a densitometric evaluation of Coomasie 
stained gels with known concentration of albumin standards, followed by graph 
plotting of albumin standards that allowed concentrations of S100A8-GST and 
S100A9-GST protein concentrations to be determined. At least 2 batches of 
each protein were generated and utilised in the subsequent experiments.
4.1.2 The effects of Smad4 status on S100A8 and S100A9- 
induced migration activity
S100A8 and S100A9 are secreted chemokines, which could affect tumour cells 
in their vicinity. Based on our recent observations that the microenvironment of 
Smad4-negative colorectal tumours had significantly reduced numbers of 
S100A8-expressing cells compared to the microenvironments of Smad4-positive 
tumours136, we questioned whether the expression of Smad4 in cancer cells 
affected their response to exogenous S100A8 and S100A9.
The chemoattractive functions of these proteins on tumour cells were firstly 
examined in vitro. The addition of purified S100A8-GST and S100A9-GST 
fusion proteins at concentrations of either 0.4 pg/mL or 2 pg/mL significantly
93
increased the migration activity of the rectal cancer cell line SW837, the colon 
cancer cell line SW480, and the pancreatic cancer cell line Panc-1 {P < 0.001, 
Figure 9) compared to the addition of purified GST control protein. The addition 
of both S100A8-GST and S100A9-GST proteins simultaneously did not 
significantly increase the response over proteins added individually (Figure 9).
S100A9-GST (40 kDa)
S100A8-GST (34 kDa)
GST (26 kDa)
Figure 8: Colloidal Coomassie Blue stained polyacrylamide gel showing 
molecular weight markers and GST-tagged recombinant proteins, including 
GST, GST-S100A8 and GST-S100A9. The purity of the recombinant proteins 
was examined using densitometric evaluation of the Coomasie blue-stained 
immunoblot of the proteins against the background staining. This has shown the 
purity to be 85 % for S100A8-GST, 86 % for S100A9-GST, and 88 % for GST.
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Smad4 (60k0a) 
(J-actin (45kDa)
A 225 SW837
Figure 9: Migratory activities of cells in response to S100A8 and S100A9 
proteins. Cell counts of indicated cell lines treated with S100A8-GST (A8-GST), 
S100A9-GST (A9-GST), S100A8-GST+S100A9-GST, or GST at concentrations
of 0.4 or 2.0 pg/mL, in medium containing 1 % FBS. ** = PO.OOl, * = P<0.05, 
n/s=non-significant. The Smad4 status of cells is shown as insets on Western 
blots. The results are representative of at least 2 independent experiments.
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Both Panc-1 and SW837 cells express Smad4 (see inset Figure 9). To determine 
whether the Smad4 status of cells influenced their response to S100A8 or 
S100A9, Smad4 expression was depleted in these cell lines and the cells’ 
migration activity in response to S100A8 and S100A9 was then examined. An 
approximate 50 % decrease in basal migration in Panc-1 cells compared to 
control siRNA treated cells was observed (Figure 10A). Smad4 knockdown 
totally suppressed migration responses towards S100A8. In contrast, S100A9- 
treated cells retained an approximate two-fold increase in migration after Smad4 
knockdown. Smad4 knockdown caused an almost total loss of basal and 
chemokine-induced migration of the less motile SW837 cells (Figure 10B).
SW480 cells do not express Smad4 (see inset Figure 9). Neomycin resistant 
clonal derivatives of SW480 cells, stably re-expressing Smad4 (SWD20) and 
negative control transfectants (SWK3) were used to determine whether 
restoration of Smad4 would alter responsiveness to S100A8 or S100A9. Both the 
Smad4-negative and Smad4-positive subclones had enhanced migration 
following incubation with S100A8-GST or S100A9-GST (Figure 11A). 
However, transient siRNA-mediated depletion of Smad4 from SWD20 cells 
resulted in a reduction in motility and a loss of responsiveness to S100A8-GST, 
but not S100A9-GST (Figure 11B). This was similar to the result obtained with 
Panc-1 cells (Figure 10A).
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Figure 10: Migratory activities of PANC1 and SW837 cells in response to 
S100A8 and S100A9 proteins following Smad4 depletion. The cell counts of 
Smad4 depleted PANC1 cells (A) and SW837 cells (B), in response to 
exogenous S100A8 and S100A9. ** = p < 0.001, * = P < 0.05, n/s = non­
significant. The Smad4 status of cells is shown as insets on Western blots. The 
results are representative of at least 2 independent experiments.
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Figure 11: Migratory activities of clonal derivative of SW480 cells or Smad4 
depleted cells in response to S100A8 and S100A9 proteins. Cell counts of clonal 
derivative of SW480 cells that stably re-expresses Smad4 (SWD20) and its 
Smad4-negative control (SWK3) (A), or Smad4 depleted SWD20 (B), in 
response to exogenous S100A8 and S100A9. ** = />< o.OO \,* = P< 0.05, n/s = 
non-significant. The Smad4 status of cells is shown as insets on Western blots. 
The results are representative of at least 2 independent experiments.
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4.1.3 The effects of Smad4 status on S100A8 and S100A9-
induced proliferation.
Similarly, the effects of SI00AS and S100A9 on tumour cell proliferation were 
examined and the roles of Smad4 status in this context were explored. Incubation 
of SW837 and SW480 cells with 2 pg/mL of S100A8-GST or S100A9-GST 
resulted in modest, though statistically significant increases in MTS readings 
(Figure 12A & B). No increase was observed using 0.4 pg/mL recombinant 
proteins and Panel cells did not show an increased MTS response at all (Figure 
12C). In the case of SW837 cells, the simultaneous addition of S100A8-GST and 
S100A9-GST proteins at 2 pg/mL significantly improved the response over 
proteins added individually (Figure 12A), although this effect was not observed 
with SW480 or Panc-1 cells (Figure 12B & C).
The Smad4-negative SW480 subclone, SWK3 showed enhanced proliferation in 
response to 2 pg/mL S100A9-GST (Figure 13A), whilst the Smad4 re­
expressing subclone, SWD20, responded to both S100A8-GST and S100A9- 
GST, although the response to S100A9-GST was greater (Figure 13B). 
Following depletion of Smad4 from SWD20 cells, responsiveness to S100A8- 
GST was lost (Figure 13C). S100A9-GST continued to induce proliferation, 
although the extent of proliferation reached was not as great as that observed in 
control siRNA treated cells (Figure 13C). Depletion of Smad4 from Panc-1 cells 
gave a similar result (Figure 13D) although the increase in MTS readings in 
response to S100A9 was very small.
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Figure 12: Proliferation of cells in response to S100A8 and S100A9. MTS 
readings of indicated cell lines treated with S100A8-GST (A8-GST), S100A9- 
GST (A9-GST), S100A8-GST+S100A9-GST, or GST at concentrations of 0.4 
or 2.0 pg/mL, in medium containing 1% FBS. * = P < 0.05, n/s = non­
significant, ** = the simultaneous addition of S100A8-GST and S100A9-GST 
proteins at 2 pg/mL significantly improved the response over proteins added 
individually. The results are representative of at least 2 independent experiments.
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Figure 13: The roles of Smad4 status on S100A8 and S100A9-induced 
proliferation.MTS readings of A) SWK3 cells, B) SWD20 cells, Smad4 depleted 
C) SWD20 cells and D) PANC1 cells, in response to S100A8-GST (A8-GST), 
S100A9-GST (A9-GST), or GST at a concentration of 2.0 pg/mL. * = PO.Ol, ¥ 
= P < 0.05. The results are representative of at least 2 independent experiments.
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4.1.4 The effects of exogenous S100A8 and S100A9 on Smad4 
signalling and RAGE
The results above indicated that the effects of exogenous S100A8 and S100A9 
were influenced to an extent by the presence of Smad4 in tumour cells. To 
examine whether these proteins could signal via Smad4, cells were incubated for 
1 hour with 2 pg/mL of S100A8-GST or S100A9-GST and the activation of 
members of the Smad pathway examined. Both recombinant SI00 proteins 
alone, but not GST, induced increased levels of phospho-Smad2, phospho- 
Smad3, but not phospho-Smadl/5/8 in Panc-1 cells (Figure 14A). Furthermore, 
phospho-Smad2/3 was shown to accumulate in the nucleus following incubation 
with S100A8-GST or S100A9-GST, but not GST (Figure 14B).
S100A8/A9 heterodimers are known to stimulate cells through binding to the 
cellular receptor RAGE, although it is unclear whether the individual proteins 
are ligands for this receptor. RAGE expression was observed in the cell lines 
used in this study (Figure 15A). To determine whether S100A8 and S100A9 
were activating the Smad pathway through RAGE, RAGE-blocking antibody 
was used at two concentrations, 40 pg/mL and 80 pg/mL. When Panc-1 cells 
were pre-treated with the RAGE-blocking antibody, a dose-dependent reduction 
of phopho-Smad2 and phospho-Smad3 levels was observed in response to 
S100A8-GST or S100A9-GST stimulation (Figure 15B).
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GST 2.0
A8-GST 2.0
Figure 14: The effects of exogenous S100A8 and S100A9 on Smad4 signalling. 
A) Western detection of phospho-Smad2, phospho-Smad3, phospho-Smad 1/5/8 
levels following treatment of Panc-1 cells with 2 pg/ml of S100A8-GST (A8- 
GST), S100A9-GST (A9-GST) or GST. B) Cyto-immunofluorescence showing 
accumulation of phospho-Smad2/3-heteromeric complex to the nucleus (green) 
following 1 h treatment of PANC1 cells with 2 pg/mL of S100A8-GST or 
S100A9-GST. Actin filaments have been labelled with phalloidin (Red). TGF-P 
(10 ng/mL) and 10 % FBS were the positive control for phospho-Smad2/3 and 
phospho-Smad 1/5/8 activation respectively.
10% FBS
A9-GST 2.0
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Figure 15: S100A8 and S100A9 activated the Smad pathway through RAGE. 
A) Western detection of RAGE expression in indicated cell lines. B) Western 
detection and densitometric representation of the levels of phospho-Smad2 and 
phospho-Smad3 which were reduced in Panc-1 cells pre-treated with RAGE- 
blocking antibody (R) (40 pg/mL and 80 pg/mL) before the addition of 0.4 
pg/mL or 2 pg/mL of S100A8-GST or S100A9-GST.
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4.2 Discussion
The inflammatory chemoattractants> S100A8 and S100A9, apart from serving as 
markers of phagocytes (intracellular S100A8/A9) or as biomarkers of 
inflammatory disease conditions (secreted extracellular S100A8/A9), are now 
recognized to play important roles themselves in the pathogenesis of 
inflammatory disorders and more recently in cancer153.
Hiratsuka and colleagues196 showed that S100A8/A9 were powerful 
chemoattractants, whose tumour-induced presence in the lungs of tumour 
bearing mice, could stimulate the migration of Lewis Lung carcinoma cells and 
B16 melanoma cells to that organ, where they formed secondary tumours. 
Coupled with the evidence that loss of Smad4 affects tumour microenvironment 
and promote invasion226, 221, and our previous observation that the 
microenvironments of colorectal and pancreatic137 tumours which lacked Smad4 
had significantly reduced SlOOAS-expressing but not S100A9-expressing 
inflammatory cells, we sought to determine whether the response of tumour cells 
to S100A8/A9 was potentially influenced by their Smad4 status. Both S100A8 
and S100A9 were highly chemotactic for rectal, colon and pancreatic cancer cell 
lines, regardless of whether the cells expressed Smad4 or not. In Smad4 
expressing cells, such as Panc-1 cells or the SWD20 cells, where Smad4 
expression has been stably restored, transient depletion of Smad4 expression was 
accompanied by a loss of responsiveness to S100A8-induced migration activity 
but not that of S100A9, suggesting that S100A8 elicits its response through a 
Smad4 dependent pathway. Transient Smad4 depletion, such as we undertook in 
our siRNA experiments, may not allow sufficient time for cells to adapt and to
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allow S100A8 to signal in a Smad4-independent manner. Our observation of 
increased levels of phosphor-Smad2 and phospho-Smad3 in response to cell 
treatment with S100A8 and S100A9 provide supporting evidence that these 
proteins can activate the Smad4 signalling pathway.
S100A8/A9 induced proliferation of the cancer cell lines studied was also 
observed, although at concentrations higher that those required to induce 
migration activity. S100A8/A9 may contribute to apoptosis153, however the 
apoptotic role of these proteins was not investigated in this study. Ghavami and 
colleagues192 reported that S100A8 and S100A9 proteins promoted growth of 
human breast cancer and neuroblastoma cells and confirmed that these proteins 
activate the multi-ligand receptor, RAGE, triggering the MAP kinase signalling 
pathway. The mitogenic effects of S100A8/A9, coupled with previous 
observation in our research unit that high levels of A8/A9 infiltrate were 
associated with larger tumours suggest that the proteins may contribute to the 
growth of these tumours. Interestingly, while the Smad4-restored SWD20 cells 
showed increased proliferation in response to S100A8-GST and S100A9-GST, 
their Smad4-negative clonal counterpart, SWK3 cells showed increased 
proliferation in response to S100A9-GST only, suggesting that Smad4 is 
important in regulating the proliferative response to exogenous S100A8. 
Transient Smad4 knockdown in SWD20 and Panc-1 was accompanied by a loss 
of response to S100A8-GST. Thus, although the measured proliferation effects 
of S100A8/A9 were not as marked as their chemotactic effects, the dependence 
on Smad4 for S100A8 signalling was a recurrent theme. Our RAGE blocking 
experiments provide evidence that S100A8 and S100A9 activation of the Smad4 
pathway occurs at least in part through RAGE. The ability of advanced glycation
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end products to activate TGF-[3 signalling via RAGE and MAPKs has been 
established by Li and colleagues294.
Interestingly, our data provides important evidence that S100A8 and S100A9 
share similarity to TGF-|3, in that they activate the Smad pathway and their 
effects can be Smad-dependent or Smad-independent, as revealed by our motility 
and proliferation assays. In normal epithelial and haematopoietic cells, TGF-P 
acts as a tumour suppressor with anti-proliferative property. In cancers, TGF-|3 
can function as an oncogenic factor facilitating proliferation, angiogenesis, cell 
migration, invasion and metastasis. Several complex molecular mechanisms 
have been identified to allow cancer cells to evade from the tumour suppressive 
effect of TGF-p while switching to its oncogenic factor295. This double-edged 
sword effect of TGF-p is in a way, similar to S100A8/A9, where these SI00 
proteins are powerful apoptotic agents produced by immune cells but on the 
other hand, they have also been shown to facilitate tumour development, cancer 
invasion or metastasis. The molecular pathways associated with the dichotomous 
role of these SI00 proteins have not been fully understood currently, while the 
signal transduction pathways of TGF-P (Smad-dependent and Smad- 
independent) have been increasingly elucidated.
A limitation of this study has been the use of recombinant S100A8 and S100A9 
proteins produced in E. coli. Although we do not know whether these proteins 
existed as homo- or heterodimers in our experiments, purified recombinant 
S100A8 and S100A9 proteins can exist as homodimers, or they can form 
heterodimers, tetramers or oligomers depending on the presence of calcium156. 
Furthermore, the addition of both S100A8-GST and S100A9-GST proteins
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simultaneously did not significantly increase the motility response over proteins 
added individually, although in the case of SW837 cells, the simultaneous 
addition of S100A8-GST and S100A9-GST proteins at 2 pg/mL significantly 
improved the proliferative response over proteins added individually, although 
this effect was not observed with SW480 or Panc-1 cells. It is not entirely clear 
to us why the addition of both proteins did not always enhance the effects 
observed. We can suggest two possible reasons: the individual proteins at the 
concentrations used have generated a maximum response for that concentration, 
such that the combined proteins cannot exceed that affect; the proteins when 
added in combination do not heterodimerise adequately due to interference by 
the GST portion. GST is a relatively large size with 220 amino acids (26kDa) 
and is fused to the N-terminus of a protein. GST-tagged recombinant proteins 
have been used extensively in research, with the advantage of maintaining 
functional integrity compared to the native protein while providing the sufficient 
quantities to further study structure and function. One recent study by Viterbo 
and colleagues296 demonstrated that GST tagged recombinant protein from E. 
coli (pancreatitis associated protein) has similar functional immunomodulatory 
integrity as with the native protein. In all of our experiments GST protein alone 
was used as a control for the GST-tagged S100 proteins. We have shown that 
GST does not have an effect on cancer cell motility, proliferation or cellular 
Smad4 signalling, although some loss/interference in function due to the GST 
tag cannot be ruled out. Other researchers192 (using untagged S100A8/A9 
purified from human blood neutrophils) have also demonstrated some of our 
positive findings regarding the ability of S100A8 and S100A9 to promote 
motility and proliferation.
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A second limitation of our study is that the physiological concentrations of 
S100A8 and S100A9 in the microenvironment of colorectal tumours are 
unknown. The concentrations of S100A8-GST and S100A9-GST used in our in 
vitro experiments (0.4 pg/mL and 2.0 pg/mL) are however in agreement with 
other research groups. For instance, Ghavami and colleagues192 showed that 
S100A8/A9 has cell growth-promoting properties at concentration between 0 
and 25 pg/mL. Consistent with our data, Turovskaya and colleagues193 also 
demonstrated growth-promoting effect of S100A8/A9 at 1 ug/mL in colon 
cancer cells. Hiratsuka and co-workers1963197 used lower concentrations (pg/mL) 
to demonstrate motility-promoting effect.
Finally, the generation and use of recombinant proteins from E. coli raises the 
concern of impurity, in that soluble factors such as lipo-polysaccharide from the 
bacteria may produce, or contribute to the observed effects in our in vitro 
experiments. The research group in our unit is currently performing in vitro 
experiments using S100A8 and S100A9 antibodies along with the recombinant 
GST-tagged SI00 proteins, further examining the functional aspects of these 
proteins. These experiments have shown that recombinant S100A8 and S100A9 
proteins can be inhibited through the use of S100A8 and S100A9 antibodies 
respectively, suggesting the reliability of the observed functions of these 
recombinant SI00 proteins.
In summary, we provide evidence on the cancer-promoting activity of S100A8 
and S100A8 proteins, suggesting the roles of inflammatory cytokines in 
promoting tumour development/spread. Moreover, we have shown for the first 
time, that the effects of these proteins on cancer cells are in part related to the
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Smad4 status of these cancer cells in orchestrating the crosstalk between cancer 
cell and its microenvironment.
110
CHAPTER 5:
THE CLINICAL RELEVANCE OF 
TUMOURAL HSP27 EXPRESSION AS A 
PREDICTIVE MARKER OF RESPONSE 
TO ADJUVANT THERAPY IN 
COLORECTAL CANCER
in
5.1 Result
5.1.1 Patient selection for analyses
To examine whether the level of tumoural HSP27 expression affects patient 
response to chemotherapy, neoadjuvant and adjuvant data for 404 colorectal 
cancer patients, for which the tumoural HSP27 levels had already been 
characterised (by Ms Elizabeth Tweedle) were obtained from the Clatterbridge 
Centre for Oncology, Liverpool, while the colorectal cancer-specific death data 
were obtained from the North West Cancer Intelligence Service, Liverpool.
Of these 404 patients, only the patients with Dukes’ C cancers (n = 178), who 
would be routinely considered for adjuvant therapy were explored (Figure 16). 
While there were 50 patients that received either neoadjuvant, adjuvant or both, 
these patients were excluded from analyses as the treatments that they have 
received were not directly comparable. However, there were 58 patients who 
received only adjuvant 5-FU following surgery, while 70 patients did not receive 
any form of neoadjuvant or adjuvant therapy. Therefore, these two cohorts of 
patients were selected for further analyses.
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60 Dukes'A tumours 1 Dukes'D tumours
165 Dukes'B tumours
Noneoadjuvaut or adjuvant 
data on 2 patients
16 received neoadjuvant 
only, no adjuvant7 received neoadjuvant AND adjuvant
J 7 received other forms of 
first line chemo/radiotherapy8 received first line 5 -FU AND 
radiotherapy
58 received first 
line 5-FIT only
178 Dukes' C turnout's
106 received neoadjuvaut or adjuvant
404 CRC tumours (1993-20Q3)
83 received adjuvant only, no neoadjuvant
70 received no neoadjuvaut 
or adjuvant
Figure 16: Patient selection for statistical analyses. Seventy patients treated with 
surgery and 58 patients treated with surgery followed by adjuvant 5-FU were 
selected for analyses.
5.1.2 Patient demographics and clinico-pathological features
The two cohorts of patients selected for analyses showed no significant 
difference in respect of the parameters of gender, tumour site, tumour size, 
degree of cancer cell differentiation, tumour resection margin, T-stage, N-stage 
or 5-year cancer-specific death rates (Table 13). However, there was a significant 
difference between the ages of the two patient groups. The median age of patient
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in the study was 68 years. In the cohort of patients who underwent surgery only, 
a large proportion (74.3 %, 52/70) were 68 years or older, compared to patients 
treated with adjuvant 5-FU, where only 13/45 patients (28.9 %) were 68 years or 
older (P < 0.0001, Table 13).
Dukes’ C CRC, treated 
with Surgery only
Total, n = 70
Dukes' C CRC, treated with 
Surgery' + adjuvant 5-FC
Total, n = 58
P value
Gender
Male 33 38 0.232*
Female 37 20
Age (median = 68 |35-90|)
>68 52 13 <0.0001*
<68 18 45
Tumour site
Colon 42 29 0.257*
Rectum 28 29
Tumour Size (median = 50mm)
>50 39 32 0.951*
<50 31 26
Degree of differentiation
Well 1 0 0.289*
Moderate 61 55
Poor 8 3
Resection margin
Positive 12 6 0.270*
Negative 58 52
T-Stage
I 1 2 0.171*
II 4 7
III 49 43
IV 16 6
N-Stage
I 36 32 0.672*
II 34 26
5-year cancer-specific death
Yes 33 28 0.898*
No 37 30
J Chi-squared test 
* Fisher-exact test
Table 13: Patient demographics and clinico-pathological features.
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Associations were sought between HSP27 levels and clinico-pathological 
parameters of gender, age, tumour site, tumour size, degree of cancer cell 
differentiation, resection margin, T-stage and N-stage (Table 14), although none 
were found. However, among patients treated with surgery and adjuvant 5-FU, 
there was a positive association between high tumoural HSP27 and death within 
5 years. In this treatment group, 68.2 % (15/22) of patients had died within 5 
years compared to only 36.1 % (13/36) patients with low tumoural HSP27 {P = 
0.017, Table 14). For patients who underwent surgery only, there was no 
association between HSP27 levels and 5-year cancer specific death (Table 14).
Dukes' ( '. Surgery only
Total, 
n = 70
Low HSP27 
expression, n = 38
High HSP27 
expression, n = 32
P value
Gender
Male 33 19 14 0.601:
Female 37 19 18
Age (median = 68 
135-90])
>68 52 27 25 0.500*
<68 18 11 7
Tumour site
Colon 42 26 16 0.117*
Rectum 28 12 16
Tumour Size 
(median = 50mm)
>50 39 23 16 0.377*
<50 31 15 16
Degree of 
differentiation
Well 1 0 1 0.522*
Moderate 61 34 27
Poor 8 4 4
Resection margin
Positive 12 6 6 0.743*
Negative 58 32 26
T-Stage
1 1 0 1 0.739*
II 4 2 2
III 49 27 22
IV 16 9 7
N-Stage
I 36 20 16 0.826*
II 34 18 16
5-year cancer- 
specific death
Yes 33 18 15 0.967*
No 37 20 17
Dukes' (', Surgery + adjiisant 5-IT
Total, Low HSP27 High HSP27 Pvalue
n = 58 expression, n = 36 expression, n = 22
38 24 14 0 813*
20 12 8
13 6 7 0.179*
45 30 15
29 19 10 0.588*
29 17 12
32 23 9 0.087*
26 13 13
0 0 0 >0.999*
55 34 21
3 2 1
6 4 2 >0.999*
52 32 20
2 1 1 0.706*
7 4 3
43 26 17
6 5 1
32 21 11 0.535*
26 15 11
28 13
15 ( 0.01? )
30 23 7 ---------^
J Chi-squared test 
* Fisher-exact test
Table 14: Association between HSP27 expression and clinico-pathological 
features.
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5.1.3 HSP27 expression and association with cancer-specific 5- 
year survival
To further examine the observed difference in cancer-specific death rates, 
Kaplan-Meier survival analyses were performed on the two cohorts. Among 
patients treated with surgery followed by adjuvant 5-FU, patients with high 
tumoural HSP27 had significantly poorer survival (P = 0.01, Figure 17A), while 
HSP27 expression was not associated with outcome in patients treated with 
surgery only {P = 0.89, Figure 17B). Patients with high tumoural HSP27 did not 
have improved survival following surgery and adjuvant 5-FU compared to 
patients with high tumoural HSP27 who have received surgical treatment only {P 
= 0.54, Figure 17C). Furthermore, among patients with low tumoural HSP27 
expression, there was an observed better survival among patients treated with 
surgery and adjuvant 5-FU compared to patients treated with surgery only, 
although this did not reach statistical significant level (P = 0.087, Figure 17D). 
Unfortunately, the relatively small number of patients treated with surgery and 
adjuvant 5-FU in this study has precluded analysis according to anatomical site 
(n = 29 each for the colonic and rectal cancer patient group).
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1
All patients with Dukes' C colorectal tumours of low 
HSP27 levels.
n = 38 Patients treated with curative 
surgery and adjuvant 5-FU. 
Patients treated with curative 
surgery only.
£ ‘
P = 0.087
Time (month)
Life table 38 25 22 15 13 10
36 32 28 24 22 17
Figure 17: Kaplan-Meier graphical analysis of colorectal cancer patients 
selected for this study. (A) Patients treated with surgery and adjuvant 5-FU, with 
high tumoural HSP27 had significantly poorer survival. (B) HSP27 expression 
did not have survival prognostic value in patients treated with surgery only. (C) 
Patients with high tumoural HSP27 treated with surgery and adjuvant 5-FU had 
similar survival compared to patients with high tumoural HSP27 treated with 
surgery only. (D) In patients with low tumoural F1SP27 expression, there was an 
observed improved survival among patients treated with surgery and adjuvant 5- 
FU compared to patients treated with surgery only.
5.1.4 Univariate analysis and multivariate Cox proportional 
hazards regression analysis
Having observed that patients treated with surgery and adjuvant 5-FU, with high
tumoural HSP27 expression tumours had poorer survival, univariate and
multivariate Cox proportional hazards regression analyses were performed in
order to assess whether HSP27 was an independent predictive marker in this
cohort of patients. There were 58 patients treated with surgery and adjuvant 5-
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FU, divided into tumours with high HSP27 expression (n = 22) and low HSP27 
expression (n = 36) (Table 15). Parameters associated with cancer-specific 
survival on univariate analysis with a P value of < 0.1 were considered 
significant and included in the multivariate model using a forward stepwise 
approach . Univariate analysis revealed that cancer cell differentiation, N- 
stage and high HSP27 expression were associated with poorer survival (Table 
15). Subsequent multivariate Cox regression analysis revealed that only high 
HSP27 expression as an independent predictive marker of poor survival (Hazard 
Ratio 2.639 [1.233 - 5.647], /> = 0.012).
Predictors Univariate Multivariate
HR (95% Cl) Pvalue HR (95% Cl) Pvalue
Age 0.975(0.938-1.014) 0.204 -
Gender 1.695(0.799-3.595) 0.168 -
Tumour site 1.026(0.489-2.153) 0.946 -
Maximumtumour diameter 0.994(0.985-1.004) 0.215 -
Differentiation 3.627(1.089-12.080) 0.035 2.714(0.768-9.588) 0.121
Positive resection margin 1.107(0.334-3.669) 0.867 -
T stage 0.674(0.203-2.234) 0.518
N stage 2.441(1.135-5.247) 0.022 2.144(0.960-4.785) 0.062—-------
High HSP27 expression 2.574(1.217-5.446) 0.013 2.639 (1.233-5.647^ 0.012
Table 15: Univariate and multivariate analyses of patients treated with surgery 
and adjuvant 5-FU.
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5.1.5 HSP27 knockdown
My observation that patients treated with adjuvant 5-FU with high tumoural 
HSP27 expression had poorer outcome compared with patients with low 
tumoural HSP27 expression, suggested that high HSP27 levels were predictive 
of poor response to adjuvant 5-FU. At the time of undertaking this study, there 
was only one published study examining the effects of HSP27 levels on the 
response of colon cancer cell lines to 5-FU290. This study, however showed that 
HSP27 overexpression was not accompanied by increased resistance to 5-FU. 
We therefore sought to examine whether depleting HSP27 expression would 
enhance efficacy of 5-FU, other chemotherapeutic agents and irradiation on 
colorectal cancer cells.
HSP27 expression was observed in the four colorectal cancer cell lines, 
HCT116, SW480, HRT18 and SW837 (Figure 18A), with HRT18 cells 
exhibiting the lowest level in the non-induced state. In the cases of SW480, 
HCT116 and FIRT18 cells, significant HSP27 depletion was apparent at 3 days 
post incubation with HSP27-targeting siRNA incubation, a time point when cells 
were collected for further experiments. HSP27 levels remained low at 7 days 
post-treatment with HSP27-targetting siRNA, compared to controls, although a 
small degree of recovery of HSP27 was evident in SW480 cells (Figure 18B). In 
the case of SW837 cells, HSP27 depletion was not apparent at 3 days (data not 
shown) but the depletion of this protein was observed 4 days post siRNA 
incubation, and was still low at 11 days post-knockdown (Figure 18C).
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Figure 18: Western blots illustrating transient HSP27 depletion using siRNAs, 
and for comparison, control siRNAs, on colorectal cancer cell lines. (A) HSP27 
expression was observed in the cell lines used in this study. (B) HSP27 depletion 
in SW480, HCT116 and HRT18 cells. (C) HSP27 depletion in SW837 cells.
121
5.1.6 HSP27 depletion enhanced cell apoptosis in response to 
chemo- or irradiation
Using MTS assay, the half maximal inhibitory concentrations (IC50) of three 
chemotherapy agents - 5-FU, irinotecan, oxaliplatin, and of gamma irradiation 
on HCT116, SW480, HRT18 and SW837 cells were measured (Figure 19). For 
ease of comparison, all of the IC50S from Figure 19 were tabulated (Table 16). 
Based on these data, the rectal cancer cells, SW837, exhibited the highest IC50 
values and therefore the most resistance to 5-FU, oxaliplatin and gamma 
irradiation (1,000 pM, 150 pM and 15 Gy respectively, Figure 19D & E, Table 
16). The other rectal cancer cells, HRT18, were the most resistant to irinotecan 
(75 pM), but at the same time, the most sensitive to 5-FU and oxaliplatin (100 
pM and 1.56 pM respectively) compared to other cancer cell lines in this study 
(Figure 19C). The colon cell line HCT116 showed the lowest IC50 value and 
therefore was most sensitive to 5-FU (Figure 19A). These IC50S were then used 
in apoptosis assays to examine the effects of HSP27 depletion on cellular 
sensitivity to chemotherapy and radiotherapy.
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C 2.5
Radiation dose (Gray)
HCT 1X6 
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ICsoOf Gamma Radiation: 
HCT-10G (4 days) 
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Figure 19: IC50 of chemo and radiotherapy for colorectal cancer cells lines. Cells 
were harvested and 3,000 cells/well were plated for 24 hr prior to addition of 
variable concentrations of chemotherapy or gamma irradiation. HCT116, SW480 
and HRT18 cells were incubated for 4 days following treatment with 
chemotherapeutic agents and gamma irradiation, whilst SW837 cells were 
incubated for 5 days following addition of chemotherapeutic agents and 7 days 
after treatment with gamma irradiation. Using MTS assays, IC50 of 5-FU, 
irinotecan and oxaliplatin for A) HCT116, B) SW480, C) HRT18, D) SW837 
cells and gamma radiation for D) 4 cell lines were detennined. The results are 
representative of at least 2 independent experiments with five wells utilized for 
each treatment.
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\lC50 value
Cell line
5-FU (pM) Irinotecan
(pM)
Oxaliplatin
(pM)
Gamma
irradiation
(Gray)
HCT116 250 12.5 5 10
SW480 500 25 4.69 10
HRT18 100 75 1.56 10
SW837 1000 50 150 15
Table 16: Tabulated IC50 values of chemotherapeutic agents and gamma 
irradiation for colorectal cancer cell lines used in this study.
When HCT116 cells were subjected to siRNA transfection, HSP27 depletion 
alone did not result in a significant increase in cell apoptosis (quadrants A2 + 
A4, compared to cells treated with control siRNAs) (shown as flow cytometry 
two-colour fluorescence dot plot in Figure 20A, and the same of average of 
repeated experiments shown in graphical form in Figure 21 A). Treatment of 
HSP27-depleted HCT116 cells with 5-FU (Figure 20B), oxaliplatin (Figure 
20C), irinotecan (Figure 20D) and gamma radiation (Figure 20E), was 
accompanied in every case by a significant increase in apoptotic cells compared 
to the control siRNA treated cells (P < 0.05, Figure 21 A). This significant 
increase in cell chemo-radio sensitivity following HSP27 depletion was also 
consistently shown in SW480, HRT18 and SW837 cells (Figure 21B, C & D 
respectively). For HSP27-depleted cells, there was a 10-20 % increase in the 
apoptotic population compared with non-HSP27-treated cells upon treatment 
with 5-FU, oxaliplatin or irinotecan (Figure 21). This magnitude of increase in 
cell apoptosis was smaller upon treatment with gamma irradiation, ~10 %.
Furthermore, the most 5-FU-, oxaliplatin-, and irradiation-resistant cells, SW837
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showed a similar increase in cell response to these treatments following HSP27 
depletion compared with other cell lines. There was however, no difference 
between colon (HCT116 and SW480) and rectal cancer cells (HRT18 and 
SW837) in the extent of response to chemo- or radiation upon HSP27 depletion. 
The depletion of HSP27 expression following treatment with HS27-targetting 
siRNAs in every experiment was confirmed by western blotting.
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Figure 20: Flow cytometry two-colour fluorescence dot plot of HCT116 cells 
labelled with annexin-V and propidium iodide. Three days following 
transfection with HSP27-targeting and control siRNAs, HCT116 cells were 
treated with 4 days of A) normal culture media, B) 5-FU, C) Oxaliplatin, D) 
Irinotecan, and E) Gamma irradiation, followed by cell collection for annexin- 
V/propidium iodide staining and flow cytometry analysis. The x-axis represents 
annexin-V-related fluorescence (FL1 log) and the y-axis represents propidium 
iodide-related fluorescence (FL2 log). The percentages of cells in quadrants are 
representative of cell debris (quadrant Al), late apoptotic cells (quadrant A2), 
viable cells (quadrant A3), and early apoptotic cells (quadrant A4). Cell 
apoptosis was calculated by adding percentages in quadrants A2 and A4. The 
results are representative of at least 2 independent experiments.
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Controlsirnai Figure 211 The proportion of apoptotic cells in response to chemo-radiotherapy
Control$iRNA2
HSP27siRNA2 following HSP27 depletion. Upon HSP27 depletion, the proportion of apoptotic 
cells was significantly increased in response to 5-FU, irinotecan, oxaliplatin and 
gamma-radiation in A) HCT116 cells, B) SW480 cells, C) HRT18 cells, and D) 
SW837 cells compared to control siRNA treated cells. The results are 
representative of at least 2 independent experiments. * = P < 0.05, n/s = non­
significant.
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5.1.7 Cell cycle analysis, cell proliferation and cell migration
Cell cycle analysis was performed on HCT116 (Figure 22) and HRT18 (Figure 
23) cells following HSP27 depletion. In HCT116 cells, HSP27 depletion resulted 
in a significantly larger proportion of cells in Gq/Gi phase compared to the 
control siRNA treated cells {P < 0.05, Figure 22B), with a corresponding lower 
proportion of cells in S phase and G2/M phase, although this did not reach 
statistical significance. These changes in the cell cycle profile following HSP27 
depletion were more pronounced in HRT18 cells, where HSP27 depletion 
resulted in a significant G1 block, accompanied by a considerably lower 
proportion of cells in S phase and G2/M phase compared to controls {P < 0.05, 
Figure 23B).
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Figure 22: Cell cycle profiles of HCT116 cells following HSP27 depletion. 
HCT 116 cells were harvested for cell cycle analysis following 3 days of 
incubation with siRNAs. The resulting cytograms are shown for cells treated 
with Ai) siRNA control 1, Aii) siRNA control 2, Aiii) HSP27-targeting siRNA 
1, and Aiv) HSP27-targetting siRNA 2, while B) shows the percentages of cells 
in various stages of the cell cycle representative of two independent experiments. 
Ml denotes Sub-Go phase cells, indicative of fragmented DNA dying/dead cells. 
M2 denotes Gq/Gi phase cells, which indicates a period in the cell cycle where 
cells exist in a quiescent state. M3 denotes S phase cells, indicative of synthesis 
phase, when DNA synthesis or replication occurs. M4 denotes G2/M phase, 
when cells undergo rapid growth and mitosis. The results are representative of at 
least 2 independent experiments. * = P< 0.05, n/s = non-significant.
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Figure 23: Cell cycle profiles of HRT18 cells following HSP27 depletion. HRT18 cells 
were harvested for cell cycle analysis following 3 days of incubation with siRNAs. The 
resulting cytograms are shown for cells treated with Ai) siRNA control 1, Aii) siRNA 
control 2, Aiii) HSP27-targeting siRNA 1, and Aiv) HSP27-targetting siRNA 2, while B) 
shows the percentages of cells in various stages of the cell cycle representative of two 
independent experiments. M1 denotes Sub-Go phase cells, indicative of fragmented DNA 
dying/dead cells. M2 denotes Gq/Gi phase cells, which indicates a period in the cell cycle 
where cells exist in a quiescent state. M3 denotes S phase cells, indicative of synthesis 
phase, when DNA synthesis or replication occurs. M4 denotes G2/M phase cells, when 
cells undergo rapid growth and mitosis. The results are representative of at least 2 
independent experiments. * = P < 0.05, n/s = non-significant.
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Along with these changes in cell cycle profiles, HSP27 depletion was 
consistently accompanied by retardation in cell proliferation in HCT116, 
SW480, HRT18 and SW837 cell lines (Figure 24A, B, C & D). In addition, in 
vitro cell motility assays showed that there was significant reduction in cell 
migration in response to 10 % FBS placed in the lower motility chamber, 
demonstrated by HCT116, SW480 and SW837 cells (P < 0.05, Figure 25), 
although this effect was not observed in the less motile cells, HRT18 (Figure 
25).
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Figure 24: Cell proliferation analysis following HSP27 depletion. Following 
HSP27 depletion experiments (3 days for HCT116, SW480 and HRT18 cells, 
and 4 days for SW837 cells following treatment with HSP27 targeting siRNAs 
or non-targeting controls) , cells were collected and plated into 96-well plate 
(3,000 cells/well) and incubated for 24, 48 and 72 hours when MTS assays were 
performed on these time point. MTS readings at absorbance of 450 nm of 
indicated cells following HSP27 depletion A) HCT116, B) SW480, C) SW837, 
D) HRT18. The results are representative of at least 2 independent experiments 
with five wells utilized for cells treated with each siRNAs.
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Figure 25: Cell motility following HSP27 depletion. Cells were collected 
following HSP27 depletion experiment and plated into a modified Boyden 
chamber, followed by 18 hours incubation before the inserts were stained and 
cells were counted. The results are representative of at least 2 independent 
experiments. * = P< 0.05, n/s = non-significant.
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5.2 Discussion
Following surgical resection, the 5-year survival for node-positive, Dukes’ C 
cancer is only 30-40 %56. Hence, patients in this poor prognostic group are 
routinely considered for adjuvant therapy. The mainstay of adjuvant 
chemotherapy in colorectal cancer is 6 months administration of 5-fIuorouraciI 
(5-FU), which confers a 30 % proportional reduction in risk of death, equivalent 
to an additional survival gain of 10-15 %298. A large proportion of patients 
receiving 5-FU unfortunately will not actually derive benefit from it, either 
because surgery alone would be curative or because the disease will ultimately 
relapse despite the additional treatment.
Can the current adjuvant treatments be improved? They could be improved if 
they were better tolerated, more effective, or targeted more closely to the patients 
who would actually benefit/respond. At present, there is no molecular marker 
that is sufficiently accurate to be used in the clinical practice as a predictive 
factor for response to adjuvant chemo-radiotherapy in colorectal cancer.
The relatively large Liverpool colorectal cancer patient cohort (n = 404), which 
had previously undergone characterisation for HSP27 expression , has afforded 
smaller subgroup analysis of Dukes’ C cancer patients treated with adjuvant 5- 
FU (n = 58).
Our observation of an association between high tumoural HSP27 and poor 
cancer-specific 5-year survival among Dukes’ C cancer patients who had 
undergone surgery and had received adjuvant 5-FU suggests that high HSP27 
confers resistance to 5-FU and therefore leads to early recurrence and poor
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survival. Moreover, our finding that for patients with low tumoural HSP27, 
treatment with adjuvant 5-FU was accompanied by an improvement in survival 
compared to patients with low tumoural HSP27 treated with surgery only is 
consistent with a role for HSP27protecting against the effects of treatment.
Furthermore, our finding that patients with high tumoural HSP27 who received 
adjuvant 5-FU did not have an improved outcome compared to patients who did 
not receive adjuvant 5-FU, suggests that high HSP27 may be predictive of 
patients who will not derive benefit from 5-FU. Unfortunately, the number of 
patients in this study was too small to allow us to clarify whether this 
observation is true in both colon and rectal cancer patients. Moreover, we did not 
perform genomic analysis on the tumours, such as KRAS mutational status, 18q 
loss of heterozygosity or MSI, which could potentially affect patient outcomes.
Our findings coincide with a smaller cohort analysis (n = 20) by Choi and 
colleagues279, which found that HSP27 expression levels of colorectal tumour 
specimens from irinotecan-non-responding patients were significantly higher 
compared to those of irinotecan-responding patients. This suggested that HSP27 
is associated with irinotecan resistance in human colorectal cancer. Contrary to 
the findings by Choi and colleagues and our analyses, Rau and colleauges 
found no correlation between differential HSP27 expression and the level of 
clinical response in patients treated with pre-operative chemotherapy, 
radiotherapy or hyperthermia for locally advanced rectal cancer (n= 23).
Based on the perceived clinical relevance of HSP27 in chemo- or radiation 
resistance in colorectal and other cancers, the consequences of depleting HSP27 
levels on cell sensitivity to chemotherapy and radiotherapy has been intensely
139
studied. For many cancer cell lines grown in culture, siRNA or antisense 
oligonucleotide-mediated depletion of HSP27 has been shown to enhance 
apoptosis in response to chemotoxic treatments. Specific examples include 
enhanced apoptosis following HSP27 depletion in response to vincristine and 
adriamycin in human gastric cancer cells ; paclitaxel in prostate and 
bladder283 cancer cells; cisplatin in cervical cancer cells286; gemcitabine in 
pancreatic cancer cells275; irmotecan279 and doxorubicin290 in colonic cancer cells 
and gamma-irradiation in several cancer cell lines289. However, of particular 
relevance to our observation that high tumoural HSP27 was associated with poor 
cancer-specific 5-year survival among patients who had received adjuvant 5-FU, 
we were aware that Garrido and colleagues290 found no changes in cell 
sensitivity to 5-FU in their stably transfected colonic cells with HSP27 cDNA 
sense. Moreover, there was no published study reporting on the effects of HSP27 
levels on chemosensitivity of rectal cancer cell lines. This prompted us to 
examine whether we could, in a variety of cell lines, determine the relationship 
between HSP27 and sensitivity to 5-FU and other chemotoxic treatments. We 
showed that both colon and rectal cancer cell apoptosis was significantly 
enhanced in response to 5-FU, irinotecan, oxaliplatin and gamma irradiation 
following transient HSP27 depletion. Our data are consistent with a recent study, 
which described a colonic cancer cell line transiently transfected with a HSP27- 
expression vector299. The work showed that resistance to 5-FU was significantly 
enhanced following the overexpression of the protein, and that sensitivity to 5- 
FU was increased following HSP27 down-regulation.
Cell proliferation and migration are prerequisites for cancer growth, invasion 
and metastasis. We demonstrated that HSP27 depletion resulted in suppression
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of cell proliferation without an increase in cell apoptosis, while Rocchi and 
colleagues281, 284, 285 and Zoubeidi and co-workers287 observed cell growth 
suppression which could be attributed to an increase in cell apoptosis. Our 
findings can be explained by the cell cycle analysis, that following HSP27 
depletion, the fraction of cells in Gq/Gi phase was significantly higher, along 
with lower fraction of cells in S phase and G2/M phase compared to the controls, 
suggesting cell cycle arrest and therefore retardation in cell growth. It is however 
interesting to note, that although HSP27 depletion resulted in arrest of the cell 
cycle in Gj, it was nonetheless accompanied by an increased in cell apoptosis in 
response to 5-FU, despite the fact that 5-FU is an S-phase-specific agent. It is 
possible that the effects of metabolites of 5-FU which also result in DNA and 
RNA damage (in a non-S-phase dependent manner), may have contributed to 
the enhanced apoptosis observed300. With the lack of HSP27 in inhibiting 
apoptotic pathways and maintaining cell repair mechanisms, the presence of 
DNA and RNA damage will ultimately direct cells to commit apoptosis. 
Together with our observation, in vivo studies on mice bearing prostate284 and 
bladder 1 cancers confirmed that treatment with HSP27 anti-sense 
oligonucleotide inhibited tumour growth and decreased tumour volume.
We demonstrated that cell motility was also shown to be significantly reduced 
following HSP27 depletion. Consistent with our findings, Shin and colleagues301 
reported that HSP27 depletion in breast cancer cells inhibited cell motility and 
invasion. The group also showed that this is achieved via blocking of protein 
kinase C-dependent phosphorylation of HSP27. HSP27 has been recognised as a 
potent regulator of cytoskeletal dynamics in actin microfilaments and stabilises
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F-actin microfilaments247. Hence, HSP27 depletion results in cytoskeletal 
instability which leads to impediment in cell motility.
In summary, we have shown for the first time, the clinical relevance of high 
HSP27 as a predictive marker of poor response to adjuvant 5-FU in patients with 
resected Dukes C colorectal cancer. This, coupled with our data demonstrating 
that targeting HSP27 could enhance colorectal cancer cell sensitivity to 
chemotherapy and radiotherapy suggest a potential new avenue in the 
management of colorectal cancer.
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CHAPTER 6: 
CONCLUSION
The roles of endogenous DAMPs in sustaining cancer cell proliferation, motility, 
migration, interaction with stromal cells, endurance from external insults (i.e, 
chemo-radiotherapy) are now accepted paradigms of carcinogenesis. We provide 
evidence that the extracellular DAMPs from inflammatory cells, S100A8 and 
S100A9, signal with colorectal cancer cells, in part via Smad4, through the 
RAGE receptor promoting cell proliferation and motility. Further research into 
S100A8/A9 signalling in the tumour microenvironment, elucidating cancer cell 
cytokines involved in recruiting S100A8/A9-secreting inflammatory cells, will 
shed light on how these proteins orchestrate crosstalk in promoting tumour 
development/spread.
We also showed that the intracellular DAMP, HSP27, plays an important role in 
maintaining migratory and proliferative activity of colorectal cancer cell, where 
its depletion resulted in inhibition of cell growth and motility. While high 
expression level of HSP27 in resected colorectal cancer specimens before 5-FU 
treatment correlated with poor clinical response of the cancer patients, our in 
vitro experiments showed that following HSP27 depletion, both colon and rectal 
cancer cell sensitivity was increased not just to 5-FU but also to irinotecan, 
oxaliplatin and gamma radiation. Our finding of HSP27 levels as a predictive 
marker of response to chemotherapy warrants validation with a large patient 
sample from a randomised controlled trial. This will inform the potential use of 
HSP27 as a biomarker in clinical practice and future drug development.
Taken as a whole, this study describes the discovery and assay development 
phase of S100A8, S100A9 and HSP27 as potential biomarkers in colorectal 
carcinogenesis. Also, our experiments delineate the roles of S100A8, S100A9
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and HSP27 in carcinogenesis and yield impoitant insights that could lead to 
potential therapeutic targets for colorectal cancer treatment.
145
CHAPTER 7: 
BIBLIOGRAPHY
1. Bowel cancer statistics - key facts, http://info.cancerreseai'chnk.org/cancerstats/tvnes/bowel/. 
[accessed on 21/08/2010].
2. Quality Improvement & Open Reporting.
http://www.nbocap.org.uk/resources/reports/report2007.pdf [17/09/2007.
3. Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ. Population-based audit of 
colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, 
Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br JSurg 
1997;84(12): 1731-1736.
4.Sakorafas GH, Zouros E, Peros G. Applied vascular’ anatomy of the colon and rectum: clinical 
implications for the surgical oncologist. Surg Oncol 2006;15(4): 243-255.
5. Glymie-Jones R, Mathur P, Elton C, Train ML. The multidisciplinary management of 
gastrointestinal cancer. Multimodal treatment of rectal cancer. Best Bract Res Clin 
Gastroenterol 2007;21(6): 1049-1070.
6. Hidovic-Rowe D, Claridge E. Modelling and validation of spectral reflectance for the colon. 
Phys Med Biol 2005;50(6): 1071-1093.
7. Leslie A, Pratt NR, Gillespie K, Sales M, Kemohan NM, Smith G, Wolf CR, Carey FA, 
Steele RJ. Mutations of APC, K-ras, and p53 are associated with specific chromosomal 
aberrations in colorectal adenocarcinomas. Cancer Res 2003;63(15): 4656-4661.
8. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, 
Wolf CR. Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal 
cancer. Proc Natl Acad Sci USA 2002;99(14): 9433-9438.
9. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects 
and overview of colorectal tumorigenesis. Br Med Bull 2002;64: 27-43.
10. Dunican DS, McWilliam P, Tighe O, Paiie-McDermott A, Croke DT. Gene expression 
differences between the microsatellite instability (MIN) and chromosomal instability (CIN) 
phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 
2002;21(20): 3253-3257.
11. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H. Evolving 
molecular* classification by genomic and proteomic biomarkers in colorectal cancer: Potential 
implications for the surgical oncologist. Surg Oncol 2008.
12.Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal 
cancer. Br JSiirg2W6\93(4)\ 395-406.
13. Perucho M. Microsatellite instability: the mutator that mutates the other mutator. Nat Med 
1996;2(6): 630-631.
14. Sanchez J-C, Cordials, Gariy L., Hochstrasser, Denis F. Biomedical applications of 
proteomics. Weinheim : Wiley-VCH, 2004.
15. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, Dickersin GR, 
Ewing S, Geller S, Kasimian D, et al. The National Polyp Study. Patient and polyp 
characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 
1990;98(2): 371-379.
16. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of 
rectosigmoid adenomas. A£«g//Med 1992;326(10): 658-662.
17. Granqvist S. Distribution of polyps in the large bowel in relation to age. A colonoscopic 
study. Scand J Gasfroenterol 1981; 16(8): 1025-1031.
147
18. Vogelstein B, Fearon ER, Hamilton SR, Kem SE, Preisinger AC, Leppert M, Nakamura Y, 
White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J 
Med 1988;319(9): 525-532.
19. Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstmp DM, MacCarty RL. Natural history of 
untreated colonic polyps. Gastroenterology 1987;93(5): 1009-1013.
20. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, 
Schapiro M, Bond JH, Panish JF, et al. Prevention of colorectal cancer by colonoscopic 
polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329(27): 1977-1981.
21. Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS, Bond JH,
Waye JD, Schapiro M, Panish JF, et al. Risk of colorectal cancer in the families of patients with 
adenomatous polyps. National Polyp Study Workgroup. AEWg/ JMed 1996;334(2): 82-87.
22. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. 
Gastroenterology', 13 8(6): 2088-2100.
23. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007;21(20): 2525-2538.
24. Gatalica Z, Torlakovic E. Pathology of the hereditary colorectal carcinoma. Fam Cancer 
2008;7(1): 15-26.
25. St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES. Cancer risk 
in relatives of patients with common colorectal cancer. Ann Intern Med 1993 ;118(10): 785-790.
26. Saydali SH, Platz EA, Rifai N, Poliak MN, Brancati FL, Helzlsouer KJ. Association of 
markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer 
Epidemiol Biomarkers Prev 2003;12(5): 412-418.
27. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol 
Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 2006;21(4): 400- 
404.
28. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic 
syndrome and risk of incident colorectal cancer. Cancer 2006;107(1): 28-36.
29. Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, Wu MS. Association of 
metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol 
Hepatol 2007;5(2): 221-229; quiz 141.
30. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, Rliee PL, 
Kim JJ, Rhee JC, Choi YH. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer 
Epidemiol Biomarkers Prev 2007; 16(8): 1543-1546.
31. Stunner T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for 
colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev 
2006;15(12): 2391-2397.
32. Chan AO, Jim MH, Lam KF, Monis JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM,
Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S, Szeto ML, Wong 
BC, Lam SK. Prevalence of colorectal neoplasm among patients with newly diagnosed 
coronary artery disease. Jama 2007;298(12): 1412-1419.
33. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist 
DA, Melton LJ, 3rd, Sellers TA, Cerhan JR. Clinically confirmed type 2 diabetes mellitus and 
colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 
2006;101(8): 1872-1879.
148
34. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal 
adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis 
Colon Rectum 2008;51(5): 593-597.
35. Flood A} Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E, Schatzkin A. Elevated serum 
concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. 
Gastroenterology 2007;133(5): 1423-1429.
36. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking 
increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10(7): 725-731.
37. Botteri E, lodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and 
adenomatous polyps: a meta-analysis. Gastroenterology 200S;134(2): 388-395.
38. Chia VM, Newcomb PA, Bigler J, Morimoto LM, Thibodeau SN, Potter JD. Risk of 
microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal 
anti-inflammatory drug use. Cancer Res 2006;66(13): 6877-6883.
39. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK, 
Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF 
mutations in colon cancer. JNatl Cancer Inst 2006;98(23): 1731-1738.
40. Bowel cancer statistics - key facts.
http://info.cancerresearchuk.org/cancerstats/types/bowel/inortality/?a=5441 [accessed on 
17/08/2008 2010].
41. West NJ, Poullis AP, Leicester RJ. The NHS Bowel Cancer Screening Programme - a 
realistic approach with additional benefits. Colorectal Dis 2007.
42. Huang CS, Lai SK, Farraye FA. Colorectal cancer screening in average risk individuals. 
Cancer Causes Control 2005; 16(2): 171-188.
43. Dukes CE. The classification of cancer of the rectum. The Journal of Pathology and 
Bacteriology 1932;35: 323-332.
44. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the 
colon and rectum. Ann Surg 1954;139(6): 846-852.
45. Phillips RKS. A companion to specialist surgical practice : Colorectal Surgery (2nd Edition 
edn). W.B. Saunders Company Limited, 2001.
46. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J 
Clin 2004;54(6): 295-308.
47. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process 
for continuous improvement of the TNM classification. Cancer 2004; 100(1): 1-5.
48. Griffin MR, Bergstralh EJ, Coffey RJ, Bear! RW, Jr., Melton LJ, 3rd. Predictors of survival 
after curative resection of carcinoma of the colon and rectum. Cancer 1987;60(9): 2318-2324.
49. Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, Colquhoun K. A 
multivariate analysis of clinical and pathological valuables in prognosis after resection of lai'ge 
bowel cancer. Br JSurg 1985;72(9): 698-702.
50. Minsky BD, Mies C, Rich TA, Recht A. Lymphatic vessel invasion is an independent 
prognostic factor for survival in colorectal cancer. IntJRadiat Oncol Biol Phys 1989; 17(2): 
311-318.
51. Bognel C, Rekacewicz C, Mankarios H, Pignon JP, Elias D, Duvillard P, Prade M, Ducreux 
M, Kac J, Rougier P, et al. Prognostic value of neural invasion in rectal carcinoma: a
149
multivariate analysis on 339 patients with curative resection, Eur JCancer 1995;31A(6): 894- 
898.
52. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 
1987;1(8545): 1303-1306.
53. Patt DJ, Brynes RK, Vardiman JW, Coppleson LW. Mesocolic lymph node histology is an 
important prognostic indicator for patients with carcinoma of the sigmoid colon: an 
immunomorphologic study. Cancer 1975;35(5): 1388-1396.
54. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. 
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.
N Engl J Med 2000;342(2): 69-77.
55. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between 
chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 
2005;41(14): 2060-2070.
56. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American 
Joint Committee on Cancer sixth edition staging. JNatl Cancer Inst 2004;96(19): 1420-1425.
57. The Cancer Research UK (CR-UK) Prognostic/predictive biomarker (BM) roadmap.
http ://science. cancerresearchuk. org/prod consump/groups/cr common/@fre/@fun/document
s/generalcontent/cr 027481.pdf, [accessed on 05/03/2011].
58. Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on 
carcinogenesis and possible biomarkers. Proteomics 2006;6(20): 5650-5661.
59. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, 
Hayes DF, Bast RC, Jr. ASCO 2006 update of recommendations for the use of tumor markers 
in gastrointestinal cancer. JClin Oncol 2006;24(33): 5313-5327.
60. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, 
Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group 
on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43(9): 1348-1360.
61. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde 
CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219(2): 174- 
182.
62. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow 
up after curative resection for colorectal cancer: systematic review and meta-analysis of 
randomised trials. Bmj 2002;324(7341): 813.
63. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal 
C. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC 
Cancer 2003 ;3: 26.
64. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic 
colorectal cancer. Cochrane Database Syst Rev 2007(1): CD002200.
65. Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 
1999;26(5): 556-560,
66. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, 
Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, 
Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl 
JMed 2008;359(17): 1757-1765.
150
67. Van Cutsem E, Rougier, P.5 Kohiie, C.H., Stroh C., Schlichting, m., Bokemeyer, C. A meta­
analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy as 1st- 
line treatment for patients with metastatic colorectal cancer: results according to KRAS and 
BRAF mutation status. Eur J Cancer 2009;7: 6077 (abstr).
68. (NICE) NlfHaCE. Cetuximab for the first line treatment of metastatic colorectal cancer. 
2009.
69. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, 
Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite- 
instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for 
colon cancer. N Engl J Med 2003;349(3): 247-257.
70. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. 
Colorectal cancer. /xmcer;375(9719): 1030-1047.
71. Van Cutsem E, Dicato M, Hausteimans K, Arber N, Bosset JF, Cunningham D, De Gramont 
A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, 
Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, 
Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and 
management of rectal cancer: expert discussion and recommendations derived from the 9th 
World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 2008; 19 Suppl 6: vil- 
8.
72. Simmonds PC, Prinnose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection 
of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J 
Cancer 2006;94(7): 982-999.
73. Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C. Mechanism of action of 
fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Semin Owx?/2000;27(5 Suppl 10): 72-77.
74. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider 
JS, Emerson WA, Tormey DC, Glick JH, et al. Intergroup study of fluorouracil plus levamisole 
as adjuvant therapy for stage II/Dukes' B2 colon cancer. JClin Oncol 1995;13(12): 2936-2943.
75. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider 
JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Fluorouracil plus 
levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final 
report. Ann Intern Med 1995;122(5): 321-326.
76. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. 
Jama 1990;264(11): 1444-1450.
77. Zhang ZG, Harstrick A, Rustum YM. Modulation of fluoropyrimidines: role of dose and 
schedule of leucovorin administration. Semin Oncol 1992; 19(2 Suppl 3): 10-15.
78. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini 
G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg 
RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: 
who benefits and by how much? JClin Oncol 2004;22(10): 1797-1806,
79. Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Snrg 2005;22(6): 401-414.
80. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, Cassidy J, Cervantes 
A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, 
Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski
151
J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III 
colon cancer. N Engl J Med 2005;352(26): 2696-2704.
81. Maughan TS, Janies RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, 
Hopwood P, Jolinston C, Stephens RJ. Comparison of survival, palliation, and quality of life 
with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised 
trial. Lancet 2002;3 59(9317): 1555-1563.
82. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage 
II colon cancer: a systematic review from the Cancer Cain Ontario Program in evidence-based 
cam's gastrointestinal cancer disease site group. J Clin Oncol 2004;22(16): 3395-3407.
83. Figueredo A, Coombes ME, Mukheijee S. Adjuvant therapy for completely resected stage II 
colon cancer. Cochrane Database Syst Rev 2008(3): CD005390.
84. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr 
DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised 
study. Lancet 2007;370(9604): 2020-2029.
85. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999;35(3): 371-379.
86. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, 
Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan 
versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic 
colorectal cancer. Lancet 1998;352(913 8): 1407-1412.
87. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson 
T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil 
compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a 
multicentre randomised trial. Lancet 2000;355(9209): 1041-1047.
88. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland 
SP, Locker PK, Pirotta N, Elffing GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for 
metastatic colorectal cancer. Irinotecan Study Group. NEngl JMed 2000;343(13): 905-914.
89. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer 
RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone 
as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 
2007;25(23): 3456-3461.
90. Van Cutsem E, Labianca, R., Hossfeld, G., et al. Randomised phase III trial comparing 
infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon 
cancer patients (PETACC 3). J Clin Oncol 2005;23 (suppl):3s: Abstract 8.
91. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and 
antineoplastic activity. Semin Oncol 1998;25(2 Suppl 5): 4-12.
92. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes- 
Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, 
Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as 
first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16): 2938-2947.
93. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay 
BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, 
irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic 
colorectal cancer. J Clin Oncol 2004;22(1): 23-30.
152
94. Andre T, Boni C, Navarro M, Tabemero J5 Hickish T, Tophani C, Bonetti A, Clingan P, 
Bridgewater J5 Rivera F, de Gramont A. Improved overall survival with oxaliplatin, 
fluoroui'acil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC 
trial. JClin Oncol 2009;27(19): 3109-3116.
95. Kuebler JP, Wieand HS, O'Coimell MJ} Smith RE, Colangelo LH, Yothers G, Petrelli NJ, 
Findlay MP, Seay TE, Atlcins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, 
Conley BA, Flymi PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin 
combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for 
stage II mid III colon cancer: results from NSABP C-07. JClin Oncol 2007;25(16): 2198-2204.
96. Prolongation of the disease-free interval in surgically treated rectal carcinoma. 
Gastrointestinal Tumor Study Gxoxap. NEngl JMed 1985;312(23): 1465-1472.
97. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, 
Poon MA, Meyers WC, Mailliard JA, et al. Effective surgical adjuvant therapy for high-risk 
rectal carcinoma. NEngl JMed 1991;324(11): 709-715.
98. Monga DK, O'Connell MJ. Surgical adjuvant therapy for colorectal cancer: current 
approaches mid future directions. Ann Surg Oncol 2006;13(8): 1021-1034.
99. Marks G, Mohiuddin M, Rakinic J. New hope and promise for sphincter preservation in the 
management of cancer of the rectum. Semin Oncol 1991;! 8(4): 388-398.
100. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in 
blood shed from the surgical field. Arch Surg 1995;130(4): 387-393.
101. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22
randomised trials. 2001 ;358(9290): 1291-1304.
102. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, 
Tsclnnelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. 
Preoperative versus postoperative chemoradiotherapy for rectal cancer. NEngl JMed 
2004;351(17): 1731-1740.
103. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish 
Rectal Cancer Trial. N Engl JMed 1997;336(14): 980-987.
104. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, 
Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative 
radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer 
(MRC CR07 andNCIC-CTG C016): a multicentre, rmidomised trial. Lancet 2009;373(9666): 
811-820.
105. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth 
factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas mid adenomas. 
Tumour Biol 2000;21(2): 105-115.
106. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic 
significance of proliferating cell nuclear mitigen, epidermal growth factor receptor, and mdr 
gene expression in colorectal cancer. Cancer 1993;71(8): 2454-2460.
107. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor 
monoclonal antibody, for treatment of head mid neck cancer. Expert Opin Biol Ther 2001 ;1(4): 
719-732.
153
108. Saltz LB, Rubin, M., Hochster, H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) 
is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor 
receptor (EGFR). Proc Am Soc Clin Oncol 2001;20: 3a.
109. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser 
M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab 
plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl JMed 2004;351(4): 
337-345.
110. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, Kerin MJ, Monson 
JR. Preoperative serum vascular* endothelial growth factor can predict stage in colorectal cancer. 
Clin Cancer Res 1998;4(5): 1279-1285.
111. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, 
Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first- 
line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 
2005;23(16): 3697-3705.
112. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, 
Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N 
Engl J Med 2004;350(23): 2335-2342.
113. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz 
MA, Benson AB, 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and 
leucovorm (FOLFOX4) for previously treated metastatic colorectal cancer: results from the 
Eastern Cooperative Oncology Group Study E3200. JClin Oncol 2007;25(12): 1539-1544.
114. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 
2001;357(9255): 539-545.
115. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. N Engl J Med 1986;315(26): 1650-1659.
116. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1): 57-70.
117. Colotta F, Allavena P, Sica A, Garianda C, Mantovani A. Cancer-related inflammation, the 
seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7): 1073-1081.
118. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 
2008;454(7203): 436-444.
119. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with 
inflammatory bowel disease: a population-based study. Cancer 2001;91(4): 854-862.
120. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a 
meta-analysis. Gw/L2001;48(4): 526-535.
121. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams 
CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance 
program for neoplasia in ulcerative colitis. Gastroenterology 2006;130(4): 1030-1038.
122. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, 
Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian 
cohort of patients with ulcerative colitis: results of a population-based study. Inflammatory 
bowel diseases 2006;12(3): 205-211.
154
123. Winther KV, Jess T, Langholz E, Mmikholm P, Binder V. Long-term risk of cancer in 
ulcerative colitis: a population-based cohort study from Copenhagen County. Clin 
Gastroenterol Hepatol 2004;2(12): 1088-1095.
124. Jess T, Loftus EV, Jr., Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck 
CD, Tremaine WJ, Melton LJ, 3rd, Munkholm P, Sandbom WJ. Risk of intestinal cancer in 
inflammatory bowel disease: a population-based study Rom olmsted county, Minnesota. 
Gastroenterology 2006;130(4): 1039-1046.
125. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in 
inflammatory bowel disease. Aliment Pharmacol Ther 2003;18 Suppl 2: 1-5.
126. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 
1993;72(4): 1171-1177.
127. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal 
cancer. Cancer 1994;74(7): 1847-1854.
128. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. 
Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333(10): 609-614.
129. Peleg, II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti­
inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 
1994; 154(4): 394-399.
130. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004;31(2 
Suppl 7): 12-21.
131. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: 
consistent evidence from randomised and observational studies. Lancet 2007;369(9573): 1603- 
1613.
132. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. 
Jama 2009;302(6): 649-658.
133. Boolbol SK, Dannenberg AJ, Chadbum A, Martucci C, Guo XJ, Ramonetti JT, Abreu- 
Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM. Cyclooxygenase-2 
overexpression and tumor formation are blocked by sulindac in a murine model of familial 
adenomatous polyposis. Cancer Res 1996;56(11): 2556-2560.
134. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, 
Kelloff GJ, Verma A, Moser AR, Dove WF. Chemoprevention of spontaneous intestinal 
adenomas in the Ape Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. 
Cancer Res 1996;56(4): 710-714.
135. Srikrishna G, Freeze HH. Endogenous damage-associated molecular' pattern molecules at 
the crossroads of inflammation and cancer. Neoplasia 2009; 11(7): 615-628.
136. Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park BK, 
Schwarte-Waldhoff I, Khattak I, Azadeh B, Dodson A, Kalirai H, Neoptolemos JP, Rooney PS, 
Costello E. Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal 
tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. 
Carcinogenesis 2010;31(9): 1541-1551.
137. Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, 
Campbell F, Dodson A, Prime W, Cmogorac-Jurcevic T, Lemoine NR, Costello E. The 
expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 
status of pancreatic cancer cells. Proteomics 2007;7(11): 1929-1940.
155
138. Tweedle EM, Kliattak, L, Ang C.W., Nedjadi, T., Jenkins, R., Pai*k, B.K., Kalirai, H., 
Dodson, A., Azadeh, B., Terlizzo, M., Grabsch, H., Myint, S., Clark, P., Wong, H., Greenhalf, 
W., Neoptolemos, J.P., Rooney, P.S., Costello, E. Low molecular weight heat shock protein, 
HSP27 is a prognostic indicator in rectal cancer, but not colon cancer. Gut 2010; 56: 1501- 
1510.
139. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annual review of immunology 
2002;20: 197-216.
140. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12: 
991-1045.
141. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008;3: 99- 
126.
142. Poste G, Paruch L. Stephen Paget, M.D., F.R.C.S., (1855-1926). A retrospective. Cancer 
Metastasis Rev 1989;8(2): 93-97.
143. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the 
malignant phenotype. Mol Med Today 2000;6(8): 324-329.
144. Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. 
Trends Cell Biol 1998;8(11): 437-441.
145. Aboseif S, El-Sakka A, Young P, Cunha G. Mesenchymal reprogramming of adult human 
epithelial differentiation. Differentiation 1999;65(2): 113-118.
146. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma- 
associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer 
Res \999\S9(\9)\ 5002-5011.
147. Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res 
1998;400(l-2): 439-446.
148. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 
2001;411(6835): 375-379.
149. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between 
epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 
2000;275(12): 8806-8811.
150. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the 
treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 
2000;52(2): 237-268.
151. Bowden ET, Barth M, Thomas D, Glazer RI, Mueller SC. An invasion-related complex of 
cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular- matrix 
degradation. Oncogene 1999;18(31): 4440-4449.
152. Roberts AB, McCune BK, Spom MB. TGF-beta: regulation of extracellular matrix. Kidney 
Int 1992;41(3): 557-559.
153. Ehrchen JM, Sunderkotter C, Foell D, Yogi T, Roth J. The endogenous Toll-like receptor 4 
agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and 
cancer. JLeukoc Biol 2009;86(3): 557-566.
154. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to 
function and pathology (including an update of the nomenclature). Biochem Biophys Res 
Commun 2004;322(4): 1111-1122.
156
155. Heizmann CW, Fritz G, Schafer BW. SI00 proteins: structure, functions and pathology. 
Front Biosci 2002;7: dl356-1368.
156. Komdorfer IP, Brueckner F, Skerra A. The ciystal structure of the human 
(S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of 
interacting alpha-helices can determine specific association of two EF-hand proteins. J Mol Biol 
2007;370(5): 887-898.
157.Strupat K, Rogniaux H, Van Dorsselaer A, Roth J, Yogi T. Calcium-induced noncovalently 
linked tetramers of MRP8 and MRP 14 are confirmed by electrospray ionization-mass analysis.
J Am Soc Mass Specfrom 2000;11(9): 780-788.
158. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the 
SI00 protein family as prominent players in innate immunity. Microsc Res Tech 2003;60(6): 
569-580.
159. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917): 860-867.
160. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. 
Biochem Pharmacol 2006;72(11): 1622-1631.
161 .Frosch M, Yogi T, Waldherr R, Sorg C, Sunderkotter C, Roth J. Expression of MRP8 and 
MRP 14 by macrophages is a marker for severe forms of glomerulonephritis. JLeukoc Biol 
2004;75(2): 198-206.
162. Harrison CA, Raftery, M J., Alewood, P., Geczy, C.L. Structure/function studies of 
S100A8/A9. Letters in Peptide Science 1999;6: 359-369.
163. Yogi T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz 
MP, Nacken W, Wemer S, Sorg C, Roth J. MRP8 and MRP 14 control microtubule 
reorganization during transendothelial migration of phagocytes. Blood 2004; 104(13): 4260- 
4268.
164. Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C. MRP 8 and MRP 14, 
S-100-like proteins associated with myeloid differentiation, are translocated to plasma 
membrane and intermediate filaments in a calcium-dependent manner. Blood 1993;82(6): 1875- 
1883.
165. Goebeler M, Roth J, van den Bos C, Ader G, Sorg C. Increase of calcium levels in 
epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor- 
related protein 8 (MRP8) and MRP 14 to keratin intermediate filaments. Biochem./1995;309 ( 
Pt 2): 419-424.
166. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein 
(MRP) 8 and MRP 14, calcium-binding proteins of the SI 00 family, are secreted by activated 
monocytes via a novel, tubulin-dependent pathway. JBiol Chem 1997;272(14): 9496-9502.
167. Robinson MJ, Tessier P, Poulsom R, Hogg N. The SI00 family heterodimer, MRP-8/14, 
binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. 
JBiol Chem 2002;277(5): 3658-3665.
168. Srikrishna G, Panneerselvam K, Westphal V, Abraham V, Varki A, Freeze HH. Two 
proteins modulating transendothelial migration of leukocytes recognize novel carboxylated 
glycans on endothelial cells. J Immunol 2001;166(7): 4678-4688.
169. Viemann D, Strey A, Janning A, Turk K, Klimmek K, Yogi T, Hirono K, Ichida F, Foell D, 
Kehrel B, Gerke V, Sorg C, Roth J. Myeloid-related proteins 8 and 14 induce a specific
157
inflaminatory response in human microvascular endothelial cells. Blood 2005;105(7): 2955- 
2962.
170. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of 
SI00: proteins SI00AS, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion.
JImmunol 2003; 170(6): 3233-3242.
171. Newton RA, Hogg N. The human SI 00 protein MRP-14 is a novel activator of the beta 2 
integrin Mac-1 on neutrophils. J Immunol 1998;160(3): 1427-1435.
172. Clohessy PA} Golden BE. Calprotectin-mediated zinc chelation as a biostatic mechanism 
in host defence. Scand J Immunol 1995;42(5): 551-556.
173. Mui’thy AR, Lehrer RI, Harwig SS, Miyasaki KT. In vitro candidastatic properties of the 
human neutrophil calprotectin complex. J Immunol 1993; 151(11): 6291-6301.
174. Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of 
recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis 
2000; 182(4): 1272-1275.
175. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory 
arthritis. Nat Clin Bract Rheumatol 2007;3(7): 382-390.
176. Glinsky GV, Krones-Herzig A, Glmskii AB. Malignancy-associated regions of 
transcriptional activation: gene expression profiling identifies common chromosomal regions of 
a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. 
Neoplasia 2003 ;5(3): 218-228.
177. Shen J, Person MD, Zhu J, Abbmzzese JL, Li D. Protein expression profiles in pancreatic 
adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as 
detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 
2004;64(24): 9018-9026.
178. Stulik J, Osterreicher J, Koupilova K, Knizek, Macela A, Bures J, Jandik P, Langr F, Dedic 
K, Jungblut PR. The analysis of S100A9 and S100A8 expression in matched sets of 
macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 
positive cells underlie and invade tumor mass. Electrophoresis 1999;20(4-5): 1047-1054.
179. Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, 
Schwaerzler P, Zeimet A, Marth C, Illmensee K. Calgranulins in cystic fluid and serum from 
patients with ovarian carcinomas. Cancer Res 2003;63(21): 7507-7514.
180. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of SI00 proteins in normal 
human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and 
S100A11 are all overexpressed in common cancers. Histopathology 2005;46(3): 256-269.
181. Aral K, Teratani T, Nozawa R, Yamada T. Immunohistochemical investigation of S100A9 
expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor 
differentiation. Oncol Rep 2001 ;8(3): 591-596.
182. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R. S100A9 expression in invasive 
ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated 
with poor tumour differentiation. EurJ Cancer 2004;40(8): 1179-1187.
183. Arai K, Yamada T, Nozawa R. Immunohistochemical investigation of migration inhibitory 
factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol
2000; 17(3): 183-188.
158
184. Ito Y, Aral K, Ryushi, Nozawa, Yoshida H, Tomoda C, Urmio T, Miya A, Kobayashi K, 
Matsuzuka F, Kuma K, Kakudo K, Miyauchi A. S100A9 expression is significantly linked to 
dedifferentiation of thyroid carcinoma. Pathol Res Pract 2005;201(8-9): 551-556.
185. Hermani A, Hess J5 De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D. 
Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate 
cancer. Clin Cancer Res 2005;11(14): 5146-5152.
186. Aral K, Takano S, Teratani T, Ito Y} Yamada T5 Nozawa R. S100A8 and S100A9 
overexpression is associated with poor pathological parameters in invasive ductal carcinoma of 
the breast. Curr Cancer Drug Targets 2008;8(4): 243-252.
187. Yui S, Mikami M, Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and 
human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from 
inflammatory peritoneal exudate cells. JLeukoc Biol 1995;58(6): 650-658.
188. Yui S, Mikami M, Tsurumaki K, Yamazaki M. Growth-inhibitory and apoptosis-inducing 
activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: 
regulation by metal ions. JLeukoc Biol 1997;61(1): 50-57,
189. Nakatani Y, Yamazaki M, Chazin WJ, Yui S. Regulation of S100A8/A9 (calprotectin) 
binding to tumor cells by zinc ion and its implication for apoptosis-inducing activity. Mediators 
Inflamm 2005;2005(5): 280-292.
190. Ghavami S, Kerkhoff C, Los M, Hashemi M, Sorg C, Karami-Tehrani F. Mechanism of 
apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of 
metal ions. JLeukoc Biol 2004;76(1): 169-175.
191. Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, Hashemi M, Eshraghi 
M, Schulze-Osthoff K, Klonisch T, Los M. S100A8/9 induces cell death via a novel, RAGE- 
independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. 
Biochim Biophys Acta 2008;1783(2): 297-311.
192. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, 
Kerkhoff C, Los M. S100A8/A9 at low concentration promotes tumor cell growth via RAGE 
ligation and MAP kinase-dependent pathway. JLeukoc Biol 2008;83(6): 1484-1492.
193. Turovskaya O, Foell D, Sinlia P, Yogi T, Newlin R, Nayak J, Nguyen M, Olsson A, 
Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G. RAGE, 
carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. 
Carcinogenesis 2008;29(10): 2035-2043.
194. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, 
Yogi T, Roth J, Gabrilovich DI. Inhibition of dendritic cell differentiation and accumulation of 
myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 
2008;205(10): 2235-2249.
195. Sinlia P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. 
Proinflammatory SI 00 proteins regulate the accumulation of myeloid-derived suppressor cells. 
J Immunol 2008;181(7): 4666-4675.
196. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of 
chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 
2006;8(12): 1369-1375.
159
197. Hiratsuka S, Watanabe A, Sakurai Y, AkasM-Takamura S, Ishibaslii S5 Miyake K, Shibuya
M, Akira S, Abm-atani H, Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade 
establishes a pre-metastatic phase. Nat Cell Biol 2008;10(11): 1349-1355.
198. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5): 
759-767.
199. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, 
Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. Evaluation of candidate 
tumour suppressor genes on chromosome 18 in colorectal cancers. Nature genetics 1996; 13(3): 
343-346.
200. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, 
Preisinger AC, Thomas G, Kinzler KW, et al. Identification of a chromosome 18q gene that is 
altered in colorectal cancers. Science (New York, NY 1990;247(4938): 49-56.
201. Miyaki M, lijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara
N, Iwama T, Utsunomiya J, Kuroki T, Mori T. Higher frequency of Smad4 gene mutation in 
human colorectal cancer with distant metastasis. Oncogene 1999;18(20): 3098-3103.
202. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Bimbaum EH, Read 
TE, Fleshman JW, Kodner IJ, Moley JF. Confirmation that chromosome 18q allelic loss in 
colon cancer is aprognostic indicator. JClin Oncol 1998;16(2): 427-433.
203. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, Santini A, del Semio L. Chromosome 
18q allelic loss and prognosis in stage II and III colon cancer. International journal of cancer 
1998;79(4): 390-395.
204. Jernvall P, Makinen MJ, Kaittunen TJ, Makela J, Vihko P. Loss of heterozygosity at 18q21 
is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. British 
journal of cancer 1999;79(5-6): 903-908.
205. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB, 3rd, 
Hamilton SR. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. 
The New Englandjournal of medicine 2001;344(16): 1196-1206.
206. Halm SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein 
CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at 
human chromosome 18q21.1. Science (New York, NY 1996;271(5247): 350-353.
207. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19(23): 
2783-2810.
208. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. 
Cell 1998;95(6): 737-740.
209. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks 
RW. Guidelines for resection of colorectal cancer liver metastases. Gut 2006;55 Suppl 3: iiil-8.
210. Quirke P, Morris E. Reporting colorectal cancer. Histopathology 2007;50(1): 103-112.
211. Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IP, 
Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. Mutations in the SMAD4/DPC4 
gene in juvenile polyposis. Science 1998;280(5366): 1086-1088.
212. Woodford-Richens KL, Rowan AJ, Poulsom R, Bevan S, Salovaara R, Aaltonen LA, 
Houlston RS, Wright NA, Tomlinson IP. Comprehensive analysis of SMAD4 mutations and 
protein expression in juvenile polyposis: evidence for a distinct genetic pathway and polyp 
morphology in SMAD4 mutation carriers. Am J Pathol 2001;159(4): 1293-1300.
160
213. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal 
tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Ape genes. Cell 
1998;92(5): 645-656.
214. Takaku K, Miyoslii H, Matsimaga A, Oshima M, Sasaki N, Taketo MM. Gastric and 
duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res 1999;59(24): 6113-6117.
215. Tascilar M, Skinner FIG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams 
RA, Cameron JL, Kem SE, Yeo CJ, Hruban RH, Goggins M. The SMAD4 protein and 
prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7(12): 4115-4121.
216. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, 
Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal 
adenocarcinoma. JClin Oncol 2002;20(23): 4531-4542.
217. Xiangming C, Natsugoe S, Takao S, Hokita S, Ishigami S, Tanabe G, Baba M, Kuroshima 
K, Aikou T. Preserved Smad4 expression in the transforming growth factor beta signaling 
pathway is a favorable prognostic factor in patients with advanced gastric cancer. Clin Cancer 
Res 2001 ;7(2): 277-282.
218. Liu FS, Chen JT, Hsieh YT, Ho ES, Hung MJ, Lu CH, Chiou LC. Loss of Smad4 protein 
expression occurs infrequently in endometrial carcinomas. IntJ Gynecol Pathol 2003;22(4): 
347-352.
219. Stuelten CH, Buck MB, Dippon J, Roberts AB, Fritz P, Knabbe C. Smad4-expression is 
decreased in breast cancer tissues: a retrospective study. BMC Cancer 2006;6: 25.
220. Natsugoe S, Xiangming C, Matsmnoto M, Okumura H, Nakashima S, Sakita H, Ishigami 
S, Baba M, Takao S, Aikou T. Smad4 and transforming growth factor betal expression in 
patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002;8(6): 1838- 
1842.
221. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic 
adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 2000; 157(4): 
1105-1111.
222. Tanaka T, Watanabe T, Kazama Y, Tanaka J, Kanazawa T, Kazama S, Nagawa H. Loss of 
Smad4 protein expression and 18qLOH as molecular' markers indicating lymph node metastasis 
in colorectal cancer—a study matched for tumor depth and pathology. JSurg Oncol 2008;97(1): 
69-73.
223. Tanaka T, Watanabe T, Kazama Y, Tanaka J, Kanazawa T, Kazama S, Nagawa H. 
Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A 
study matched for T- and N- classification. BrJCancer 2006;95(11): 1562-1567.
224. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, 
Hemminki A, Schwartz S, Jr., Aaltonen LA, Arango D. SMAD4 as a prognostic marker in 
colorectal cancer. Clin Cancer Res 2005; 11(7): 2606-2611.
225. Alhopuro P, Alazzouzi H, Sammalkorpi H, Davalos V, Salovaara R, Hemminki A, Jarvinen 
H, Mecklin JP, Schwartz S, Jr., Aaltonen LA, Arango D. SMAD4 levels and response to 5- 
fluorouracil in colorectal cancer. Clin Cancer Res 2005; 11(17): 6311-6316.
226. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, Aoki M, 
Oshima M, Hattori M, Takabayashi A, Minato N, Taketo MM. SMAD4-defrcient intestinal 
tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 2007;39(4): 467-475.
161
227. Volmer MW, Stuhler K, Zapatka M, Schoneck A, IClein-Scory S, Scluniegel W, Meyer 
HE, Schwarte-Waldhoff I. Differential proteome analysis of conditioned media to detect Smad4 
regulated secreted biomarkers in colon cancer. Proteomics 2005;5(10): 2587-2601.
228. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellulai* 
functions of heat shock proteins: repercussions in cancer therapy. Journal of leukocyte biology 
2007;81(1): 15-27.
229. Henderson B, Henderson S. Unfolding the relationship between secreted molecular' 
chaperones and macrophage activation states. Cell Stress Chaperones 2009; 14(4): 329-341.
230. Laudanski K, De A, Miller-Graziano C. Exogenous heat shock protein 27 uniquely blocks 
differentiation of monocytes to dendritic cells. EurJImmunol 2007;37(10): 2812-2824.
231. Christians ES, Yan LJ, Benjamin IJ. Heat shock factor 1 and heat shock proteins: Critical 
partners in protection against acute cell injury. Crit Care Med 2002;30(1 Supp): S43-S50.
232. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and 
function of heat-shock proteins and molecular' chaperones. Essays Biochem 1997;32: 17-29.
233. Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in 
regulation of the heat shock response and beyond. Faseb </2001;15(7): 1118-1131.
234. Femandes M, Xiao H, Lis JT. Fine structure analyses of the Drosophila and Saccharomyces 
heat shock factor—heat shock element interactions. Nucleic Acids Res 1994;22(2): 167-173.
235. O'Neill PA, Shaaban AM, West CR, Dodson A, Jarvis C, Moore P, Davies MP, Sibson 
DR, Foster CS. Increased risk of malignant progression in benign proliferating breast lesions 
defined by expression of heat shock protein 27. Br J Cancer 2004;90(1): 182-188.
236. Wataba K, Saito T, Fukunaka K, Ashihara K, Nishimura M, Kudo R. Over-expression of 
heat shock proteins in carcinogenic endometrium. IntJCancer 2001 ;91(4): 448-456.
237. Foss AJ, Alexander RA, Guide MJ, Hungerford JL, McCartney AC, Lightman S. Estrogen 
and progesterone receptor analysis in ocular melanomas. Ophthalmology 1995;102(3): 431-435.
238. Benndorf R, Engel K, Gaestel M. Analysis of small Hsp phosphorylation. Methods Mol 
Biol 2000;99: 431-445.
239. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis.
Oncogene 2003;22(56): 9041-9047.
240. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, Kato Y, Parry GC, Han J. PRAK, a 
novel protein kinase regulated by the p38 MAP kinase. Embo J1998; 17(12): 3372-3384.
241. Laudanski K, Wyczechowska D, The distinctive role of small heat shock proteins in 
oncogenesis. Arch Immunol Ther Exp (Warsz) 2006;54(2): 103-111.
242. Kim KK, Kim R, Kim SH. Crystal structure of a small heat-shock protein. Nature 
1998;394(6693): 595-599.
243. Gusev NB, Bogatcheva NV, Marston SB. Structure and properties of small heat shock 
proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry (Mosc) 
2002;67(5): 511-519.
244. Rogalla T, Ehmsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske 
M, Arrigo AP, Buchner J, Gaestel M. Regulation of Hsp27 oligomerization, chaperone 
function, and protective activity against oxidative stress/tumor necrosis factor alpha by 
phosphorylation. J Biol Chem 1999;274(27): 18947-18956.
245. Ananthan J, Goldberg AL, Voellmy R. Abnormal proteins seive as eukaryotic stress signals 
and trigger the activation of heat shock genes. Science 1986;232(4749): 522-524.
162
246. Jakob U, Gaestel M, Engel K, Buchner J. Small heat shock proteins are molecular 
chaperones. JZho/1993;268(3): 1517-1520.
247. Liang P, MacRae TH. Molecular chaperones and the cytoskeleton. J Cell Sci 1997; 110 (Pt 
13): 1431-1440.
248. Konishi H, Matsuzaki II, Tanaka M, Takemura Y, Kuroda S, Ono Y, Kikkawa U. 
Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association 
with heat shock protein Hsp27. FEES Lett 1997;410(2-3): 493-498.
249. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan 
G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 
1997;385(6616): 544-548.
250. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. 
Apoptosis 20§3\%(l)\ 61-70.
251. Bruey JM, Ducasse C, Bomiiaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, 
Arrigo AP, Kroemer G, Solary E, Garrido C. Hsp27 negatively regulates cell death by 
interacting with cytochrome c. Nat Cell Biol 2000;2(9): 645-652.
252. Samali A, Robertson JD, Peterson E, Manero F, van Zeijl L, Paul C, Cotgreave IA, Arrigo 
AP, Orrenius S. Hsp27 protects mitochondria of thennotolerant cells against apoptotic stimuli. 
Cell Stress Chaperones 2001 ;6(1): 49-58.
253. Charette SJ, Lavoie JN, Lambert H, Landry J. Inhibition of Daxx-mediated apoptosis by 
heat shock protein 27. Mol Cell Biol 2000;20(20): 7602-7612.
254. Keeling J, McKee GT. Heat shock protein (HSP)27: a further refinement in the diagnosis 
of suspicious fine needle aspirates of breast. Cytopathology 1999; 10(1): 40-49.
255. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods 
to find biomarkers associated with breast cancer. Proteomics 2003;3(4): 433-439.
256. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat 
shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell 
lines. Cancer Res 1993;53(19): 4443-4448.
257. Damstrup L, Andersen J, Kufe DW, Hayes DF, Poulsen HS. Immunocytochemical 
determination of the estrogen-regulated proteins Mr 24,000, Mi- 52,000 and DF3 breast cancer 
associated antigen: clinical value in advanced breast cancer and correlation with estrogen 
receptor. Ann Oncol 1992;3(1): 71-77.
258. Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in 
early and advanced breast cancer. Br J Cancer 1994;69(4): 743-748.
259. Tetu B, Brisson J, Landry J, Huot J. Prognostic significance of heat-shock protein-27 in 
node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res Treat 
1995;36(1): 93-97.
260. Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, Miller WR. 
Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 
1995;1(12); 1603-1609.
261. Ciocca DR, Puy LA, Edwards DP, Adams DJ, McGuire WL. The presence of an estrogen- 
regulated protein detected by monoclonal antibody in abnormal human endometrium. J Clin 
Endocrinol Metah 1985;60(1): 137-143.
163
262. Ciocca DR, Puy LA, Fasoli LC. Study of estrogen receptor, progesterone receptor, and the 
estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and 
cervix. Cancer Res 1989;49(15): 4298-4304.
263. Storm FK, Mahvi DM, Gilchrist KW. Hsp-27 has no diagnostic or prognostic significance 
in prostate or bladder cancers. Urology 1993;42(4): 379-382.
264. Comford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, 
Neoptolemos JP, Ke Y, Foster CS. Heat shock protein expression independently predicts 
clinical outcome in prostate cancer. Cancer Res 2000;60(24): 7099-7105.
265. Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, lijima T, Imamura T, Machinami 
R. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol 
itesPractf 2000; 196(10): 665-673.
266. Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S. Analysis of the survival 
period in resectable stage IV gastric cancer. Ann Surg Oncol 2001;8(3): 215-221.
267. Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, 
Sotiropoulou-Bonikou G, Papavassiliou AG. Expression of the 27-kDa heat shock protein 
(HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, 
and its prognostic significance. JCancer Res Clin Oncol 2002;128(8): 426-432.
268. Stammler G, Volm M. Expression of heat shock proteins, glutathione peroxidase and 
catalase in childhood acute lymphoblastic leukemia and nephroblastoma. Cancer Lett 
1996;99(1): 35-42.
269. Ito T, Kawabe R, Kurasono Y, Kara M, Kitamura H, Fujita K, Kanisawa M. Expression of 
heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study.
J Oral Pathol Med 1998;27(1): 18-22.
270. Erkizan O, Kirkali G, Yorukoglu K, Kirkali Z. Significance of heat shock protein-27 
expression in patients with renal cell carcinoma. Urology 2004;64(3): 474-478.
271. Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsujinaka T, Shamma A, 
Monden M. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous 
cell carcinoma of the esophagus. Cancer 1999;85(8): 1649-1657.
272. Nakajima M, Kuwano H, Miyazaki T, MasudaN, Kato H. Significant correlation between 
expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous 
cell carcinoma. Cancer Zetf 2002; 178(1): 99-106.
273. Takeno S, Noguchi T, Takahashi Y, Kikuchi R, Uchida Y, Yokoyama S. 
Immunohistochemical and clinicopathologic analysis of response to neoadjuvant therapy for 
esophageal squamous cell carcinoma. Dis Esophagus 2001;14(2): 149-154.
274. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, 
Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, 
Kallioniemi OP. Hormone therapy failure in human prostate cancer: analysis by complementary 
DNA and tissue microaiTays. JNatl Cancer Inst 1999;91(20): 1758-1764.
275. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S, Maehara 
Y, Okita K, Nakamura K, Sakaida I. Proteomics finding heat shock protein 27 as a biomarker 
for resistance of pancreatic cancer cells to gemcitabine. IntJ Oncol 2007;31(6): 1345-1350.
276. Seymour L, Bezwoda WR, Meyer K. Tumor factors predicting for prognosis in metastatic 
breast cancer. The presence of P24 predicts for response to treatment and duration of survival. 
Cancer 1990;66(11): 2390-2394.
164
277. Ciocca DR, Green S, Elledge RM, Clark GM, Pugh R, Ravdin P, Lew D, Martino S, 
Osborne CK. Heat shock proteins hsp27 and hsp70: lack of correlation with response to 
tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a 
Southwest Oncology Group Study). Clin Cancer Res 1998;4(5): 1263-1266.
278. Ran B, Gaestel M, Wust P, Stahl J, Mansmann U, Schlag PM, Benndorf R. Preoperative 
treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment 
efficacy and heat-shock response. Radiat Res 1999;151(4): 479-488.
279. Choi DH, Ha JS, Lee WH, Song JK, Kim GY, Park JH, Cha HJ, Lee BJ, Park JW. Heat 
shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEES 
Lett 2007;581(8): 1649-1656.
280. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, 
predictive, and treatment implications. Cell Str'ess Chaperones 2005; 10(2): 86-103.
281. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka 
K, Gleave M. Heat shock protein 27 increases after androgen ablation and plays a 
cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64(18): 6595-6602.
282. Yang YX, Sun XF, Cheng AL, Zhang GY, Yi H, Sun Y, Hu HD, Hu P, Ye F, Chen ZC, 
Xiao ZQ. Increased expression of HSP27 linked to vincristine resistance in human gastric 
cancer cell line. J Cancer Res Clin Oncol 2008.
283. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using 
nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder 
cancer cells. Mol Cancer Ther 2007;6(1): 299-308.
284. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Increased 
Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer 
via signal transducers and activators of transcription 3-mediated suppression of apoptosis. 
Cancer Res 2005;65(23): 11083-11093.
285. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, Gleave M. Small 
interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and 
induces apoptosis via caspase-3 activation in vitro. BJUInt 2006;98(5): 1082-1089.
286. Zhang Y, Shen X. Heat shock protein 27 protects L929 cells from cisplatin-induced 
apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase 
activity. Clin Cancer Res 2007;13(10): 2855-2864.
287. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. 
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate 
AR transcriptional activity. Cancer Res 2007;67(21): 10455-10465.
288. Hadaschik BA, Jackson J, Fazli L, Zoubeidi A, Burt HM, Gleave ME, So AL Intravesically 
administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of 
non-muscle-invasive bladder cancer. B,JU Int 2008; 102(5): 610-616.
289. Aloy MT, Hadchity E, Bionda C, Diaz-Latoud C, Claude L, Rousson R, Arrigo AP, 
Rodriguez-Lafrasse C. Protective role of Hsp27 protein against gamma radiation-induced 
apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. 
Int J Radiat Oncol Biol Phys 2008;70(2): 543-553.
290. Garrido C, Mehlen P, Fromentin A, Hammann A, Assem M, Arrigo AP, Chauffert B. 
Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin
165
resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. Eur J 
Biochem 1996;237(3): 653-659.
291. Muller N, Reinacher-Schick A, Baldus S, van Hengel J, Berx G, Baar A, van Roy F, 
Schmiegel W, Schwarte-Waldhoff I. Smad4 induces the tumor suppressor E-cadherin and P- 
cadherin in colon carcinoma cells. Oncogene 2002;21(39): 6049-6058.
292. Schwarte-Waldhoff I, Klein S, Blass-Kampmann S, Hintelmann A, Eileit C, Dreschers S, 
Kalthoff H, Halm SA, Sclmiiegel W. DPC4/SMAD4 mediated tumor suppression of colon 
carcinoma cells is associated witlr reduced urokinase expression. Oncogene 1999; 18(20): 3152- 
3158.
293. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider 
IS, Emerson WA, Tonney DC, Glick JH, et al. Levamisole and fluorom'acil for adjuvant 
therapy of resected colon carcinoma. N Engl JMed 1990;322(6): 352-358.
294. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY. 
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and 
independent mechanisms: implications for diabetic renal and vascular disease. Faseb J 
2004;18(1): 176-178.
295. Seoane J. Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 
2006;27(11): 2148-2156.
296. Viterbo D, Zenilman ME, Bluth MH. Comparison of His and GST tagged versions of 
recombinant pancreatitis associated protein 2 in modulation of inflammatory responses.
Inflamm Res.
297. Walter SD, Feinstein AR, Wells CK. A comparison of multivariable mathematical methods 
for predicting survival—II. Statistical selection of prognostic variables. J Clin Epidemiol 
1990;43(4): 349-359.
298. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre 
Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345(8955): 939- 
944.
299. Tsuruta M, Nishibori H, Hasegawa H, Ishii Y, Endo T, Kubota T, Kitajima M, Kitagawa 
Y. Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. Oncol 
Rep 2008;20(5): 1165-1172.
300. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical 
strategies. Nat Rev Cancer 2003;3(5): 330-338.
301. Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM, Han DC. 
Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a 
synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem 2005;280(50): 41439- 
41448.
166
Carcinogenesis vgl,31 no.9 pp.1541-1551,2010
doi: 10.1093/carcin/bgq 137
Advance Access publication July 9, 2010
Smad4 loss is associated with fewer SlOOAS-positive monocytes in colorectal tumors and 
attenuated response to S100A8 in colorectal and pancreatic cancer cells
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SI00A8 and its dimerization partner S100A9 are emerging as 
important chemokines in cancer. We previously reported that 
Smad4-negative pancreatic tumors contain fewer stromal 
SlOOAS-positive monocytes than their Smad4-positive counter­
parts. Here, we studied S100A8/A9-expressing cells in colorectal 
tumors relating their presence to clinicopathological parameters 
and Smad4 status. Two-dimensional gel electrophoresis (« = 12) 
revealed variation in the levels of S100A8 protein in colorectal 
cancer tumors, whereas immunohistoehemical analysis {» = 313) 
showed variation in the numbers of stromal SlOOAS-positive and 
S100A9-positive cells. Loss of Smad4 expression was observed in 
42/304 (14%) colorectal tumors and was associated with reduced 
numbers of SlOOAS-positive (P = 0.03) but not S100A9-positive 
stromal cells {P — 0.26). High S100A9 cell counts were associated 
with large tumor sizes {P = 0.0006) and poor differentiation 
grade (P = 0.036). However, neither S100A8 nor S100A9 cell 
counts predicted poor survival, except for patients with Smad4- 
negative tumors {P = 0.02), To address the impact of environ­
mental S100A8/A9 chemokines on tumor cells, we examined the 
effects of exogenously added S100A8 and S100A9 proteins on 
cellular migration and proliferation of colorectal and pancreatic 
cancer cells. S100A8 and S100A9 enhanced migration and pro­
liferation in Smad4-positive and Smad4-negative cancer cells. 
However, transient depletion of Smad4 resulted in loss of respon­
siveness to exogenous S100A8, but not S100A9. S100A8 and 
S100A9 activated Smad4 signaling as evidenced by phosphoryla­
tion of Smad2/3; blockade of the receptor for the advanced gly- 
cation end products inhibited this response. In conclusion, Smad4 
loss alters the tumor’s interaction with stromal myeloid cells and 
the tumor cells’ response to the stromal chemokine, S100A8.
Introduction
The complex interaction between tumor cells and surrounding non- 
malignant stromal host cells is increasingly understood to be a vital
Abbreviations: MTS, (3-(4,5-dimelhylthiazol-2-yl)-5-(3-carboxymethoxy- 
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium); RAGE, receptor for the advanced 
glycation end products; siRNA, small interfering Ribonucleic acid.
^These authors contributed equally to this work.
regulator of cancer growth and progression (1). Bone marrow-derived 
myeloid cells are an important component of the tumor microenvi­
ronment. Several bone marrow-derived myeloid cells, such as macro­
phages, Tie-2 expressing monocytes, neutrophils and mast cells have 
been shown to contribute to tumor angiogenesis (2). They have also 
been implicated in processes of tumor invasion and metastasis [for 
review see Joyce et al (3)]. The presence of S100A8- and S100A9- 
positive myeloid cells in the pancreatic cancer microenvironment was 
previously characterized, revealing an association between the num­
bers of S100A8-expressing cells and the expression in tumor cells of 
the tumor suppressor protein Smad4 (4). The Smad4 gene is mutated 
at a high frequency in pancreatic and colon cancer and to a lesser 
extent in a variety of other cancers (5). The microenvironment of 
pancreatic tumors, which lacked expression of Smad4, was found to 
have significantly fewer SlOOAB-expressing cells compared with the 
microenvironment of Smad4-positive tumors (4). This finding sug­
gested a phenotypic difference in the myeloid-derived infiltrate 
related to the Smad4 status of these tumors.
S100A8 (calgranulin A, MRP8) and S100A9 (caigranulin B, 
MRP14) are low-molecular weight members of the S100 family of 
calcium-binding proteins, which are abundantly expressed in cells 
of the myeloid lineage, including monocytes and neutrophils and 
early-differenliation slates of macrophages (6,7). They are secreted 
inflammatory chemoattractants that mediate further recruitment of 
inflammatory cells to sites of tissue damage (8) and have been impli­
cated in a variety of chronic inflammatory conditions such as cystic 
fibrosis, rheumatoid arthritis, tuberculosis and transplant rejection 
(9,10). Recent attention has focused on the involvement of S100A8/ 
A9 in cancer (11). These inflammatory proteins have been reported to 
promote tumorigenesis (12) and cause cancer metastasis by stimulating 
the migration of monocytes and tumor cells to metastatic sites (13,14).
In this study, stromal S100A8 and S100A9-expressing myeloid 
cells in colorectal tumors were thoroughly examined. The relationship 
between these myeloid cells and the Smad4 status of the colorectal 
cancers was determined as was the effect of exogenous S100A8 and 
S100A9 on Smad4-positive and Smad4-negative colorectal and pan­
creatic cancer cells.
Materials and methods
Two-dimensional sodium dodecyl sulfate-polyaoyknmk gel electrophoresis, 
protein identification and immunodetection
Proteins were extracted from frozen colectomy specimens, separated by two- 
dimensional electrophoresis and S100A8 identified as described previously 
(4,15). Colorectal cancer tissue microarrays were obtained from the Liverpool 
Tissue Bank, University of Liverpool and contained duplicate or triplicate 
cores from 313 independent specimens of adenocarcinoma. Fourteen cores 
of normal colon and 10 cores each of normal kidney, liver and testis were 
included as control tissue. Immunohistochemistry was undertaken as described 
previously (16) using polyclonal goat anti-S100A8, polyclonal rabbit anti- 
S100A9 or monoclonal anti-Smad4 (Clone-B8; .Santa Cruz Biotechnology, 
Heidelberg, Germany) primary antibodies, SS00A8 and S100A9 antibodies 
detect single bands in stimulated HL60 monocytic cells (supplementary 
Figure 1A is available at Carcinogenesis Online). Co-immunofluorescence 
was performed on duplicate formalin-fixed colorectal tumor sections 
using the following primary antibodies; a monoclonal mouse anti-S100A8 
and polyclonal rabbit anti-S100A9 (Santa Cruz), monoclonal mouse anti- 
CD68 (Dako, Ely, Cambridgeshire, UK) and monoclonal mouse anti-CDM 
(Novocastra, Newcastle, UK). Microarrays were scored by a specialist his- 
topalhologist (author B.A.) and an independent evaluator. The intensity of 
Smad4 staining (using a 0-3 scale) was recorded and a score of <0.5 (mean 
score of al least two cores per tumor) was classified as Smad4 negative. The 
number of stromal cells positive for S100A8 and S100A9 cells was counted 
(using x40 magnification) for each tumor core and the mean number per 
tumor obtained by averaging the number of positive cells across all the tumor 
cores scored for that patient.
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Generation of recombinant S100A8 and S100A9 proteins 
pGEX4T-l plasmids encoding S100A8-GST and S100A9-GST (13) were 
kindly provided by Y.Maru, Tokyo Women’s Medical University School of 
Medicine, Japan, Proteins were expressed in Escherichia coli following 
induction with isopropyl-b-o-thiogalactopyranoside (VWR international, 
Lutterworth, Leicestershire, UK) and purified with glutathione sepharose 
beads (GE Healthcare, Amersham, Buckinghamshire, UK), The quantity of 
recombinant S100A8-GST and S100A9-GST was determined by performing 
one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
against serial dilutions of a reference standard of bovine serum albumin (1-15 pg/ 
lane) followed by densitometric evaluation of the Coomassie-stained gels (GS- 
800 scanner; Bio-Rad, Bath, UK) using QuantilyOne software (Bio-Rad). All 
experiments using fusion proteins were performed with at least two independent 
batches of each protein.
Cell lines and western blotting
The rectal cell line SW837 was purchased from the European Collection of 
Cell Cultures in March 2008. Tire colonic cell line SW480 and the pancreatic 
adenocarcinoma cell line Panc-1 were obtained from American Type Culture 
Collection in 1999. Neomycin-resistant clonal derivatives of Smad4-deficient 
SW480 cells, stably reexpressing Smad4 (SWD20) and a negative control 
transfectant (SWK3), described previously (17,18) were maintained in medium 
containing geneticin (0.2 mg/ml;Gibco, Paisley, UK), All cell lines were last 
authenticated in October 2009 using short tandem repeat profiling against the 
international reference standard for cel! line.
Western blot analysis was perfonned as described previously (16) using mouse 
anti-Smad4 monoclonal antibody (Santa Cruz Biotechnology, Santa Cmz, CA), 
anti-phospho-Smad2, anti-phospho-Smad3, anti-phospho-Smadl/5/8 antibodies 
(Cell Signaling Technology, Massachusetts, MA) and mouse anli-P-actin 
monoclonal antibody (Sigma-Aldrich, Gillingham, Dorset, UK).
In vitro cell migration assay
Cells were plated (5 x 10“ for SW837/SW480/SWD20/SWK3 and 5 x 103 for 
Panc-1) in medium containing 1% fetal bovine serum for Boyden Chamber 
assays, conducted over 18 h, as described previously (16), Recombinant proteins, 
SIOOA8-GST, S100A9-GST or GST in medium containing 1% fetal bovine 
serum were added to the lower transwell chamber's. Migrated cells were stained 
and counted (16), n — 2 inserts per treatment, and the average number of 
migrated cells were calculated. Experiments were performed at least three times.
Cell proliferation assay
Cells (3 x 103/200 pi medium, supplemented with 1% fetal bovine serum) 
were plated in wells of 96-well plates and recombinant S100A8-GST, S100A9- 
GST or GST added, Proliferation was assessed at 24, 48 and 72 h using the 
EZ4U non-radioactive cell proliferation assay (Biomedica, Vienna, Austria) 
according to the manufacturer's instructions. Absorbance readings at 450 nm 
were taken at 4 h following incubation with the 3-(4,5-dimethyIthiazoi-2-yl)- 
5-(3-carix)xymethoxyphenyl)-2-(4-sulfaphenyl)-2H-tetrazolium (MTS) reagents. 
Experiments were performed at least three times and five wells utilized for each 
treatment.
Cellular phospho-Smad expression and blocking of receptor of advanced 
glycation end products with specific blocking antibody 
Cells were cultured for 48 h in serum-free medium supplemented with bovine 
serum albumin (10 pg/ml; Sigma-Aldrich) and human insulin (5 pg/ml; 
Sigma-Aldrich) and then treated with S100A8-GST, S100A9-GST, GST or 
transforming growth factor-(1 (10 ng/ml; PeproTech EC Ltd, London, UK) 
for 1 h, followed by cell collection for western blotting as described above. 
For receptor of advanced glycation end products (RAGE) blocking, cells 
were treated with RAGE-blocking antibody (40 or 80 pg/ml; R&D Systems, 
Abingdon, UK) for 1 h before the addition of recombinant proteins.
Transient Smad4 knockdown
Small interfering Ribonucleic acid (siRNA) experiments were perfonned as 
described previously (16). Smad4-targeling siRNAs, GUGUGCAGUUG- 
GAAUGUAA (Smad4 siRNAl) and GUACAGAGUUACUACUUAG (Smad4 
siRNA2) were purchased from Dharmacon (Chicago, IL). Two non-targeting 
control siRNAs were used, control 1 (siControl non-targeting siRNA J from 
Dharmacon) and control 2 (GGACGCAUCCUUCUUAA, a gift from M.Boyd, 
University of Liveipool, UK). Smad4 levels diminished between 48 and 72 h 
post-transfection with Smad4-targeting siRNAs and remained low out to 120 h 
(data not shown).
Cellular immunofluorescence
Cells were fixed with 4% formaldehyde for 15 min at room temperature and 
penneabilized with 0.1% Triton X-100 for 10 min. Phospho-Smad2/3 was 
detected with anti-phospho-Smad2/3 antibody (Cell Signaling Technology)
and visualized with a fluorescein isothiocyanate-conjugated goat ;mti-rabbit IgG 
secondary antibody (Jackson ImmunoResearch Laboratories West Grove, PA). 
Actin filaments were labeled with phalloidin (Invitrogen, Renfrew, UK).
Statistical analysis
Comparisons between two groups were made using nonparamotric continuity 
corrected chi-square test or chi-squared test, when more than two groups were 
analyzed. Continuous variables were compared using the Mann-Whitney 
(/-test or the Wilcoxon signed-rank test, To evaluate the effect of stromal 
S100A8 or S100A9 cells on patient survival, life tables were constructed 
and Kaplan-Meier curves plotted. Overall survival was measured from date 
of initial surgery to date of death, counting death from any cause as the end 
point or the last date of information as the end point if no event was docu­
mented. To analyze data from 'motility' or ‘proliferation’ experiments, con­
tinuous variables were compared using the Student’s /-test and were expressed 
as mean. All analyses were performed using Statview Version 5.01 (SAS 
Institute Cary, North Carolina). A /■’-value of <0.05 was considered significant.
Results
Variable S100A8 and SI00A9 levels in colorectal cancer 
microenvironments
Two-dimensional gels displaying proteins extracted from 12 individual 
undissected colorectal tumors revealed variation (Figure 1A-C) in the 
intensity of a spot (arrowed in Figure 1A and B) that was suspected, on 
the basis of its gel location, to contain S100A8. Protein recovered from 
this spot was trypsin digested and analyzed by Liquid Chromatography- 
Mass Spectrometry/Mass Spectrometry (Figure ID). This resulted in 
the detection of five peptides, providing sequence coverage of 37.6% 
and confirmed the identification of S100A8 (National Centre for 
Biotechnology Information accession no. CAG28602). To establish 
the cellular basis for the variability of S100A8, immunohistochemistry 
of formalin-fixed colorectal adenocarcinomas was undertaken, for the 
detection of S100A8 and its dimerization partner S100A9. This revealed 
the expression of both proteins in cells scattered throughout lire tumor 
stroma [Figure 2A(i-iv)]. While S100A9 expression was not detected 
in cancer- cells, a very low intensity of cytoplasmic S100A8 staining was 
observed in tumor cells of virtually all cases and was not subjected to 
analysis. Co-immunofluorescence indicated extensive colocalization of 
S100A8 and S100A9 in stromal cells [Figure 2B(i)j. Furthermore, co 
localization of S100A8 or S100A9 was observed in some cells with the 
monocyte marker CD 14 [Figure 2B(ii and ill), respectively] but not the 
macrophage marker' CD68 [Figure 2B (iv and v), respectively).
The number of S100A8-positive or S100A9-positive cells in each 
of 313 patient tumors (mean of at least two Tissue Microatray cores 
per tumor case) was determined. Numbers ranged from 0 (4.5% of 
cases) to 288 and from 0 (0.65% of cases) to 882 for S100A8 and 
S100A9, respectively. The median number of stromal S100A8- 
expressing cells was 23 [Inter-quartile range (IQR) 6-70], whereas 
the median number of stromal S100A9-exptessing cells was 65 (IQR 
27-126) with 284/308 (92%) tumors showing more S100A9 
than S100A8-expressing cells in the stroma. Although tumors gener­
ally contained fewer SlOOAS-positive than S100A9-positive cells 
(P < 0.0001, Wilcoxon signed-rank test), there was a strong positive 
relationship between SI00AS and S100A9 counts (n = 302 indepen­
dent tumor cases; R2 = 0.76, P < 0.0001). This is entirely consistent 
with our observation that S100A8 colocalized with S100A9. The 
median S100A9:S100A8 ratio was 2.2 (IQR 1.3-4.4). To examine 
whether a relationship existed between the numbers of stromal 
SlOOAS-positive or S100A9-positive cells and the Smad4 tumor 
status, the expression of Smad4 protein was determined by immuno­
histochemistry [Figure 2A (v and vi)]. Forty-two of 304 patients 
(14%) were categorized as Smad4 negative based on mean cytoplas­
mic intensity scores of <0.5. The remaining 262 of 304 patients 
(86%) were categorized as Smad4 positive. Loss of Smad4 expression 
in primary colorectal tumor cells was associated witli a significantly 
lower median count of S 100A8-positive stromal cells (14, IQR 5-37) 
compared with a median SlOOAS-positive cell count of 25 (IQR 6-76) 
in the Smad4-positive group [Figure 2C (i)], P — 0,03, Mann- 
Whitney CZ-test). A similar relationship was not observed between
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Fig. 1. (A) Colloidal Coomassie Blue-stained two-dimensional gel image of a colorectal cancer lysate, with the S 100A8-containing spot arrowed. (B) Insets from 
12 independent colorectal tumor gels showing different intensities in the S100A8 protein spot. (C) Normalized S100A8 levels (S100A8 spot intensity/total spots 
intensity). (D) Mass Spectrometry/Mass Spectrometry spectrum of the peptide ALNSIIDVYHK from S100A8.
tumor cell Smad4 expression and S100A9-positive stromal mono­
cytes [Figure 2C (ii)], P — 0.26).
Relationship between S100A8/A9-positive stromal cells and 
clinicopathological characteristics
To examine for associations between stromal S100A8-positive cells 
and patient clinicopathological parameters, patients were catego­
rized as having mean S100A8-positive cell counts that were low 
(< median of 23) or high (>23). Similarly, for S100A9, patients 
were categorized as having low (< median of 65) or high (>65) 
cell counts. The degree of stromal S100A8/A9-positive infiltration 
showed no correlation with the parameters of age at surgery, gen­
der. site of tumor, depth of tumor invasion or nodal metastases 
(Table I). However, high cell S100A8 and S100A9 counts were
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Fig. 2. Colorectal cancer tissue illustrating a low [A(i and iii)], and a high [A(ii and iv)] infiltrate of S100A8- and S10()A9-positive cells, respectively; the absence 
and presence, respectively, of Smad4 staining [A(v and vi)]; colocalization of S100A9 and S100A8 [B(i>], S100A8 or S100A9 and CD14 (B(ii and iii)]; lack of 
colocalization of S100A8 or S100A9 and CD68 [B (iv and v)]. The mean numbers of S100A8-positive [C(i)] or S100A9-positive cells [C(ii)] per tumor were 
plotted for Smad4-negative and Smad4-positive tumors.
associated with larger tumor size (P = 0.01 and 0.0006, 
respectively). These proteins are co-expressed to a high degree. 
Nevertheless, we wished to determine whether either protein was 
independently associated with tumor size. We therefore performed 
logistic regression analyses. Both high S100A8 and high S100A9 
cell counts were associated with large tumor size on univariate
analysis (P = 0.01 and 0.0007, respectively; supplementary Table 1 
is available at Carcinogenesis Online). However, on multivariate 
analysis, only high S100A9 cell counts remained independently 
associated with large tumor sizes (P = 0.02). High S100A9 cell 
counts were also associated with poor differentiation grade 
(P = 0.036).
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Table I. Clinicopathological characteristics and correlation with S100A8 and S100A9 expression
All cases, 
n = 313 (%)
S100A8-positive cells, 
n = 309
P value8 S100A9-positive cells, 
n = 306
P value1
Low < 23 cells (%), 
n = 156
High > 23 cells (%), 
n = 153
Low < 65 cells (%), 
n = 159
High > 65 cells (%), 
n = 147
Age 70 (IQR 62-76 years)
Young (Cmedian) 155 (49) 75 (48) 80 (52) 0.459 75 (47) 78 (53) 0.303
Old (>median) 158 (51) 81 (52) 73 (48) 84 (53) 69 (47)
Gender
Male 188 (60) 93 (60) 92 (60) 0.926 97 (61) 85 (58) 0.570
Female 125 (40) 63 (40) 61 (40) 62 (39) 62 (42)
Site of tumor
Colon 188 (60) 89 (57) 96 (63) 0.307 94 (59) 90 (61) 0.707
Rectum 125 (40) 67 (43) 57 (47) 65 (41) 57 (39)
Size 50 (IQR 38-60 mm)
Small-medium (<60 mm) 214 (69) 116(74) 94 (61) 0.014 123 (77) 87 (59) 0.0006
Large (>60 mm) 99 (31) 40 (26) 59 (39) 36 (23) 60(41)
Differentiation grade
Well 5(2) 2(1) 2(1) 0.819 2(1) 3(2) 0.036
Moderate 283 (90) 140 (90) 140 (92) 150 (94) 127 (86)
Poor 21 (7) 12(8) 9(6) 5(4) 15 (11)
Uncategorized/DNA 4(1) 2(1) 2(1) 2(1) 2(1)
Excision margin
Clear 270 (86) 130 (83) 138 (90) 0.055 134(84) 130 (88) 0.199
Involved 39(13) 25 (16) 12(8) 24(15) 14(10)
Uncategorized/DNA 4(1) 1 (1) 3(2) 1 (1) 3(2)
T-stage
T1 13(4) 8(5) 5(3) 0.766 8(5) 5(3) 0.356
T2 47 (15) 22 (14) 25 (16) 21 (13) 24 (16)
T3 206 (66) 104 (67) 101 (66) 110(69) 92 (63)
T4 44 (14) 19(12) 22(15) 18 (12) 25 (17)
Uncategorized/DNA 3(1) 3(2) 0 2(1) 1 (1)
N-stagc
NO 177 (56) 82 (53) 93 (61) 0.446 90 (57) 82 (56) 0.332
N1 71 (23) 38 (24) 32 (21) 40 (25) 30 (20)
N2 62 (20) 33 (21) 28 (18) 27 (17) 34 (23)
U ncategorized/DN A 3(1) 3(2) 0 2(1) 1 (I)
AJCC/UICC stage groupings
I 39 (13) 22(14) 17(11) 0.319 21 (13) 17(12) 0.860
II 136 (43) 60 (38) 74 (48) 68 (43) 65 (44)
III 132 (42) 70 (45) 60 (39) 66 (41) 63 (43)
Uncategori zcd/DN A 6(2) 4(3) 2(2) 4(3) 2 (1)
Chemoradiotherapy
Neoadjuvant only 35(11) 21 (13) 14(9) 0.630 19(12) 15 (10) 0.724
Adjuvant only 77 (25) 37 (24) 40 (26) 37 (23) 40 (27)
Neoadjuvant and adjuvant 12(4) 6(4) 5(3) 6(4) 4(3)
No chemoradiotherapy 188 (60) 92 (59) 93 (61) 97 (61) 87 (59)
DNA 1 (0.3) 0(0) 1 (1) 0(0) 1 (1)
AJCC/UICC, American Joint Committee on Cancer/Intemational Union Against Cancer; DNA, data not available. 
“Chi-squared test.
Neither SI00A8-positive nor S100A9-positive stromal cell counts 
were associated with patient survival [Figure 3A (i and ii)]. However, 
for the smaller cohort of patients exhibiting loss of Smad4 expression, 
high S100A8 or S100A9 cell counts predicted poor 3 year survival 
[Figure 3B (i and ii)]. The number of Smad4-negative tumor patients 
in the study was too small to detennine whether either of the proteins 
was independently associated with poor outcome. No survival dif­
ference was observed for either high S100A8 or S100A9 counts at 
60 months in this Smad4-negative cohort. For patients with Smad4- 
positive tumors, neither SI00A8-positive nor S100A9-positive counts 
predicted overall short- or long-term survival [Figure 3C (i and ii)].
The effects of Smad4 status on S100A8- and S100A9-induced 
migration activity
S100A8 and S100A9 are secreted chemokines, which could affect 
tumor cells in their vicinity. We next investigated their chemoattrac- 
tive functions on tumor cells in vitro. The addition of purified 
S100A8-GST and S100A9-GST fusion proteins (see supplementary
Figure IB, available at Carcinogenesis Online) at concentrations of 
either 0.4 or 2 pg/ml significantly increased the migration activity of 
the rectal cancer cell line SW837, the colon cancer cell line SW480 
and the pancreatic cancer cell line Panc-1 (Figure 4A) (P < 0.001) 
compared with the addition of purified GST control protein. The 
addition of both S100A8-GST and S100A9-GST proteins simulta­
neously did not significantly increase the response over proteins 
added individually (see supplementary Figure S2, available at Carci­
nogenesis Online) and may be due to failure of the recombinant 
proteins to interact correctly.
Both Panc-1 and SW837 cells express Smad4 (see inset Figure 4A). 
To determine whether the Smad4 status of cells influenced their re­
sponse to S100A8 or S100A9, we depleted Smad4 in these cell lines 
and examined their migration activity in response to S100A8 and 
S100A9. An ~50% decrease in basal migration in Panc-1 cells com­
pared with control siRNA-treated cells was observed (Figure 4B), 
consistent with previously published data (19). Smad4 knockdown 
totally suppressed migration responses toward S100A8. In contrast, 
S100A9-treated cells retained an ~2-fold increase in migration after
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A (i) ------- Low SI00A8 (<median) A(ii) -------  Low S100A9 (<median)
High S1OOA8 (>median) High S100A9 (>median)
S100A9:Smad4-negative group, n = 39S100A8:Sinad4-negative group, n = 38
n = 17
n = 22n= 14
p = 0.02p = 0.02
12 24 36 48 60 72 84 96
Time (months)Tine (months)
Life table
C(i) C(ii)
123 103 85 76 66 52 37 26 13
Fig. 3. Kaplan-Meier graphical analysis showing (A) no survival difference based on S100A8 [A(i)] or S100A9 [A(ii)] cell counts in all patients, (B) a survival 
difference in patients with Smad4-negativc tumors based on S100A8 [B(i)] or SI00A9 [B(ii)] cells counts and (C) no survival difference in patients with Smad4- 
positive tumors based on S100A8 [C(i)] or S100A9 [C(ii)J cell counts.
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Fig. 4. Migration activities of indicated cell lines treated with S100A8-GST (A8-GST). S100A9-GST (A9-GST), GST at concentrations of 0.4 or 2.0 ng/ml, in 
medium containing 1% fetal bovine serum (FBS) (A) or Smad4-depleted Panc-1 cells (B) or clonal derivative of SW480 cells that stably reexpresses Smad4 
(SWD20) and its Smad4-negative control (SWK3) (C) or Smad4-depleted SWD20 (D). “P < 0.001, 'P < 0.05. The Smad4 status of cells is shown as insets on 
western blots.
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Smad4 knockdown. Smad4 knockdown caused an almost total loss of 
basal and chemokine-induced migration of the less motile SW837 
cells (supplementary Figure 3 is available at Carcinogenesis Online).
SW480 cells do not express Smad4 (see inset Figure 4A). 
Neomycin-resistant clonal deiivatives of SW480 cells, stably reex­
pressing Smad4 (SWD20) and negative control transfectants 
(SWK3) (17,18) were used to determine whether restoration of Smad4 
would alter responsiveness to S100A8 or S100A9. We found that both 
the Smad4-negative and Smad4-positive subclones had enhanced mi­
gration following incubation with S100A8-GST or S100A9-GST 
(Figure 4C). However, transient siRNA-mediated depletion of Smad4 
from SWD20 cells resulted in a reduction in motility and a loss of 
responsiveness to S100A8-GST, but not S100A9-GST (Figure 4D), 
This was similar to the result obtained with Panc-1 cells (Figure 4B).
The effects of Smacl4 status on S100A8- and S100A9-induced 
proliferation
Similarly, we sought to examine the effects of S100A8 and S100A9 
on tumor cell proliferation and explore whether Smad4 status was 
important in this context, Incubation of SW837 and SW480 cells with 
2 pg/ml of S100A8-GST or S100A9-GST resulted in modest, though 
statistically significant increases in MTS readings (Figure 5A). No 
increase was observed using 0.4 pg/ml recombinant proteins (data not 
shown) and Panel cells did not show an increased MTS response at all 
(supplemental^ Figure 4A, available at Carcinogenesis Online). In 
tire case of SWS37 cells, the simultaneous addition of S100A8-GST 
and S100A9-GST proteins at 2 pg/ml significantly improved tire re­
sponse over proteins added individually (see supplementary Figure 4B, 
available at Carcinogenesis Online), although this effect was not 
observed with SW480 or Panc-1 cells (supplementary Figure 4C and 
D is available at Carcinogenesis Online).
The Smad4-negative SW480 subclone, SWK3 showed enhanced 
proliferation in response to 2 pg/ml S100A9-GST (Figure 5B), 
whereas the Smad4 reexpressing subclone, SWD20, responded to 
both S100A8-GST and S100A9-GST, although the response to 
S100A9-GST was greater (Figure 5B). Following depletion of 
Smad4 from SWD20 cells, responsiveness to S100A8-GST was 
lost (Figure 5C). S100A9-GST continued to induce proliferation, 
although the extent of proliferation reached was not as great as that 
observed in control siRNA-treated cells (Figure 50). Depletion of 
Smad4 from Panc-1 cells gave a similar result (supplementary 
Figure 5 is available at Carcinogenesis Online) although the increase 
in MTS readings in response to S100A9 was very small.
The effects of exogenous SI 00A8 and S100A9 on Smad4 signaling and 
RAGE
Our results indicated that the effects of exogenous S100A8 and 
S100A9 were influenced to an extent by the presence of Smad4 in 
tumor cells. To examine whether these proteins could signal via 
Smad4, cells were incubated for 1 h with 2 pg/ml of S100A8-GST 
or S100A9-GST and the activation of members of the Smad pathway 
examined. Both recombinant S100 proteins alone, but not GST, in­
duced increased levels of phospho-Smad2, phospho-Smad3, but not 
phospho-Smad 1/5/8 in Panc-1 cells [Figure 5D (i)]. Furthermore, 
phospho-Smad2/3 was shown to accumulate in the nucleus following 
incubation with S100A8-GST or S100A9-GST, but not GST (supple­
mentary Figure 6 is available at Carcinogenesis Online). Similar re­
sults were obtained with SWD20 cells (data not shown). S100A8/A9 
heterodimers are known to stimulate cells through binding to the 
cellular receptor RAGE (20,21), although it is unclear whether the 
individual proteins are ligands for this receptor. RAGE expression was 
observed in the cell lines used in this study [Figure 5D (ii)]. To de­
termine whether SI00A8 and S100A9 were activating the Smad path­
way through RAGE, we used a RAGE-blocking antibody at two 
concentrations, 40 and 80 pg/ml. When Panc-1 cells were pretreated 
with the RAGE-blocking antibody, a dose-dependent reduction of 
phopho-Smad2 and phospho-Smad3 levels was observed in response 
to S100A8-GST or S100A9-GST stimulation [Figure 5D (Hi)].
Discussion
The inflammatory chemoattractants, S100A8 and S100A9, apart from 
serving as markers of phagocytes (intracellular S100A8/A9) or as 
biomarkers of inflammatory disease conditions (secreted extracellular 
S100A8/A9), are now recognized to play important roles themselves 
in the pathogenesis of inflammatory disorders and more recently in 
cancer (11). The presence of S100A8- and S100A9-positive cells has 
been reported previously in smaller studies of colorectal cancer 
(12,22). Here, we provide a comprehensive analysis, in which we 
quantified the numbers of S100A8/A9 cells infiltrating the environ­
ment of colorectal tumors. We also noted expression of S100A8/A9 
proteins in neutrophils localized in the tumor vasculature, although 
this cell type was not studied further. S1G0A8 and S100A9 proteins 
were largely co-expressed in the same cells, and the majority of 
tumors (92%) contained more S100A9-positive cells than S100A8- 
positive cells, which may reflect the differentiation state of tire mye­
loid cells expressing these proteins (23). There was overlap in the 
expression of S100A8 and S100A9 and the monocyte/macrophage 
marker CD 14, although the S100A8/A9-positive cell population did 
not express the mature macrophage marker CD68, indicating that 
the S100A8/A9 population may be at an early stage of monocyte/ 
macrophage maturation.
Relatively little is known about tumor-associated monocytes in 
colorectal cancer, although CD68'! tumor-associated macrophages have 
been analyzed in detail. High infiltrates of CD68+ tumor-associated 
macrophages in colorectal tumors were shown to correlate with absence 
of vascular and lymph node invasion (24) and improved survival 
(25,26). No evidence was found for an association between the numbers 
of S100A8/A9-positive cells and either depth of tumor invasion or nodal 
metastases. High S100A9 infiltrate, however, was associated with poor 
diflerentiation grade and correlated strongly with larger tumor size. In 
contrast to tire reported links between high CD68+ infiltrate and im­
proved outcome, when the entire cohort of ~300 patients was examined 
as a whole, no association was found between S100A8/A9 levels and 
survival. Nonetheless, the short-term survival of patients with Smad4- 
negative tumors and high A8/A9 infiltrate was significantly poorer than 
Smad4-negative patients with low A8/A9 infiltrate. This suggests that 
Smad4-negative tumors have a shorter time to recurrence or metastases 
in the presence of high stromal S100A8- or S100A9-expressing mono­
cytes. Mutations or inactivation of Smad4 in colorectal carcinoma 
coincide with progression to metastatic disease; the highest percentages 
of inactivation (>30%) are observed in patients with distant organ 
metastasis (27). In our study, only non-metastatic tumors with stages 
L-III disease were included, which accounts for the lower frequency of 
Smad4 loss (14%) in our cohort.
One of the main aims of our study was to determine if the extent of 
the S100A8/A9-positive infiltrate was influenced by tire Smad4 status 
of the colorectal tumors under examination. The motivation to exam­
ine this stemmed from the previous observation that Smad4-negative 
pancreatic tumors contained fewer S 100A8-positive str omal cells than 
Smad4-negative pancreatic tumors (4). Furthermore, using a mouse 
model of colon cancer, Kitamura et al. (28) reported that Smad4- 
negative tumors recruited a specific type of myeloid cell, which pro­
moted invasion through cross talk with tumor cells. We observed 
a distinctive reduction in the numbers of S100A8-positive, but not 
S100A9-positive stromal cells in Smad4-negative colorectal tumors, 
resulting in a change in the relative levels of S100A8 to S100A9. The 
S100A8/A9 myeloid cell population that we have studied does not 
appear1 to be identical to that observed in the mouse study of Kitamura 
et al. (28) because the mice cells lacked expression of CD 14. How­
ever, our observation that the loss of Smad4 is accompanied by 
a change to the phenotype of the myeloid infiltrate is consistent with 
that of Kitamura et al. and provides important evidence in human 
colorectal cancer that the phenotype of the myeloid infiltrate is influ­
enced by the Smad4 status of the tumor.
Hiratsuka et al. (13) showed that S100A8/A9 were powerful che­
moattractants whose tumor-induced presence in the lungs of tumor­
bearing mice could stimulate the migration of Lewis Lung carcinoma
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cells and B16 melanoma cells to that organ, where they formed sec­
ondary tumors. We sought to determine whether the response of tumor 
cells to S100A8/A9 was potentially influenced by their Smad4 status.
Both S100A8 and S100A9 were highly chemotactic for rectal, colon 
and pancreatic cancer cell lines, regardless of whether the cells ex­
pressed Smad4 or not. In Stnad4-expressing cells, such as Pane-1 cells
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or the SWD20 cells, where Smad4 expression has been stably re­
stored, transient depletion of Smad4 expression was accompanied 
by a loss of responsiveness to S100A8-induced migration activity 
but not that of S100A9, suggesting that S100A8 elicits its response 
through a Smad4-dependent pathway. Transient Smad4 depletion, 
such as we undertook in our siRNA experiments, may not allow 
sufficient time for cells to adapt and to allow S100A8 to signal in 
a Smad4-independent manner. Our observation of increased levels of 
phosphor-Smad2 and phospho-Smad3 in response to cell treatment 
with S100A8 and S100A9 provide supporting evidence that these 
proteins can activate the Smad4 signaling pathway.
S100A8/'A9-induced proliferation of tlie cancer cell fines studied was 
also observed, although at concentrations higher that those required to 
induce migration activity. S100A8/A9 may contribute to apoptosis (11), 
however, the apoptotic role of these proteins was not investigated in this 
study, Ghavami et al (21) reported that S100A8 and S100A9 proteins 
promoted growth of human breast cancer and neuroblastoma cells and 
confirmed that these proteins activate the multiligand receptor, RAGE, 
triggering the mitogen-activated protein kinase signaling pathway. The 
mitogenic effects of S100A8/A9, coupled with our observation that 
high levels of A8/A9 infiltrate were associated with larger tumors sug­
gest that the proteins may contribute to the growth of these tumors. 
Interestingly, while the Smad4-restored SWD20 cells showed increased 
proliferation in response to S100A8-GST and S100A9-GST, then- 
Smad4-negative clonal counterpail, SWK3 cells showed increased pro­
liferation in response to S100A9-GST only, suggesting that Smad4 is 
important in regulating the proliferative response to exogenous 
S100A8. Transient Smad4 knockdown in SWD20 and Panc-i was 
accompanied by a loss of response to S100A8-GST. Thus, although 
the measured proliferation effects of S100A8/A9 were not as marked as 
their chemotactic effects, the dependence on Smad4 for S100A8 sig­
naling was a recurrent theme. Our RAGE-blocking experiments pro­
vide evidence that S100A8 and S100A9 activation of the Smad4 
pathway occurs at least in part through RAGE. The abiiity of Advanced 
Glycation Endproducts to activate transforming growth factor-p 
signaling via RAGE and mitogen-activated protein kinases has been 
established by Li et al. (29).
Monocytes, once recruited from blood initially express both S100A8 
and S100A9 and as they mature, they lose S100A8 expression, leaving 
only S100A9, which is also subsequently lost as the cell matures further 
(30). We postulate that myeloid cells (such as monocytes) expressing 
both S100A8 and S100A9 are recruited to the tumor microenvironment 
of Smad4-positive tumors, where they secrete S100A8/A9 that may 
promote further recruitment of inflammatory cells as well as cancer 
cell growth and invasion. In the case of Smad4-negative tumors, our 
data suggest that the myeloid cells recruited express S100A9, but ex­
hibit lower S100A8 expression. Alternatively, the myeloid celts re­
cruited are similar in the case of Smad4-positive and Smad4-negative 
tumors, however, the rate of differentiation, once recruited to the envi­
ronment of Smad4-negative tumors is different, such that S100A8 ex­
pression becomes very transient, leaving relatively greater numbers of 
cells expressing only S100A9. Either way, our experiments indicate 
that the cross talk between Smad4-negative cancer cells and myeloid 
cells occurs in an environment that involves S100A9 to a greater extent 
than S100A8 and where the cancer cells respond better to S100A9 than 
S100A8. Further research into S100A8/A9 signaling in the tumor mi­
croenvironment will shed light on how these proteins may influence the 
processes of tumor development/spread and will provide opportunities 
for targeted intervention.
Supplementary material
Supplementary Figures 1-6 and Table 1 can be found at http://carcin 
.oxfbrdjournals.org/
Funding
National Institute for Health Research Liverpool Pancreatic Biomed­
ical Research Unit; Liverpool Experimental Cancer Medicine Centr e;
Royal College of Surgeons of England, UK; Pancreatic Cancer Re­
search Fund, UK; European Framework 6 Integrated project grant 
(LSHB-CT-2006-018771).
Acknowledgements
Conflict of Interest Statement: None declared.
References
1. Witz.l.P. (2008) Yin-yang activities and vicious cycles in the tumor 
microenvironment. Cancer Res., 68, 9-13.
2. Murdoch,C. et al. (2008) The role of myeloid cells in the promotion of 
tumour angiogenesis. Nat. Rev. Cancer, 8, 618-631.
3. Joyce,].A. et al. (2009) Microenvironmental regulation of metastasis. Nat. 
Rev, Cancer, 9, 239-252,
4. Sheikh,A.A. et al. (2007) The expression of S100A8 in pancreatic cancer- 
associated monocytes is associated with the vSmad4 status of pancreatic 
cancer cells. Proteomics, 7, 1929-1940.
5. Derynck,R. et al, (2001) TGF-beta signaling in tumor suppression and 
cancer progression. Nat. Genet., 29, 117-129.
6.0dink,K. et al. (1987) Two calcium-binding proteins in infiltrate 
macrophages of rheumatoid arthritis. Nature, 330, 80-82.
7. Roth,J. et al. (1993) Expression of calcium-binding proteins MRP8 and 
MRPI4 is associated with distinct monocytic differentiation pathways in 
HL-60 cells. Biochcm, Biophys, Res. Commun,, 191, 565-570.
8. Foell.D. et al. (2007) S100 proteins expressed in phagocytes: a novel group 
of damage-associated molecular pattern molecules. J. l.eukoc. Biol., 81, 
28-37.
9. Nacken,W. et al. (2003) S100A9/S100A8: myeloid representatives of the 
SI00 protein family as prominent players in innate immunity, Microsc. Res. 
Tech., 60, 569-580.
iO.Striz,!. et al. (2004) Calprotectin—a pleiotropic molecule in acute and 
chronic inflammation. Physiol. Res., 53, 245-253.
11. Ehrchen,J.M. et al, (2009) The endogenous Toll-like receptor 4 agonist 
S100A8/S100A9 (calprotectin) as innate amplifier of infection, 
autoimmunity, and cancer. J, Leukoc, Biol,, 86, 557-566.
12. Turovskaya,0. et al. (2008) RAGE, carboxylaled glycans and S100A8/A9 
play essential roles in colitis-associated carcinogenesis. Carcinogenesis, 
29, 2035-2043.
13. Hiratsuka,S. et al. (2006) Tumour-mediated upregulation of chemoattrac­
tants and recruitment of myeloid cells predetermines lung metastasis. Nat. 
Cell Biol., 8, 1369-1375.
14. Hiratsuka,S. et al. (2008) The S100A8-serum amyloid A3-TLR4 paracrine 
cascade establishes a pre-metastatic phase. Nat. Cell Biol, 10, 
1349-1355.
15.Shekouh,A.R. et al. (2003) Application of laser capture microdissection 
combined with two-dimensional electrophoresis for the discovery of 
differentially regulated proteins in pancreatic ductal adenocarcinoma. 
Proteomics, 3, 1988-2001,
16.Thompson,C.C. et al. (2007) Pancreatic cancer cells overexpress gelsolin 
family-capping proteins, which contribute to their cell motility. Gat, 56, 
95-106.
17.Schwarte-Waldhoff,I. et al. (1999) DPC4/SMAD4 mediated tumor 
suppression of colon carcinoma cells is associated with reduced urokinase 
expression. Oncogene, 18, 3152-3158.
18, Muller,N. et al. (2002) Smad4 induces the tumor suppressor E-cadherin and 
P-cadherin in colon carcinoma cells. Oncogene, 21, 6049-6058.
19, Jazag.A. et al. (2005) Smad4 silencing in pancreatic cancer cell lines using 
stable RNA interference and gene expression profiles induced by 
transforming growth factor-beta. Oncogene, 24, 662-671.
20, Gebhaidt,C, et al (2008) RAGE signaling sustains inflammation and 
promotes tumor development. J. Exp. Med., 205, 275-285,
21, Ghavami,S. et al. (2008) S100A8/A9 at low concentration promotes tumor 
cell growth via RAGE ligation and MAP kinase-dependent pathway. 
J. Leukoc. Biol, 83, 1484-1492.
22.Stulik,J. et al. (1999) The analysis of S100A9 and S10QA8 expression in 
matched sets of macroscopically normal colon mucosa and colorectal 
carcinoma: the S100A9 and S100A8 positive cells underlie and invade 
tumor mass. Electrophoresis, 20, 1047-1054.
23.Roth,J. et al (1993) MRP8 and MRP14, S-100-like proteins associated 
with myeloid differentiation, are translocated to plasma membrane 
and intermediate filaments in a calcium-dependent manner. Blood, 82, 
1875-1883.
1550
Dow
nloaded from carcin.oxfordjournals.org at Sydney Jones Library, University of Liverpool on M
arch 26, 2011
S100AS, S100A9 and Smad4 in colorectal cancer
24. Funada.Y. et at. (2003) Prognostic significance of CD8+ T cell and 
macrophage peritumoral infiltration in colorectal cancer. Oncot. Rep., 10, 
309-313.
25. Khoruna,A.A. et at. (2003) Vascular endothelial growth factor, CD68, and 
epidermal growth factor receptor expression and survival in patients with 
Stage 11 and Stage III colon carcinoma: a role for the host response in 
prognosis. Cancer, 97, 960-968.
26. ForssellJ. et at. (2007) High macrophage infiltration along the tumor front 
correlates witli improved survival in colon cancer. Clin. Cancer Res., 13, 
1472-1479.
27. Miyaki,M. et at. (2003) Role of Smad4 (DPC4) inactivation in human 
cancer. Biochem. Biophys. Res. Conn nun., 306, 799-804.
28. Kilamura,T. et ah (2007) SMAD4-delicient intestinal tumors recruit 
CCR1+ myeloid cells that promote invasion. Nat. Genet., 39, 
467-475.
29. Li,.T.H. et at. (2004) Advanced glycation end products activate Smad 
signaling via TGF-beta-dependent and independent mechanisms: 
implications for diabetic renal and vascular disease. FASEB J., 18, 
176-178.
30. Zwadlo,G, et at. (1988) Two calcium-binding proteins associated with 
specific stages of myeloid cell differentiation are expressed by subsets of 
macrophages in inflammatory tissues. Clin. Exp. hmnun., 72, 510-515.
Received February 6, 2010; revised May 29, 2010; accepted June 29, 2010
1551
Dow
nloaded from
 cardn.oxfordjournals.org at Sydney Jones Library, U
niversity of Liverpool on M
arch 26, 2011
Downloaded from gut.bmj.com on March 26, 2011 - Published by group.bmj.com
Colon cancer
Low molecular weight heat shock protein HSP27 
is a prognostic indicator in rectal cancer but not 
colon cancer
Elizabeth M Tweedle,1,2 Ilyas Khattak,1 Chin Wee Ang,1 Taoufik Nedjadi,1 
Rosalind Jenkins,2 B Kevin Park,2,3 Helen Kalirai,4 Andy Dodson,5 Bahram Azadeh,5 
Monica Terlizzo,6 Heike Grabsch,7 Wolfram Mueller,8 Sun Myint,9 Peter Clark,2,8 
Helen Wong,6 William Greenhalf,1 John P Neoptolemos,1,2 Paul S Rooney,10 
Eithne Costello1,2
► Additional figures and tables 
are published online only. To 
view these files please visit the 
journal online (http://gut.bm]. 
com).
1 Division of Surgery and 
Oncology, Royal Liverpool 
University Hospital, University of 
Liverpool, Liverpool. UK 
2Liverpool Experimental Cancer 
Medicine Centre, University of 
Liverpool. Liverpool, UK 
3MRC Centre for Drug Safety 
Science, Department of 
Pharmacology and Therapeutics. 
University of Liverpool,
Liverpool, UK
4Cancer Tissue Bank Research 
Centre. Department of 
Pathology, University of 
Liverpool, Liverpool, UK 
department of Pathology. Royal 
Liverpool University Hospital, 
Liverpool. Liverpool, UK 
department of Pathology, 
University Hospitals Aintree, 
Fazackerley, Liverpool. UK 
'Section of Pathology and 
Tumour Biology, Leeds Institute 
of Molecular Medicine, 
University of Leeds, Leeds, UK 
demeinschaftspraxis 
Pathologie Starnberg, Germany 
dentre for Clinical Oncology, 
Clatterbridge, Wirral, UK 
'department of Colorectal 
Surgery. Royal Liverpool 
University Hospital. Liverpool, 
UK
Correspondence to
Eithne Costello, Division of 
Surgery and Oncology, Royal 
Liverpool University Hospital, 
5th Floor UCD Building, Daulby 
Street, University of Liverpool. 
Liverpool. CH48 4DQ. UK; 
ecostell(s>liv.ac.uk.
Accepted 4 June 2010
ABSTRACT
Objective There are currently no biomarkers in 
routine clinical use for determining prognosis in rectal 
cancer. In a preliminary proteomic study, variation in 
the levels of heat shock protein 27 (HSP27) in colorectal 
cancer samples was observed. The expression of 
HSP27 in a cohort of 404 patients with colorectal 
cancer with a predominantly poor prognosis was 
characterised and an investigation was undertaken 
of whether the differences were related to clinical 
outcome. HSP27 levels in diagnostic rectal biopsies were 
compared with matched surgical samples to determine 
whether changes in expression occurred in the time 
between biopsy and surgery and to investigate whether 
preoperative radiotherapy affected expression. Finally, 
the relationship between HSP27 expression and outcome 
was examined in an independent cohort of 315 patients 
with a predominantly good prognosis.
Methods HSP27 levels were determined using 
combined two-dimensional gel electrophoresis and 
tandem mass spectrometry (12 cases) and by 
immunohistochemistry using tissue microarrays of 
colorectal cancers sampled at surgery and 80 diagnostic 
rectal biopsies.
Results HSP27 overexpression was strongly associated 
with poor cancer-specific survival in rectal cancer 
(n=205, p=0.0063) but not colon cancer (n=199, 
p=0.7385) in the cohort with a poor prognosis. 
Multivariate Cox regression confirmed nodal metastases 
(p=0.0001) and HSP27 expression (p=0.0233) as 
independent markers of survival in rectal cancer.
HSP27 levels remained unchanged in the majority of 
cases (65/80, 81%) between diagnostic biopsies and 
matched surgical samples, regardless of whether 
patients had undergone preoperative radiotherapy.
In the cohort with a good prognosis the association 
between HSP27 and survival was not observed in 
patients with either rectal (n=115; p=0.308) or colon 
cancer (n=200; p=0.713).
Conclusion In a large cohort of patients with a poor 
prognosis, HSP27 is an independent marker of poor 
outcome in rectal cancer; its expression is not altered by 
neoadjuvant radiotherapy. This finding requires validation 
in an independent similar cohort of patients with rectal 
cancer. HSP27 levels merit evaluation as a stratification 
factor for treatment of rectal cancer.
Significance of this study
What is already known about this subject?
► Prognostic markers that will inform the treat­
ment of patients with rectal cancer are badly 
needed.
► HSP27 is a well-characterised anti-apoptotic 
protein.
► The prognostic value of HSP27 has been 
demonstrated in some tumours such as prostate 
cancer.
What are the new findings?
► Analysis of a cohort of 404 patients with 
colorectal cancer showed that HSP27 over­
expression was strongly associated with poor 
cancer-specific survival in rectal cancer (n=205, 
p=0.0063) but not colon cancer (n=199, 
p=0.7385).
► In a smaller independent cohort of patients with 
colorectal cancer (n=315) characterised by 
earlier stage disease and significantly better 
overall survival, a relationship between HSP27 
expression and outcome was not observed in 
either rectal cancer (n=115; p=0.308) or colon 
cancer (n=200; p=0.713).
► HSP27 levels remain largely unchanged 
between diagnostic biopsies and matched 
surgical samples and do not appear to be 
altered by administration of neoadjuvant 
therapy.
How might it impact on clinical practice in the
foreseeable future?
► Our finding merits validation in a large cohort of 
patients with rectal cancer in whom treatment 
has been standardised.
► Patients with stage II rectal cancer and high 
HSP27 should be considered for adjuvant therapy.
INTRODUCTION
Globally, around one million people per year are 
diagnosed with colorectal cancer.1 Two-thirds of 
cases have cancer of the colon and the remaining 
one-third have cancer of the rectum. The primary 
prognostic variables for patients with this disease 
remain depth of invasion and extent of nodal 
involvement.2 Nonetheless, 20% of node negative
Gut 2010,59:1501-1510. doLIO.1136/gut.2009.196626 1501
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patients have disease recurrence, indicating the need for addi­
tional prognostic biomarkers that can complement clinical 
staging. For locally advanced rectal cancer, preoperative therapy 
is standard treatment and can result in significant downstaging 
and downsizing of tumours.3 4 Prognostic biomarkers measur­
able in the preoperative biopsy are wanted to facilitate the 
selection of patients for treatment. We describe the first 
comprehensive analysis of heat shock protein HSP27 expression 
in colorectal cancer and its relationship to prognosis.
Heat shock proteins are ubiquitous molecular chaperones 
that fold new proteins correctly, enabling them to attain their 
functional conformation. They also prevent existing proteins 
from aggregating under conditions of stress.5 6 A variety of 
stimuli—including heat, oxidative stress or exposure to chemo­
therapeutic compounds—induce the expression of HSP27 
leading to protection against apoptotic cell death.6 HSP27 
regulates apoptosis through interaction or modulation of key 
components of the apoptotic signalling pathways, including 
preventing the activation of caspases,7 sequestering cytochrome 
c following its release from mitochondria8 and stabilising F-actin 
which maintains compartment integrity and supports protein 
trafficking.9-11 HSP27 also exerts an inhibitory effect on 
apoptosis by regulating the activation of Akt, a protein kinase 
that targets many apoptotic proteins.12 13
In this study we report the analysis of HSP27 in 719 patients 
with colorectal cancer in two independent cohorts. In the largest 
cohort analysed, high HSP27 expression was associated with 
poor outcome in rectal cancer. In the smaller cohort, which had 
approximately half the number of patients with rectal cancer 
and was characterised by earlier stage disease and significantly 
better overall survival, the relationship between HSP27 over­
expression and poor outcome was not observed. The levels of 
HSP27 in preoperative diagnostic rectal biopsies were similar to 
those observed in matched surgical samples and were not 
affected by preoperative radiotherapy.
METHODS
Patients
Tissue microarrays from 404 formalin-fixed paraffin-embedded 
primary tumours (199 colon, 205 rectal) from consented patients 
who underwent surgery at the Royal Liverpool University 
Hospital, UK between 1993 and 2003 were obtained from the 
Cancer Tissue Bank Research Centre, University of Liverpool. 
One hundred and twenty-one patients (30%) underwent 
chemotherapy. In the 103 patients (85%) in whom the chemo­
therapy agents were known, all received 5-fluorouracil and four 
(4%) received an additional agent (irinotecan or oxaliplatin). 
Second-line and third-line chemotherapy was given in 37/103 
(36%) and 19/103 (18%) patients, respectively. Additional agents 
(irinotecan, oxaliplatin, mitomycin C or levamisole) were 
administered in 9/37 (24%) second-round and 10/19 (53%) third- 
round patients. Thirteen per cent of patients with rectal cancer 
underwent short-course radiotherapy as part of the CR07 trial14 
(25 Grey administered in 5 fractions over 1 week with surgery 
within 1 week of treatment), while 15% underwent long-course 
radiotherapy (offered to patients with bulky tumours and 
consisting of 45 Grey administered in 25 daily fractions over 
5 weeks followed by surgery after 6—10 weeks). Clinicopatho- 
logical data including age, gender, site of tumour, stage 
(according to TNM and the American Joint Committee on 
Cancer guidelines15) are shown in table 1. The median follow-up 
was 49.5 months (IQR 19.6—74.6, range 0.23—146.5) and 284 
deaths from any cause were reported, including 176 deaths due 
to colorectal cancer. Seven patients died within 30 days of
surgery and were censored in the survival analysis. Four addi­
tional patients were censored at the point of last follow-up as no 
date of death was recorded.
Tissue preparation and two-dimensional electrophoresis
Twelve stage III cancers (9 colonic and 3 rectal) with varying 
survival times were submitted to two-dimensional electropho­
resis with the aim of detecting proteins associated with prog­
nosis. The surgical specimens were cryofixed in liquid isopentane 
and stored in liquid nitrogen. Tumour lysates were prepared by 
solubilising 30 X 8 pm undissected frozen sections in 400 (.d 
lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 40 mM Tris- 
base). Protein quantities were normalised and two-dimensional 
SDS-PAGE was undertaken as described previously.16 Gels were 
fixed and Coomassie Blue stained according to Neuhoff et at}7 
The gels were scanned using a GS-800 scanner (Bio-Rad, 
Hercules, Caliomia, USA) and images were acquired using 
PDQuest software (Bio-Rad V6.2). Image analysis was performed 
with Progenesis SameSpots imaging software (Nonlinear 
Dynamics, Newcastle upon Tyne, UK).
Identification of proteins by liquid chromatography tandem mass 
spectrometry (LC-MS/MS)
HSP27 was identified following gel spot excision and trypsin 
digestion according to Courchesne and Patterson.18 The tryptic 
digest was delivered into a QSTAR Pulsar i hybrid mass spec­
trometer (AB Sciex, Warrington, UK) by automated in-line RP- 
LC (integrated LCPackings System, 5 mm C18 p-precolumn 
cartridge and 75 pm X 15 cm C18 column, Dionex, California, 
USA) via a nano-electrospray source head and a 10 mm id 
PicoTip (New Objective, Massachusetts, USA) as previously 
described.19 Data were submitted to MASCOT and the NCBI 
database was searched with the MS tolerance set to 1.2 Da and 
the MS/MS tolerance to 0.6 Da with carboxamidomethyl as 
a variable modification.
Tissue microarray construction, staining and scoring
Six purpose-built colorectal cancer tissue microarrays (TMAs) 
were constructed, containing 2—6 cores from 404 independent 
cases of adenocarcinoma in addition to 36 cores of normal colon 
and 16 cores each of normal kidney, liver and testes, which 
served as control tissues. Immunohistochemistry was under­
taken as described previously20 using mouse monoclonal anti- 
HSP27 (Novocastra, Newcastle-upon-Tyne, UK) diluted 1:50. 
TMAs were scored independently by two specialist histopa- 
thologists (authors BA and MT) who were blinded to all clini- 
copathological data. The intensity of staining on a scale of 0—3 
and the extent of HSP27 staining on a scale of 0-3 according to 
the percentage of positive tumour (0, <5% positive cells; 1, 
5—30%; 2, 30—70%; and 3, >70%) were recorded.
Statistical analysis
Comparisons were made using the non-parametric continuity 
corrected x2 test (2 groups) or x2 test (>2 groups). Life tables 
and Kaplan—Meier curves were used to evaluate the effect of 
HSP27 expression on cancer-specific survival; p values were 
calculated using the log rank test. Survival was measured from 
date of diagnosis to date of death, counting death from colo­
rectal cancer as the end point; deaths from other causes were 
censored in the analysis. If no event occurred, the date of 
last follow-up was used as the end point. Multivariate Cox 
regression analysis was conducted using a stepwise forward 
selection approach starting with the most significant variable on 
univariate analysis and including every variable with a p value of 
<0.10.21 All analyses were performed using Statview Version
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5.01 (SAS Institute Inc, Cary, North Carolina, USA). A p value of 
<0.05 was considered significant.
Assessment of HSP27 in an independent patient cohort
To determine whether the findings obtained using the patients 
from Liverpool, UK were also observed in an independent cohort 
of patients, TMAs containing 200 colon cancers and 115 rectal 
cancers resected consecutively from 1990 to 1995 in Diisseldorf, 
Germany*"2 *'3 were stained for HSP27 expression and scored as 
described above; x2 testing was used to compare clinicopatho- 
logical variable between the cohorts. HSP27 scores were 
compared between cohorts using the Mann-Whitney U test 
and correlation with cancer-specific survival was determined 
using Kaplan-Meier curves.
RESULTS
Proteomic analysis and identification of HSP27
Comparison of two-dimensional protein gels of 12 colorectal 
cancer specimens (figure 1A—C) revealed considerable variation 
in the intensities of the protein spot, indicated with an arrow 
(figure 1A, B). The spot was excised, subjected to in-gel trypsin 
digestion followed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) which sequenced the peptide 
TKDGWErTGK (figure ID). This led to the identification of HSP27.
Correlation of parameters of HSP27 scoring with survival
To validate the variable HSP27 expression observed in colorectal 
cancer specimens, we undertook immunohistochemistry of
TMAs (n=404 patients; Liverpool cohort). Normal colonic 
epithelium was devoid of HSP27 expression (figure 2A), whereas 
weak HSP27 immunostaining was observed in normal liver and 
intense staining was detected in normal renal tubules, as 
expected.24 25 The variation in intensity of HSP27 expression in 
the colorectal cancer specimens was scored as follows: 
0 (n=lll), 1 (n=118), 2 (n=121), 3 (n=44) (figure 2B). The 
percentage of HSP27-positive tumour cells in the specimens 
was 0 (<10%), n=80; 1 (10-30%), n=99; 2 (30-70%), n-107; 
3 (>70%), n=118 (figure 2C). A combined score or 0—9 index 
was calculated by multiplying the intensity by the extent of 
staining for every patient. For analysis, the intensity, extent and 
combined index were dichotomised by the median; intensity 
(low <1.5 vs high >1.5), extent (low <2 vs high >2) and 
combined index (low s3 vs high >3). These factors were subject 
to univariate Cox regression to assess which aspects of HSP27 
staining were correlated with cancer-specific survival (see table 1 
in online supplement). Neither the intensity (p=0.0955) nor the 
extent (p=0.7056) of staining was related to cancer-specific 
survival. However, the combined index (p=0.0320) was predic­
tive of survival and was therefore the measure used in the 
construction of all subsequent Kaplan—Meier curves and life 
tables.
Clinicopathological data and correlation with HSP27 expression
Associations were sought between HSP27 expression (combined 
index) and gender, age, anatomical location, size of tumour, 
resection margin status, differentiation grade, depth of invasion
Figure 1 (A) Colloidal Coomassie Blue
stained two-dimensional gel image of 
a colorectal cancer lysate with the 
HSP27-containing spot arrowed. (B) 
Insets from 12 independent colorectal 
tumour gels showing different intensities 
in the HSP27 protein spot. (C) 
Normalised HSP27 levels ((HSP27 spot 
intensity/(spot intensity, all spots)) less 
gel background). (D) MS/MS spectrum 
of peptides 113-123 from HSP27.
Gel Number
2* Ion, m/z 573.8 
TKDGWEITGK
B
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Figure 2 (A) Benign control tissue showing absence of detectable HSP27 in normal colonic epithelium, weak staining in normal liver and intense 
staining of normal renal tubules. (B) Colorectal cancer tissue illustrating the range of intensities of HSP27 immunostaining from 0 to 3. (C) Colorectal 
cancer tissue depicting varying percentages of HSP27 staining in different tumours.
(T stage), presence of nodal metastases (N stage) and treatment 
(adjuvant chemotherapy and neoadjuvant radiotherapy). The 
entire cohort of 404 patients was examined, in addition to 
separate analyses of the subgroups of patients with colon cancer 
(n=199) and rectal cancer (n=205). No significant correlations 
were found between the HSP27 index and these parameters in 
any of the groups analysed, except for an association between 
high HSP27 expression and incomplete resection margins in 
patients with rectal cancer (p=0.009; table 1).
HSP27 expression and association with survival
Elevated HSP27 was associated with poor survival (p=0.0312) 
when the entire Liverpool cohort of 404 patients was examined 
(figure 3A). However, when the patients with colon and rectal 
cancer were analysed separately, HSP27 expression was not 
associated with survival in the colon cancer group (p=0.7385; 
figure 3B), but was significantly associated with poor survival in 
the rectal cancer group (p=0.0063; figure 3C). At 5 years, rectal 
cancer-specific survival for high versus low HSP27 expressers 
was 63% vs 73%. Survival was assessed across all stages at 
presentation in rectal and colon cancer. Elevated HSP27
predicted poor cancer-specific survival in patients with rectal 
cancer with early-stage I/II tumours (figure 3D). However, 
HSP27 was not predictive of poor survival for patients with 
rectal cancer with stage III (N+/M0) disease (p=0.2132, figure 3E). 
No difference in survival according to HSP27 expression was 
noted in the colon cancer group (see figures 1A and B in online 
supplement).
The benefits of adjuvant therapy for patients with stage III 
disease are well established, while management of patients with 
stage II rectal tumours (T3—4/N0/M0) remains controversial.26 
We next determined whether high HSP27 expression might be 
useful in identifying a high-risk group of patients with stage II 
rectal tumours (T3—4/N0/M0) who might benefit from adju­
vant therapy. We found that the overall survival of patients with 
stage II (T3—4/N0/M0) disease who had elevated HSP27 (n—29) 
was similar to that of patients with N1 disease (n=56, 
p=0.6523, figure 3F). This was not observed in colon cancer, 
where the overall survival of patients with stage II (T3—4/NO/ 
MO) disease who had elevated HSP27 (n=41) was significantly 
better than that of patients with N1 disease (n=43, p=0.0268, 
see figure 1C in online supplement).
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Figure 3 Kaplan—Meier graphs of 
8-year survival in (A) all patients, (B) 
colon cancer patients, (C) rectal 
cancer patients, (D) stage I/ll rectal 
cancer patients, (E) stage III 
rectal cancer patients and (F) stage 
IIIA/B rectal cancer patients versus 
stage II high HSP27 expressors.
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0 12 24 36 48 60 72 84 96
Time (months)
47 43 33 28 24 21 14 8 2
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Multivariate analysis
Multivariate Cox proportional hazards regression analysis was 
performed to derive risk estimates related to survival for all 
clinicopathological characteristics and HSP27 expression (table 2). 
Elements associated with cancer-specific survival on univariate 
analysis with p<0.10 were included in the multivariate model. 
Univariate analysis of 205 patients with rectal cancer showed 
that resection margin status (p=0.0894), N stage (p=0.0001) 
and HSP27 expression (p—0.0069) were significantly associated 
with survival. Only N stage and HSP27 expression remained 
independently predictive of survival with p values of 0.0001 and 
0.0233, respectively (table 2). Univariate analysis of 199 patients 
with colon cancer showed significant factors to be differentiation 
grade (p=0.0278), T stage (p=0.0008), resection margin status
(p=0.0001) and N stage (p=0.0001). HSP27 was not associated 
with survival (p=0.7382). On multivariate analysis, only resec­
tion margin status (p=0.0001) and N stage (p=0.0001) remained 
independently significant (see table 2 in online supplement).
Relationship between HSP27 expression and neoadjuvant 
treatment
The difference in survival observed in patients with rectal cancer 
but not those with colon cancer prompted us to question 
whether HSP27 expression was related to administration of 
neoadjuvant radiotherapy. Twenty-one patients with rectal 
cancer (13%) had short-course preoperative radiotherapy, 31 
(15%) had long-course radiotherapy and 147 (72%) had no 
neoadjuvant therapy (table 1). Preoperative treatment did not
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Table 2 Cox proportional hazard regression model for rectal cancer (n=205)
Univariate Multivariate
Variables Categories n(%) HR (95% Cl) x1 p Value HR (95% Cl) X* p Value
Age (years) 68 (60-74) - 1.000 (0.981 to 1.018) 0.001 0.9734 - - -
Size (mm) 45 (35-60) - 1.001 (0.998 to 1.004) 0.115 0.6934 - - -
Differentiation grade Well to moderate 187 (91) - - -
Poor 16 (9) 1.355 (0.682 to 2.693) 0.753 0.3857 - - -
T stage 11 8 (4) - 2.686 0.2611 - - -
T2 41 (20) 1.154 (0.336 to 3.967) 0.052 0.8203 - - -
13 156 (76) 1.708 (0.539 to 5.416) 0.827 0.3630 - - -
Resection margins Clear 175 (85)
Involved 30 (15) 1.563 (0.933 to 2.618) 2.884 0.0894 0.808 (0.450 to 1.453) 0.506 0.4769
N stage NO 108 (53) - 23.892 0.0001 - 20.227 0.0001
N1 56 (27) 1.557 (0.962 to 2.521) 3.250 0.0714 1.539 (0.947 to 2.500) 3.026 0.0820
N2 41 (20) 3.259 (2.027 to 5.240) 23.766 0.0001 3.289 (1.956 to 5.532) 20.150 0.0001
HSP27 expression Negative 113 (55)
Positive 92 (45) 1.720 (1.160 to 2.550) 7.293 0.0069 1.607 (1.066 to 2.422) 5.143 0.0233
affect levels of HSP27 in the resected tumour (p=0.629, table 1). 
Diagnostic biopsy material was available for 80 of these patients 
and was stained and scored for HSP27 expression and compared 
with matched tissue from the TMAs (figure 4A; table 3 in online 
supplement). In 65/80 cases (81%), HSP27 expression was iden­
tical in the biopsy and the tumour. Five tumours (6%) showed 
upregulation of HSP27 and 10/80 (13%) showed downregulation 
of HSP27 in the surgical samples compared with the biopsy
material (see table 3 in online supplement). Neoadjuvant therapy 
did not alter HSP27 expression between the biopsy and tumour 
specimens (p=0.6423, table 4 in online supplement).
Neoadjuvant therapy is not associated with cancer-specific 
survival
Having shown that neoadjuvant radiotherapy did not influence 
HSP27 expression, we sought to determine whether the type of
Figure 4 (A) HSP27 staining in 
diagnostic biopsy material compared 
with (B) matched tumour cores.
(C) Kaplan—Meier survival curves 
showing that the level of HSP27 
remains predictive of cancer-specific 
survival in patients with rectal cancer 
who have not received neoadjuvant 
radiotherapy and (D) that the mode of 
neoadjuvant radiotherapy received did 
not correlate with cancer-specific 
survival.
—* No radiotherapy 
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neoadjuvant radiotherapy received contributed to the survival 
difference observed in the rectal cancer group. Survival analysis 
performed for the 147 patients with rectal cancer who did 
not receive radiotherapy treatment confirmed that high 
HSP27 expression in this group was associated with poor 
survival (p=0.0078, figure 4B). No difference in cancer-specific 
survival was seen in the rectal cancer group according to type of 
radiotherapy received (p=0.4317, figure 4C).
Analysis of HSP27 expression in an independent cohort of 
patients
Finally, to examine the relationship between HSP27 expression 
and outcome in an independent cohort of patients with colo­
rectal cancer, analysis of HSP27 expression was undertaken for 
315 patients with colorectal cancer resected consecutively 
between 1990 and 1995 in Diisseldorf, Germany. We observed 
a lower median proportion of tumour staining for HSP27 in 
the Diisseldorf cohort (1.25 vs 2.0, p<0.0001; see table 3 in 
online supplement), although intensity of staining and HSP27 
index showed no significant difference (p=0.064 and p—0.207, 
respectively; table 3 in online supplement). The Diisseldorf 
cohort was dichotomised by the median HSP27 index score into 
s2.5 (n=159) or >2.5 (n=156), as was the case for the Liverpool 
cohort. No significant difference in survival was observed by 
HSP27 expression in the Diisseldorf group overall (p=0.327; 
figure 2A in online supplement) and, consistent with the Liver­
pool cohort, HSP27 expression did not correlate with survival of 
patients with colon cancer (n=200) in the Diisseldorf cohort 
(p=0.713; figure 2B in online supplement). However, in contrast 
to the finding that HSP27 overexpression correlated with poor 
outcome in the Liverpool cohort, HSP27 overexpression was not 
significantly associated with survival in patients with rectal 
cancer (n—115) in the Diisseldorf cohort (p—0.308; figure 2C in 
online supplement).
In order to determine why high HSP27 expression predicted 
a poor outcome in the Liverpool cohort but not in the Diissel­
dorf cohort, the dinicopathological characteristics and cancer- 
specific survival of the two cohorts were compared (see table 4 in 
online supplement). The overall 5-year survival of the Diissel­
dorf cohort was 69%, which was significantly better than the 
Liverpool cohort (59%; p=0.0002). The patients with colon 
cancer had similar distributions of age (p—0.481), gender 
(p=0.089), Tand N staging (p—0.079 and 0.139, respectively) in 
the respective cohorts. Nonetheless, cancer-specific survival for 
patients with colon cancer was superior in the Diisseldorf group 
(69% vs 65% at 5 years, p=0.02) and fewer patients with colon 
cancer had adjuvant therapy in the Diisseldorf group than in the 
Liverpool group (p=0.001). With respect to rectal cancer, the 
cohorts were considerably different with fewer men (p=0.0001) 
and fewer tumours with advanced stages (T3/4 or N2 cases; 
p=0.007 and p=0.044, respectively) in the Diisseldorf group. 
Conversely, Liverpool patients were more likely to have well/ 
moderately differentiated tumours (p—0.0004) and to have had 
adjuvant therapy (p<0.0001). Patients with rectal cancer 
showed the greatest difference in cancer-specific 5-year survival 
(69% for the Diisseldorf cohort vs 56% Liverpool cohort, 
p=0.007).
DISCUSSION
Clinical staging plays a significant role in predicting survival 
and guiding treatment for patients with rectal cancer.2' 
However, it is acknowledged that patients at similar clinical 
stages can have very different outcomes, and biomarkers capable 
of identifying patients at high risk who might benefit from
adjuvant chemotherapy are particularly required. Carcinoem- 
bryonic antigen (CEA) is the only biomarker recommended by 
the American Society of Clinical Oncology and the European 
Group on Tumour Markers for use in the postoperative period 
for the early detection of recurrent or metastatic rectal cancer. 
There is evidence that high preoperative CEA levels are inde­
pendently associated with poor survival, but the data are 
insufficient to support the use of CEA to determine treatment 
with adjuvant therapy. There are currently no data to support 
the use of thymidine synthase (TS), p53 mutation, k-ras 
mutation, DNA ploidy or 18q deletion for determining prognosis 
or response to treatment in rectal cancer.28 29 Preoperative 
chemoradiotherapy is recommended for the treatment of locally 
advanced rectal cancer following the results of a number of 
randomised controlled trials.'"’0 31 DNA analysis of tumour tissue 
has revealed that genes associated with DNA repair, apoptosis 
and cell adhesion are related to radioresistance.32 However, there 
are no reliable markers which predict response to neoadjuvant 
therapy in individual patients prior to treatment.33
Here we report that, in a cohort of 205 patients with rectal 
cancer from Liverpool, high HSP27 expression is an independent 
marker of poor outcome. In the smaller Diisseldorf cohort of 
patients with rectal cancer (n=115), the relationship between 
HSP27 and survival in rectal cancer was not observed. This may 
relate to the fact that the Diisseldorf cohort had significantly 
fewer men (a poor prognostic group), a greater proportion of 
early (NO) cancers and at 7% better 5-year cancer-specific 
survival. The latest Eurocare study confirms a discrepancy in 
relative 5-year survival for patients with colorectal cancer 
between the UK and Germany (51.8% vs 61.2%),34 which is 
consistent with the difference we have observed between the 
two cohorts in this study. We postulate that the significantly 
higher proportion of early rectal tumours in the Diisseldorf 
group and the correspondingly better outcomes in these patients 
reduced our ability to detect a significant survival difference 
according to HSP27 expression in this small group of patients.
Increased HSP27 in colorectal tumour specimens has been 
reported in smaller studies35 36 with inconclusive findings. Pei 
et al reported a strong relationship between HSP27 expression 
in the primary tumour and nodal status (n=40),3''’ while Zhao 
et al*6 found no such association (n=68). Our data represent the 
largest clinical analyses of HSP27 expression in colorectal 
adenocarcinoma, and the first study in which HSP27 levels were 
analysed in colon and rectal cancer separately. Our finding that 
HSP27 expression has prognostic value in rectal but not colon 
cancer adds to accumulating evidence that rectal and colon 
tumours are distinct biological entities/’7
Given the role of HSP27 in apoptosis, it is not surprising that 
its levels in many cancer types have been examined and rela­
tionships to outcome determined.'’8 For cancers such as pros­
tate,39 40 ovarian,41 gastric42 and hepatocellular carcinoma,24 
high levels of HSP27 are associated with a poor prognosis. In 
contrast, HSP27 expression has been associated with a good 
prognosis in endometrial,43 oesophageal44 and oral squamous 
cell carcinoma.45 Findings remain inconclusive in breast cancer, 
with high HSP27 linked to poor prognosis in some studies46 47 
but no association being detected in others.48 49 Using raised 
HSP27 as a biomarker, we defined a poor prognostic group of 
stage II patients in the Liverpool cohort with survival similar to 
that of stage IIIA/B patients. Further work will be required to 
establish whether this group of patients would benefit from 
chemotherapy. HSP27 expression was independently associated 
with survival in patients with rectal cancer on multivariate 
analysis. We were interested to note that resection margin status
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was not independently significant in the multivariate analysis, 
which was contrary to our expectations. This may reflect 
non-standardised pathological data collection prior to 1999 in 
Liverpool, when total mesorectal excision and the minimum 
pathological dataset were introduced.
Our analysis of HSP27 expression in preoperative biopsy 
material from a subset of the patients with rectal cancer 
afforded us the opportunity to make two important observa­
tions. First, the expression of HSP27 levels in the tumours was 
stable over time, with 81% showing no change in expression 
between biopsy and surgical sample. The mechanism by which 
HSP27 is induced in cancer is not fully understood, although 
features of the tumour microenvironment as well as over­
production and misfolding of mutated proteins in cancer cells 
have been suggested as inducing factors. Whatever the cause of 
induced HSP27 expression in rectal cancers, our data indicate 
a sustained overproduction of the protein. Second, we observed 
that radiotherapy does not alter the expression of HSP27 
between diagnosis of rectal tumours and surgical resection. Our 
findings concur with the only published study of HSP27 
expression in relation to radiotherapy treatment of rectal cancer, 
which found no consistent change in HSP27 expression after 
radiotherapy was administered (n=23).51 The low proportion 
of patients undergoing neoadjuvant therapy in our cohort 
reflects the practice at the time of diagnosis (1993—2003) when 
preoperative radiotherapy in rectal cancer was not standard.
A variety of mechanisms by which HSP27 exerts its effects on 
survival in cancer have been proposed, including enhanced 
motility and invasion,?2 53 inhibition of apoptosis6-8 and resis­
tance to anti-cancer treatments.6 The role of HSP27 in chemo- 
resistance has been intensely studied and the protein has been 
implicated in 5-fluorouracil and irinotecan resistance in colo­
rectal cancer.64 55 Of particular interest in rectal cancer is the role 
that HSP27 plays in resistance to radiotherapy. There is in vitro 
evidence that HSP27 confers resistance to gamma-radiation in 
human cancer cell lines.66 Further work is required to establish 
whether a link exists between FiSP27 expression, resistance to 
radiotherapy treatment and prognosis in rectal adenocarcinoma.
In conclusion, elevated HSP27 is an independent marker of 
poor prognosis in rectal cancer. Expression of the protein appears 
stable between the time of biopsy and tumour specimen 
acquisition and it is not altered by neoadjuvant radiotherapy. 
Further work is necessary to validate these findings in a larger 
group of patients with rectal cancer and to determine whether 
HSP27 has a role to play in resistance to adjuvant radiotherapy 
and chemotherapy in vivo.
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